VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 17 (22-31 julio / 2023)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en Patentscope sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

CUBA

Noticias en la Web

Revelan el misterio COVID-19 más grande: ¿Por qué hay personas asintomáticas?

23 jul. Pese a que la pandemia de la COVID-19 ya no es considerada por la Organización Mundial de la Salud (OMS) como una emergencia sanitaria global, el virus sigue vigente y aún hay contagios a lo largo de todo el mundo.

En los últimos 30 días la entidad informó más de 835.000 casos y unas 4.500 muertes a nivel mundial, razón por la que los especialistas siguen remarcando la importancia de vacunarse contra el SARS-CoV-2 en el caso de estar dentro de los grupos de riesgo.

Tras la pandemia que marcó una época de la humanidad a partir del año 2020, los especialistas aún continúan estudiando los comportamientos del virus, su evolución, cómo el cuerpo reacciona a este y las forma de combatirlo.

En este sentido, un nuevo estudio reveló el porqué de uno de los misterios más grandes de la COVID-19: los contagiados asintomáticos, alrededor de un 20 % de los positivos que adquieren la infección, pero que no muestran ningún signo de ello.

Este grupo fue uno de los más riesgosos durante los peores meses de la pandemia dado que, al no presentar síntomas, los individuos seguían con su vida con normalidad, sin embargo, sí tenían la capacidad de contagiar, esparciendo así el virus con mayor facilidad.

Ahora, el científico brasileño Danillo Augusto, de la Universidad de Carolina del Norte en Charlotte, publicó un revelador informe en el que se analizó a un grupo de asintomáticos para conocer por qué no muestran signos al contagiarse de COVID-19: ¿Qué dice el estudio?

COVID-19 y asintomáticos: ¿Por qué algunas personas no tienen síntomas?

Junto a colegas de los Estados Unidos y Australia, Augusto descubrió que los contagiados de COVID-19 asintomáticos tienen una variación genética común en su ADN que parecería ser la pista a la falta de reacción ante el virus.

En el estudio publicado en la prestigiosa revista científica Nature, los profesionales compartieron su análisis de una mutación del gen HLA-B denominada HLA-B*15:01, la cual parece ser la clave de la falta de síntomas.

Fuente: El Cronista. Disponible en https://goo.su/xwkaoWP

Anvisa da registro definitivo para la vacuna bivalente COVID-19 de Pfizer

24 jul. La Agencia Nacional de Vigilancia Sanitaria (Anvisa) aprobó, el lunes 24, el registro definitivo de la vacuna Comirnaty bivalente de Pfizer contra la COVID-19.

El inmunizante está indicado para la prevención de la COVID-19 y puede ser utilizado por personas a partir de los 5 años. La indicación es que el uso es solo como dosis de refuerzo, es decir, solo se puede aplicar a quienes ya hayan sido vacunados contra la enfermedad, con aplicación de al menos tres meses después de la última dosis tomada.

La vacuna ya estaba siendo utilizada en el Programa Nacional de Inmunizaciones (PNI) del Ministerio de Salud (MS) con carácter de emergencia.

Antes del registro definitivo, el producto se utilizaba como dosis de refuerzo para el público mayor de 12 años con comorbilidades y para mayores de 18 años.

Bivalente

Según Anvisa, las vacunas bivalentes brindan mayor protección contra la enfermedad, ya que contienen una mezcla de cepas del virus Sars-CoV-2.

El Comirnaty bivalente se elabora con la variante original, que es la cepa wuhan, añadida a una variante más reciente en circulación, la cepa Ómicron.

En el escenario internacional de regulación, el Comirnaty bivalente ya está autorizado para su uso por la Agencia Europea de Medicamentos (European Medicines Agency – EMA) y por la agencia reguladora de los Estados Unidos (Food and Drug Administration – FDA).

Fuente: Valor Económico. Disponible en https://goo.su/F2kZ

La vacuna contra la malaria de la Universidad de Oxford, aprobada en Burkina Faso

25 jul. La agencia reguladora de medicamentos de Burkina Faso (ANRP, por sus siglas en francés) ha aprobado el uso en niños de la vacuna contra la malaria 'R21/Matrix-M', desarrollada por el Instituto e Investigaciones en Ciencias de la Salud (IRSS, por sus siglas en francés) y la Universidad de Oxford (Reino Unido).

Burkina Faso es el tercer país de África, tras Ghana y Nigeria, que autoriza esta vacuna, que será fabricada y comercializada por el Serum Institute of India.

En este país africano, los ensayos de fase 2b y fase 3 han demostrado "altos niveles de eficacia" y un perfil de seguridad "tranquilizador" entre los niños que recibieron tres dosis y una dosis de refuerzo un año después.

La vacuna contiene el antígeno R21, desarrollado por la Universidad de Oxford, específico del parásito de la malaria, y aprovecha 'Matrix-M' de Novavax, un adyuvante a base de saponina que potencia la respuesta inmunitaria, haciéndola más potente y duradera. Las autorizaciones se basan en los resultados del ensayo de fase 2b publicados en la revista científica 'The Lancet Infectious Diseases', así como en los resultados de confirmación de fase 3 que se publicarán en el futuro.

"En Novavax estamos encantados de ver que nuestro adyuvante 'Matrix-M' contribuye a una variedad de asociaciones para mejorar la salud pública, y estamos buscando activamente oportunidades adicionales en las que podamos aplicar esta tecnología para mejorar las vacunas", ha comentado el presidente y consejero delegado de Novavax, John C. Jacobs, a través de un comunicado.

La vacuna 'R21/Matrix-M' es una de las colaboraciones que están en curso en las que se está aprovechando la tecnología de adyuvantes de Novavax, entre las que se incluyen otras investigaciones sobre malaria, tuberculosis y otras enfermedades infecciosas, tanto en humanos como en animales.

Recientemente, la compañía anunció una colaboración con el Instituto de Investigación Médica Bill y Melinda Gates en la que se usará 'Matrix-M' para su uso en la investigación preclínica de vacunas.

Fuente: Infosalus. Disponible en https://goo.su/cMEPU

MSPAS to focus on more Covid-19 vaccines for domestic campaign

Jul 27. Guatemala is presently working so hard on purchasing more Covid-19 vaccine doses in order to continue implementing domestic campaign immunization campaign ahead of rising coronavirus cases reported recently and imminent expiration of last Pfizer batches.

As of past Saturday, 714 drugs were available, and we are rolling out some strategies to supply them before being expired at the end of the month, while we are purchasing 540,000 doses, Guatemala´s Public Health and Social Assistance Ministry (MSPAS) reported.

Without further details regarding the procurement methodology and when they might be received, the country has just over 42% of its population fully vaccinated, just more than seven million out of a total of 17.2 million inhabitants.

In the fortnights of April and May, the country´s infection toll remained 1,500 to 1,900.

By 23 June, Covid-19 cases reached 4,433, and during the two weeks up to the last closing date of 24 June it reached 5,660.

This public information confirmed one municipality on red alert (San Juan La Laguna, in the department of Sololá), 113 on orange alert and 226 on yellow alert, so it reflects the behavior of the SARS-CoV-2 virus.

MSPAS reiterated its call to population to continue respecting preventive measures including hand-washing with soap and water, social distancing and face mask-wearing.

MSPAS Minister Francisco Coma warned months ago about the possibility of an increased infection toll, but he ruled out this was a cause for concern.

Fuente: Prensa Latina. Disponible en https://goo.su/hIXC5

México emite opinión favorable a vacuna Soberana pediátrica

28 jul. La Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) de México emitió una opinión favorable para el uso de emergencia de las vacunas cubanas Soberana 02 y Soberana Plus para la población pediátrica, según anunció el Instituto Finlay de Vacunas (IFV) de Cuba en su cuenta oficial de Twitter.


SALUD
SECRETARÍA DE SALUD
COFEPRIS
COMISIÓN FEDERAL PARA LA PROTECCIÓN CONTRA RIESGOS SANITARIOS

Comunicado de prensa 84 / 2023

Comité de Moléculas Nuevas de Cofepris emite opinión favorable a vacuna Soberana pediátrica

- El uso del biológico será para población a partir de los 5 años
- El resultado representa un paso previo a la autorización de uso de emergencia

Ciudad de México, 28 de julio de 2023.- La Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) informa que el Comité de Moléculas Nuevas (CMN) analizó la información técnico-científica dando como resultado la opinión favorable para uso de emergencia de la vacuna Soberana contra COVID-19 para población pediátrica.

La opinión favorable hacia el biológico elaborado por el Instituto Finlay de Vacunas de La Habana, Cuba, es un paso previo a la autorización del uso de emergencia para dar acceso a un mayor número de personas a vacunas de calidad, seguras y eficaces, agregó el gobierno de México en su web oficial.

Destacó además, que el 31 de marzo de este año esta vacuna contó con la opinión favorable del Comité Nacional de Ciencia y Tecnología e Innovación en Salud del Consejo Nacional de Humanidades, Ciencias y Tecnologías (Conahcyt).

Dichas vacunas están compuestas por: proteína recombinante del dominio de unión al receptor del virus SARS-CoV-2 (RBD), conjugado a toxoide tetánico y proteína recombinante del dominio de unión al receptor del virus SARS-CoV-2 (RBD dimérico), respectivamente.

Fuente: Cubadebate. Disponible en https://goo.su/w2cRB

Los resultados del ensayo clínico de Fase 1, difundidos en una revista internacional, indican que la vacuna argentina ARVAC CG contra COVID-19 es segura e inmunogénica

28 jul. La vacuna argentina ARVAC Cecilia Grierson (ARVAC CG) contra COVID-19 es segura y desencadena una fuerte respuesta inmune contra las variantes Ancestral, Gamma, delta y Ómicron de SARS-CoV-2. Así lo revela un artículo publicado en la revista internacional *Nature Communications* que describe los resultados que emergen del análisis de los datos del estudio clínico fase 1 de la vacuna ARVAC CG desarrollada por el CONICET, la Universidad Nacional de San Martín (UNSAM), y el Laboratorio Cassará y que cuenta con el apoyo de la Agencia Nacional de Promoción Científica (Agencia de I+D+i), dependiente del Ministerio de Ciencia, Tecnología e Innovación.

La vacuna ARVAC CG se aplicó en el ensayo clínico de Fase 1 como dosis de refuerzo en una población de 80 voluntarios sanos de 18 a 55 años que habían recibido un esquema primario de vacunación contra SARS-CoV-2. En octubre del año pasado se había presentado el reporte interino de esta fase y ahora los resultados, difundidos en la revista internacional, se amplían con más detalles.

"Nos alegra ver que una vacuna contra COVID-19 íntegramente desarrollada en Argentina está demostrando eficacia en términos de inmunogecidad para las principales variantes de circulación del SARS-CoV-2 y que además es segura para la salud", afirma Juliana Cassataro, líder del desarrollo e investigadora del CONICET en el Instituto de Investigaciones Biotecnológicas Dr. Rodolfo Ugalde (IIB, CONICET-UNSAM).

Si bien la Organización Mundial de la Salud (OMS) declaró a comienzos de mayo pasado el fin de la emergencia de salud pública por la COVID-19, destacó que esa patología sigue siendo una prioridad de salud pública global.

Asimismo, indicó la necesidad de que los países "no bajen la guardia" y sigan desarrollando capacidades y herramientas para detectar, controlar y prevenir la transmisión del SARS-CoV-2, y recomendó dosis de refuerzo para grupos de riesgo (personas con múltiples comorbilidades, inmunosuprimidas y otros casos) y también para personas mayores de 50 años.

En este contexto, el desarrollo de una vacuna argentina contra COVID-19 es de alta relevancia para responder a necesidades de la población.

Vacuna segura e inmunogénica

Los resultados indican que la vacuna ARVAC CG es segura en humanos ya que durante todo el desarrollo del estudio y a la fecha, no se reportaron eventos adversos serios ni eventos de especial interés relacionados con la vacuna. Por otra parte, el estudio demostró que la administración de ARVAC CG como vacuna de refuerzo aumenta los títulos de anticuerpos neutralizantes de las variantes Ancestral, Gamma, delta y Ómicron de SARS-CoV-2 y la respuesta inmune celular T en individuos previamente vacunados.

Jorge Geffner, investigador del CONICET en el Instituto de Investigaciones Biomédicas en Retrovirus y SIDA

(INBIRS, CONICET-UBA) y colegas de esa institución estuvieron a cargo de los ensayos de neutralización que se realizaron para evaluar la capacidad de los plasmas de los ochenta voluntarios vacunados con ARVAC CG para inhibir la infección del virus SARS-CoV2 en células susceptibles en cultivo.

“El trabajo arrojó resultados excelentes y es importante en varios sentidos. Se trata de una vacuna construida desde la A hasta la Z en nuestro país. A nivel de seguridad, es una vacuna realmente muy segura con muy pocos efectos adversos, solo los esperados, locales y que ceden rápidamente”, destacó Geffner.

El investigador del CONICET también puntualizó que la vacuna “es muy inmunogénica, es decir, que al administrarse a los voluntarios y voluntarias del estudio una dosis de refuerzo con la vacuna ARVAC CG, los niveles de anticuerpos realmente aumentan de manera muy significativa, de forma comparable a las vacunas que se emplean a nivel internacional”. Asimismo, Geffner subraya que “en un momento en que sigue estando vigente la necesidad de darse dosis de refuerzo, al menos una en forma anual para los adultos, y particularmente una cada seis meses para personas con múltiples comorbilidades, es muy importante tener una producción local de vacunas para seguir manteniendo en el tiempo una oferta de vacunas contra COVID-19 en el país y también en la región”.

Las instituciones que participaron del estudio fase 1 son públicas y privadas como el IIB, el INBIRS, el Ministerio de Salud de la Provincia de Buenos Aires, FP Clinical Pharma SRL, Nobeltri, Fundación Pablo Cassará, Laboratorio Pablo Cassará SRL.

En la actualidad y con la autorización de la ANMAT, se está realizando la fase 2/3 de los ensayos clínicos en la que se evalúa la respuesta inmune como indicador de la eficacia y la seguridad. Actualmente hay 1816 voluntarios vacunados de la fase 2-3 de un total de 2000. Quedan entonces reclutar aproximadamente 200 voluntarios mayores de 60 años. Los interesados pueden hacerlo en la página https://arvac.com.ar/

Una vez completadas las fases 2 y 3 de los ensayos clínicos, se hará la presentación de los resultados en la ANMAT para que luego de su evaluación se pueda hacer el registro de la vacuna.

“Este proyecto ha involucrado a más de 20 instituciones publicas y privadas de Argentina, por eso creemos que haber podido unir y armar esta red de profesionales para el desarrollo de una vacuna diseñada y producida completamente en nuestro país podría servir para varios escenarios”, indicó Cassataro.

Los tres escenarios mencionados por la investigadora del CONICET y de la UNSAM son: la necesidad actual de dosis de refuerzo en personas mayores y grupos de riesgo; ante la aparición de una nueva variante de preocupación que escape a la respuesta inmune de las vacunas actuales poder actualizar la vacuna y también usar esta experiencia para ampliar las capacidades locales y trabajar para el desarrollo de nuevas vacunas. “Todo esto permitiría sustituir importaciones y exportar a la región, lo que desde el punto de vista económico podría ser muy importante para nuestro país”, destacó Cassataro.

Los estudios preclínicos fueron financiados por la Agencia Nacional de Promoción Científica (Agencia de I+D+i), dependiente del Ministerio de Ciencia, Tecnología e Innovación, mientras que el desarrollo y escalado industrial del proceso biotecnológico bajo estándares de calidad GMP (siglas en inglés de “buenas prácticas de manufactura”), así como el estudio clínico de fase I, fueron financiados por el Laboratorio Pablo Cassará. Este último está produciendo la vacuna desde el antígeno hasta el producto terminado en sus plantas habilitadas y ya en funcionamiento en nuestro país. El ensayo clínico fase 2/3 está siendo financiado por el Ministerio de Ciencia, Tecnología e Innovación.

Fuente: CONICET. Disponible en https://goo.su/Yp6Sr6u

New Covid vaccines are coming to the U.S. this fall, but uptake may be low — Here's why

Jul 29. A new round of Covid vaccines is coming to the U.S. this fall — but many Americans may not roll up their sleeves and take one.

That's largely because pandemic fatigue, the belief that Covid is "over" and confusion over personal risk levels could deter some people from getting an additional shot, experts in public health and health policy told CNBC.

But they said public health officials and health-care providers could potentially increase uptake of the new vaccines by communicating a new and simple message this fall: Covid vaccines are likely going to become a routine part of protecting your health moving forward.

In September, vaccine manufacturers Pfizer, Moderna and Novavax are slated to deliver new single-strain Covid shots targeting the omicron subvariant XBB.1.5, the most immune-evasive strain of the virus to date.

It will be a "very uphill battle" to get people to take those jabs, especially given the sluggish uptake of the most recent shots that rolled out, said Jen Kates, senior vice president of the health policy research organization KFF.

Only about 17% of the U.S. population — around 56 million people — have received Pfizer and Moderna's bivalent Covid vaccines since they were approved last September, according to the Centers for Disease Control and Prevention. Bivalent means they target two strains of the virus.

Less than half of adults 65 and older have received a bivalent shot, while rates for all other age groups sit at around 20%.



Pfizer, Moderna and Novavax have not provided exact estimates for what they expect uptake of their new shots to look like.

But a Pfizer spokesperson said overall the company expects 24% of the population, or 79 million people, to receive vaccine doses in 2023, which includes both primary doses and boosters. A Novavax spokesperson said the company has started "manufacturing at risk" and is "stockpiling enough material to support the upcoming launch for the season."

All companies have noted that they are preparing for the federal government to shift vaccine distribution to the private market, meaning manufacturers will sell their updated shots directly to health-care providers at higher prices. Previously, the government purchased vaccines directly from manufacturers at a discount to distribute to the public for free.

Regardless of that shift, experts say vaccine uptake may not look much different from that of the bivalent boosters. Here's why.

Pandemic fatigue, confusion

Fatigue over the pandemic and the general belief that Covid is "over" could potentially hinder the uptake of new shots this fall, experts said.

A June poll conducted by Gallup found that 64% of Americans think the pandemic is over in the U.S. and only 18% are worried about contracting the virus.

Ipsos and Axios released a survey with similar findings in May, the same month the U.S. ended the national Covid public health emergency amid a downward trend in cases, hospitalizations and deaths.

But Covid is still killing people every day and isn't going away anytime soon. Meanwhile, many Americans are becoming weary of recommendations for protection. That includes masking, testing for the virus and getting vaccinated.

"People have essentially moved on, especially given how long the pandemic has been," Dr. Kartik Cherabuddi, a professor of medicine at the University of Florida, told CNBC.

He said that's why it's important to stress how people will personally benefit from receiving an additional vaccine this fall.

But there's an even a bigger problem: Personal Covid risks and benefits from getting another shot have been a major area of confusion for Americans, which could also hamper the uptake.

The confusion stems from the fact that "risk levels aren't the same for everybody in the population right now," and almost everyone has a different circumstance, according to Dr. Brad Pollock, chair of UC Davis Health's department of public health sciences.

"It's this perception of the individual. 'Why should I get another booster? What is my risk? Why should I do it? Is it really worth doing now, or later?'" Pollock told CNBC. "I think everybody's confused. And when they're confused, they probably will do nothing until there's more clarity."

The CDC hasn't recommended the updated shots to specific groups yet because they haven't been approved by the Food and Drug Administration. But even after eligibility guidelines are formalized, confusion could potentially remain.

Those at high risk of severe Covid, such as older adults and immunocompromised people, could potentially benefit more than the general population.

But even those patients have different circumstances: Some high-risk people may have recently received a fifth vaccine dose, which could push back when they can get the updated vaccine. Health officials usually recommend spacing out vaccinations over a specific number of months.

Meanwhile, some healthy adults may have four doses but may be unsure about getting another because the benefit of a fifth dose for those less vulnerable to severe Covid still isn't clear, Pollock said.

People who recently had Covid may also have to wait longer to get a new shot so they can maximize the protection they get from vaccination — a recommendation made when the bivalent boosters rolled out.

But that could get even more complicated this fall, according to Cherabuddi. He said testing for Covid has dropped to new lows over the past year, "so we don't even know who has been infected in the last few months."

Those individualized circumstances will likely make it more challenging for both health officials and health-care providers to convey clear messages about the updated vaccines this fall, Cherabuddi and other experts said.

The Health and Human Services Department did not immediately respond to CNBC's request for comment.

Vaccine manufacturers have noted that they will continue to engage in a variety of outreach efforts to encourage the public to get vaccinated.

A new message may increase rates

But KFF's Kates said health officials and providers could potentially increase uptake if they communicate that Covid shots are "likely going to be more of a routine part of our health care going forward."

The FDA and CDC are hoping to transition toward a flu shot-like model for Covid vaccines, meaning people will get a single jab every year that is updated annually to target the latest variant expected to circulate in the fall and winter.

Kates said that schedule aims to simplify the process of getting vaccinated. For example, it will likely make it easier for Americans to remember to get a new vaccine every year and allow them to receive one with their flu shot during the same doctor's visit.

"People might be more open to making this a normal part of what they do," Kates said. "That contrasts with what we've seen in the past where there are different vaccines, different timing, different age groups and something new to consider every few months."

There's still uncertainty about whether the U.S. will update and distribute new shots on an annual basis, according to Kates.

Advisors to the FDA have raised concerns about shifting to yearly Covid vaccines, noting that it's unclear if the virus is seasonal like the flu.

A KFF poll released in April suggests that an annual schedule may boost uptake: More than half of the public said they would likely get an annual Covid shot if it was offered like an annual flu shot. That includes about a third who would be "very likely" to do so.

Pfizer similarly told CNBC in May that an annual Covid schedule could encourage more people to vaccinate each year. The company is preparing to shift to that schedule by developing "next-generation" versions of its shot, which aim to extend the protection people get from the virus to a full year.

Commercial market may not change much

It's unclear whether the U.S.'s shift to the commercial market will affect the uptake of the new vaccines.

It may not change much for insured Americans. Private insurers and the government-run Medicare and Medicaid programs are required to cover all shots recommended by the CDC, meaning most of the insured will continue to get Covid shots for free.

Federal and corporate programs are aiming to fill the gap for the 25 million to 30 million uninsured adults in the U.S. That includes the Biden administration's Bridge Access Program, which plans to provide free Covid vaccines to uninsured people through 2024.

Kates said it's "still hard to gauge" how many uninsured people will benefit from those efforts.

She also noted that a shift in access could potentially lower uptake among the group. "Somebody might be worried that they won't get their vaccine covered or they'll be asked to pay for it when they can't afford it. That could be a big deterrent," Kates said.

But Dr. Helen Chu, an epidemiology professor at the University of Washington School of Medicine, said the uninsured have continued to lag behind their insured counterparts in terms of vaccine uptake even "when shots were freely available to them."

A KFF survey conducted in March found that only 22% of uninsured Americans under 65 were both vaccinated and boosted against Covid, compared with 44% of insured people in that age group. Another KFF survey from mid-2021 showed similar findings.

"I'm not sure that a person's insurance status was necessarily the driver of the low uptake we've seen, or whether it will be the driver of potentially low uptake in the fall as well," Chu told CNBC.

Fuente: CNBC. Disponible en https://goo.su/PzUPl6p

Merck's investigational pneumococcal vaccine shows promise in older adults

Jul 29. Merck & Co – known as MSD outside the US and Canada – has shared positive results from two late-stage trials evaluating its investigational 21-valent pneumococcal conjugate vaccine in adults.

Pneumococcal disease is the name for any infection caused by bacteria called Streptococcus pneumoniae and is considered a "major public health problem worldwide" by the World Health Organization.

There are more than 100 different types of pneumococcal bacteria, which can affect adults differently than children. Highly aggressive strains threaten to put more people at risk for invasive pneumococcal illnesses, Merck reports, and older adults are among those most vulnerable to serious infection.

Merck's candidate, V116, is specifically designed to address the strains that represent adult pneumococcal disease, including eight unique strains which account for approximately 30% of adult disease.

If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for this patient population, according to the company.

Results from the phase 3 STRIDE-3 trial, which has been evaluating V116 in vaccine-naïve adults, demonstrated statistically significant immune responses compared with Pfizer's 20-valent vaccine, Prevnar 20, for strains common to both vaccines as well as those unique to V116.

Additionally, results from the phase 3 STRIDE-6 trial demonstrated that V116 was immunogenic for all 21 pneumococcal strains in the vaccine among adults who had received a pneumococcal vaccine at least one year prior to the study.

V116 had a safety profile comparable to the comparator in both studies, Merck said, adding that the results will now be shared with the scientific community and will support global regulatory applications.

Dr Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, said: "Despite the availability of current pneumococcal conjugate vaccines, many adults remain vulnerable to pneumococcal disease, especially those who are older.

"These results support the potential for V116 to become an important new preventative option for adults, regardless of prior pneumococcal vaccination status, by expanding coverage to include eight serotypes not currently included in any licenced vaccine."

Fuente: PMLive. Disponible en https://goo.su/klW0ck

Mpox Vaccinations Effective by Any Route

Jul 31. A recent Morbidity and Mortality Weekly Report published by the U.S. Centers for Disease Control and Prevention (CDC) confirmed the route of administration of the first dose of Bavarian Nordic JYNNEOS® (MVA-BN) vaccine was not associated with lower overall 2-dose series completion rates during the mpox outbreak in the U.S.

The U.S. Food and Drug Administration authorized the JYNNEOS vaccine in August 2022 as a 2-dose series used to prevent mpox virus infection, to be administered via a dose-sparing intradermal (ID) route. The FDA later added authorization for the subcutaneous (SC) route.

As of July 25, 2023, over 1,248,000 first and second-dose mpox vaccinations had been reported to the CDC.

And in California, 119,345 first doses were administered since August 9, 2022, with the ID route administered by 70% and 30% by the SC route.

To better understand how to administer the JYNNEOS vaccines, the California Department of Public Health investigated whether demographic disparities in vaccination series completion varied by route of administration of the recipient's first dose.

When the first dose was received by subcutaneous administration, overall series completion was 58.8% compared with 60.2% when the first dose was administered intradermally.

Among California residents who received their first dose from August 9, 2022–March 31, 2023, a total of 59.8% received a second dose.

Series completion was highest among non-Hispanic White persons (64.1%), persons aged ≥65 years

(72.6%), and adults with male sex assignment at birth (62.1%).

However, the series completion rate was lowest among non-Hispanic Black or African American persons (51.3%), persons aged 18–24 years (42.9%), and adults assigned female sex at birth (42.8%).

Odds of series completion across all race and ethnicity groups, persons aged 18–64 years, community health conditions, and persons assigned to the male sex at birth were no more significant when the first dose was administered subcutaneously compared with intradermally.

Intradermal use of the JYNNEOS vaccine did not lower overall 2-dose series completion rates, said the CDC on July 28, 2023.

Regarding vaccine effectiveness, The Lancet published results from a study on July 17, 2023, concluding that real-world data estimate vaccine effectiveness to be around 85%.

However, immunological correlates of protection are still unknown.

Previously, the CDC issued a report on June 23, 2023, confirming that a cluster of mpox cases was reported in Chicago, Illinois. And the Colorado Department of Public Health and Environment reported on June 12, 2023, three mpox cases were confirmed in vaccinated people.

As of July 31, 2023, the CDC continues encouraging people to complete the 2-dose series but is not endorsing a third JYNNEOS vaccination.

Since the mpox outbreak began in May 2022, there have been 30,637 cases and 45 related deaths in the U.S.

Fuente: Precision Vaccinations. Disponible en https://goo.su/oL3zmtG

Artículos científicos publicados en Medline

Filters activated: Publication date from 2023/07/21 to 2023/07/31. "vaccine" (Title/Abstract) 615 records.

Myopéricardite persistante après une vaccination hétérologue à ARNm anti-SRAS-CoV-2.
Wu KY, Butler CR, Koshman S, Oudit GY, Paterson DI. CMAJ. 2023 Jul 24;195(28):E965-E968. doi: 10.1503/cmaj.221510-f. PMID: 37487616

Neutralising antibodies against human metapneumovirus.
Guo L, Li L, Liu L, Zhang T, Sun M. Lancet Microbe. 2023 Jul 24:S2666-5247(23)00134-9. doi: 10.1016/S2666-5247(23)00134-9. Online ahead of print. PMID: 37499668

Viral-vectored respiratory mucosal **vaccine** strategies.
Jeyanathan M, Afkhami S, Kang A, Xing Z. Curr Opin Immunol. 2023 Jul 25;84:102370. doi: 10.1016/j.coi.2023.102370. Online ahead of print. PMID: 37499279

Systemic Lupus Erythematosus and COVID-19.
Pappa M, Panagiotopoulos A, Thomas K, Fanouriakis A. Curr Rheumatol Rep. 2023 Jul 21. doi: 10.1007/s11926-023-01110-z. Online ahead of print. PMID: 37477841

Dual delivery of antigens shows promise.
Luque-García JL, Prados-Rosales R. Elife. 2023 Jul 21;12:e90407. doi: 10.7554/eLife.90407. PMID: 37477291

Update on virus-induced asthma exacerbations.
Urbani F, Cometa M, Martelli C, Santoli F, Rana R, Ursitti A, Bonato M, Baraldo S, Contoli M, Papi A. Expert Rev Clin Immunol. 2023 Jul 24:1-14. doi: 10.1080/1744666X.2023.2239504. Online ahead of print. PMID: 37470413

Designing an effective malaria **vaccine** targeting Plasmodium vivax Duffy-binding protein.
Dickey TH, Tolia NH. Trends Parasitol. 2023 Jul 21:S1471-4922(23)00147-2. doi: 10.1016/j.pt.2023.06.011. Online ahead of print. PMID: 37481347

Current status of nano-vaccinology in veterinary medicine science.
Sadr S, Poorjafari Jafroodi P, Haratizadeh MJ, Ghasemi Z, Borji H, Hajjafari A. Vet Med Sci. 2023 Jul 24. doi: 10.1002/vms3.1221. Online ahead of print. PMID: 37487030

Understanding mechanisms of virulence in MRSA: implications for anti-virulence treatment strategies.
Hsieh RC, Liu R, Burgin DJ, Otto M. Expert Rev Anti Infect Ther. 2023 Jul 27. doi: 10.1080/14787210.2023.2242585. Online ahead of print. PMID: 37501364

Adjuvant physiochemistry and advanced nanotechnology for **vaccine** development.
Ren H, Jia W, Xie Y, Yu M, Chen Y. Chem Soc Rev. 2023 Jul 31;52(15):5172-5254. doi: 10.1039/d2cs00848c. PMID: 37462107

Intelligent Biomaterialomics: Molecular Design, Manufacturing, And Biomedical Applications.
Yi Y, An HW, Wang H. Adv Mater. 2023 Jul 25:e2305099. doi: 10.1002/adma.202305099. Online ahead of print. PMID: 37490938

Molecular and genetic characterization of bovine parainfluenza type 3 European field and **vaccine** strains.
Gaudino M, Valarcher JF, Hägglund S, Näslund K, Zohari S, Ducatez MF, Meyer G. Infect Genet Evol. 2023 Jul 22;113:105483. doi: 10.1016/j.meegid.2023.105483. Online ahead of print. PMID: 37482235

Caregivers' perception and acceptance of malaria **vaccine** for Children.
Bam V, Mohammed A, Kusi-Amponsah A, Armah J, Lomotey AY, Budu HI, Atta Poku C, Kyei-Dompim J, Dwumfour C. PLoS One. 2023 Jul 26;18(7):e0288686. doi: 10.1371/journal.pone.0288686. eCollection 2023. PMID: 37494408

Oral non-viral gene delivery platforms for therapeutic applications.
Ghaemi A, Vakili-Azghandi M, Abnous K, Taghdisi SM, Ramezani M, Alibolandi M. Int J Pharm. 2023 Jul 25;642:123198. doi: 10.1016/j.ijpharm.2023.123198. Epub 2023 Jul 3. PMID: 37406949

A narrative review of COVID-19 **vaccination** in pregnancy and breastfeeding.
Devera JL, Gonzalez Y, Sabharwal V. J Perinatol. 2023 Jul 26. doi: 10.1038/s41372-023-01734-0. Online ahead of print. PMID: 37495712

Nephrotic syndrome following COVID-19 **vaccination**: a systematic review.
Parikh C, Upadhyay H, Patel S, Sundararajan R, Shah D, Anand A, Baraskar B, Bhatt T, Verma D, Agrawal S, Mittal A, Gupta S. J Nephrol. 2023 Jul 28. doi: 10.1007/s40620-023-01710-z. Online ahead of print. PMID: 37505405

New paradigms in research on Dirofilaria immitis.
Geary TG. Parasit Vectors. 2023 Jul 21;16(1):247. doi: 10.1186/s13071-023-05762-9. PMID: 37480077

Synthetic Antigen-Conjugated DNA Systems for Antibody Detection and Characterization.
Ranallo S, Bracaglia S, Sorrentino D, Ricci F. ACS Sens. 2023 Jul 28;8(7):2415-2426. doi: 10.1021/acssensors.3c00564. Epub 2023 Jul 18. PMID: 37463359

On a mission to eliminate rabies.
Jarvis S. Vet Rec. 2023 Jul 22;193(2):65-68. doi: 10.1002/vetr.3286. PMID: 37477307

Compliance, procrastination and refusal: American COVID-19 **vaccination** trust and value orientation.
Tzeng R, Huang FY, Lee J. Vaccine. 2023 Jul 31;41(34):4950-4957. doi: 10.1016/j.vaccine.2023.06.060. Epub 2023 Jun 19. PMID: 37394373

No Need for Parental Involvement in the **Vaccination** Choice of Adolescents.
Brusa M, Barilan YM. J Bioeth Inq. 2023 Jul 21. doi: 10.1007/s11673-023-10252-9. Online ahead of print. PMID: 37477842

The third pandemic: The respiratory syncytial virus landscape and specific considerations for the allergist/immunologist.
Frenkel LD, Gaur S, Bellanti JA. Allergy Asthma Proc. 2023 Jul 26;44(4):220-228. doi: 10.2500/aap.2023.44.230030. PMID: 37236777

Behçet's patients' response to COVID-19 **vaccination**.
Gokani B, Sacoor S, Leisegang GR, Ogunkolade W, Bibi A, Grigoriadou S, Pade C, Gibbons J, Senusi A, Fortune F. Clin Immunol. 2023 Jul 21:109700. doi: 10.1016/j.clim.2023.109700. Online ahead of print. PMID: 37482118

Breast cancer **vaccination**: Latest advances with an analytical focus on clinical trials.
Vajari MK, Sanaei MJ, Salari S, Rezvani A, Ravari MS, Bashash D. Int Immunopharmacol. 2023 Jul 24;123:110696. doi: 10.1016/j.intimp.2023.110696. Online ahead of print. PMID: 37494841

Statistical and machine learning methods for immunoprofiling based on single-cell data.
Zhang J, Li J, Lin L. Hum Vaccin Immunother. 2023 Aug 1;19(2):2234792. doi: 10.1080/21645515.2023.2234792. Epub 2023 Jul 24. PMID: 37485833

Development of a Staphylococcus aureus **Vaccine**: An Ongoing Journey.
Proctor RA. Clin Infect Dis. 2023 Jul 26;77(2):321-322. doi: 10.1093/cid/ciad217. PMID: 37119277

Drivers and barriers to COVID-19 **vaccination** in Australians with cancer.
Allan C, Hyatt A, Appathurai A, Crane M, Lim C, Woolstencroft R, Slavin MA, Piper A, Spence D, Teh BW. Support Care Cancer. 2023 Jul 21;31(8):479. doi: 10.1007/s00520-023-07942-w. PMID: 37477843

Immunogenicity and safety of quadrivalent influenza **vaccine** among young and older adults in Tianjin, China: implication of immunosenescence as a risk factor.
Xiao T, Wei M, Guo X, Zhang Y, Wang Z, Xia X, Qi X, Wang L, Li X, Leng SX. Immun Ageing. 2023 Jul 27;20(1):37. doi: 10.1186/s12979-023-00364-6. PMID: 37501123

Chemical and biological conjugation strategies for the development of multivalent protein **vaccine** nanoparticles.
Park J, Pho T, Champion JA. Biopolymers. 2023 Jul 25:e23563. doi: 10.1002/bip.23563. Online ahead of print. PMID: 37490564

COVID-19 **vaccine** acceptance: A comparative longitudinal analysis of the association between risk perception, confidence, and the acceptance of a COVID-19 **vaccine**.
Martinelli M, Veltri GA. Risk Anal. 2023 Jul 27. doi: 10.1111/risa.14200. Online ahead of print. PMID: 37496470

Integrating the person-centered approach with the study of **vaccine** hesitancy: Applying latent profile analysis to identify **vaccine** hesitancy subpopulations and assess their relations with correlates and **vaccination** outcomes.
Howard MC. Vaccine. 2023 Jul 25;41(33):4823-4835. doi: 10.1016/j.vaccine.2023.06.057. Epub 2023 Jun 23. PMID: 37357075

Immediate adverse reactions following COVID-19 **vaccination** among 16-65-year-old Danish citizens.
Torp Hansen K, Kusk Povlsen F, Hammer Bech B, Nygaard Hansen S, Ulrikka Rask C, Fink P, Jørgensen T, Nielsen H, Meinertz Dantoft T, Marie Thysen S, Rytter D. Vaccine. 2023 Jul 25;41(33):4879-4887. doi: 10.1016/j.vaccine.2023.06.069. Epub 2023 Jun 23. PMID: 37391313

Call for Papers: Medicinal Chemistry of Next Generation **Vaccine** Adjuvants.
Salunke DB, Lindsley CW. J Med Chem. 2023 Jul 25. doi: 10.1021/acs.jmedchem.3c01248. Online ahead of print. PMID: 37490392

Building Africa**'s** first mRNA **vaccine** facility.
Saied AA. Lancet. 2023 Jul 22;402(10398):287-288. doi: 10.1016/S0140-6736(23)01119-4. PMID: 37481266

Modifiers of COVID-19 **vaccine** efficacy: Results from four COVID-19 prevention network efficacy trials.
Turley CB, Tables L, Fuller T, Sanders LJ, Scott H, Moodley A, Woodward Davis A, Leav B, Miller J, Schoemaker K, Vandebosch A, Sadoff J, Woo W, Cho I, Dunkle LM, Li S, van der Laan L, Gilbert PB, Follmann D, Jaynes H, Kublin JG, Baden LR, Goepfert P, Kotloff K, Gay CL, Falsey AR, El Sahly HM, Sobieszczyk ME, Huang Y, Neuzil KM, Corey L, Grinsztejn B, Gray G, Rouphael N, Luedtke A; COVID-19 Prevention Network CoVPN. Vaccine. 2023 Jul 25;41(33):4899-4906. doi: 10.1016/j.vaccine.2023.06.066. Epub 2023 Jun 23. PMID: 37385888

Surveillance of Neisseria meningitidis carriage four years after menACWY **vaccine** implementation in the Netherlands reveals decline in **vaccine**-type and rise in genogroup e circulation.
Miellet WR, Pluister G, Sikking M, Tappel M, Karczewski J, Visser LJ, Bosch T, Trzciński K, Mariman R. Vaccine. 2023 Jul 31;41(34):4927-4932. doi: 10.1016/j.vaccine.2023.06.078. Epub 2023 Jul 7. PMID: 37423800

Immunologic response and seroconversion following third-dose COVID-19 **vaccination** in solid organ transplant recipients: A meta-analysis.
Suteja RC, Salim A, Suryanov IPD, Tirtayasa PMW, Duarsa GWK. Transpl Immunol. 2023 Jul 24:101902. doi: 10.1016/j.trim.2023.101902. Online ahead of print. PMID: 37494981

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma.
Gallus M, Kwok D, Lakshmanachetty S, Yamamichi A, Okada H. Cancers (Basel). 2023 Jul 22;15(14):3726. doi: 10.3390/cancers15143726. PMID: 37509387

T cell fate decisions during memory cell generation with aging.
Sturmlechner I, Jain A, Mu Y, Weyand CM, Goronzy JJ. Semin Immunol. 2023 Jul 24;69:101800. doi: 10.1016/j.smim.2023.101800. Online ahead of print. PMID: 37494738

Epidemiology-driven approaches to surveillance in HPAI-**vaccinated** poultry flocks aiming to demonstrate freedom from circulating HPAIV.
Harder T, de Wit S, Gonzales JL, Ho JHP, Mulatti P, Prajitno TY, Stegeman A. Biologicals. 2023 Jul 24;83:101694. doi: 10.1016/j.biologicals.2023.101694. Online ahead of print. PMID: 37494751

Nanovaccine-based strategies for lymph node targeted delivery and imaging in tumor immunotherapy.
He A, Li X, Dai Z, Li Q, Zhang Y, Ding M, Wen ZF, Mou Y, Dong H. J Nanobiotechnology. 2023 Jul 23;21(1):236. doi: 10.1186/s12951-023-01989-x. PMID: 37482608

Do multiple subsets of CD11c$^+$ B cells exist? You (T)-Bet!
Tangye SG. J Allergy Clin Immunol. 2023 Jul 24:S0091-6749(23)00924-7. doi: 10.1016/j.jaci.2023.07.004. Online ahead of print. PMID: 37495119

Sociodemographic and psychosocial factors associated with **vaccine** hesitancy - results from a longitudinal study in Singapore.
Subramaniam M, Abdin E, Shafie S, Shahwan S, Zhang Y, Satghare P, Devi F, Lun P, Yuxuan Ni M, Chong SA. Hum Vaccin Immunother. 2023 Aug 1;19(2):2235964. doi: 10.1080/21645515.2023.2235964. Epub 2023 Jul 25. PMID: 37489273

A Multi-epitope **Vaccine** Candidate Against Bolivian Hemorrhagic fever Caused by Machupo Virus.
Ali Z, Cardoza JV, Basak S, Narsaria U, Bhattacharjee S, G UM, Isaac SP, Franca TCC, LaPlante SR, George SS. Appl Biochem Biotechnol. 2023 Jul 22. doi: 10.1007/s12010-023-04604-9. Online ahead of print. PMID: 37479961

Effectiveness of hospital-based strategies for improving childhood immunization coverage: A systematic review.
Reifferscheid L, Kiely MS, Lin MSN, Libon J, Kennedy M, MacDonald SE. Vaccine. 2023 Jul 25:S0264-410X(23)00857-5. doi: 10.1016/j.vaccine.2023.07.036. Online ahead of print. PMID: 37500415

Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.
Berry P, Khanna S. BioDrugs. 2023 Jul 26. doi: 10.1007/s40259-023-00617-2. Online ahead of print. PMID: 37493938

Between nudges and mandates: The drivers of COVID-19 **vaccination** intentions and subsequent uptake in Russia.
Roshchina Y, Rozhkova K, Roshchin S. Vaccine. 2023 Jul 31;41(34):5053-5062. doi: 10.1016/j.vaccine.2023.06.067. Epub 2023 Jul 3. PMID: 37419852

Establishing SARS-CoV-2 membrane protein-specific antibodies as a valuable serological target via high-content microscopy.
Williams DM, Hornsby HR, Shehata OM, Brown R, Gallis M, Meardon N, Newman TAH, Plowright M, Zafred D, Shun-Shion ASM, Hodder AJ, Bliss D, Metcalfe A, Edgar JR, Gordon DE, Sayers JR, Nicklin MJ, Carroll M; PITCH Consortium; Collini PJ, Brown S, de Silva TI, Peden AA. iScience. 2023 Jul 21;26(7):107056. doi: 10.1016/j.isci.2023.107056. Epub 2023 Jun 7. PMID: 37346049

SARS-Cov-2 mRNA **Vaccine**-Induced Immune Responses in Rheumatoid Arthritis.
Limoges MA, Lortie A, Demontier É, Quenum AJI, Lessard F, Drouin Z, Carrier N, Mbous Nguimbus L, Beaulieu MC, Boire G, Piché A, Allard-Chamard H, Ramanathan S, Roux S. J Leukoc Biol. 2023 Jul 21:qiad086. doi: 10.1093/jleuko/qiad086. Online ahead of print. PMID: 37478373

Public perception of COVID-19 **vaccines** through analysis of Twitter content and users.
Saleh SN, McDonald SA, Basit MA, Kumar S, Arasaratnam RJ, Perl TM, Lehmann CU, Medford RJ. Vaccine. 2023 Jul 25;41(33):4844-4853. doi: 10.1016/j.vaccine.2023.06.058. Epub 2023 Jun 23. PMID: 37385887

Novel insights into the management of rheumatoid arthritis: one year in review 2023.
Garaffoni C, Adinolfi A, Bortoluzzi A, Filippou G, Giollo A, Sakellariou G, Silvagni E, Sirotti S, Ughi N, Scirè CA. Clin Exp Rheumatol. 2023 Jul 24. doi: 10.55563/clinexprheumatol/nat8nl. Online ahead of print. PMID: 37497719

A Safe and Efficient Double-Gene-Deleted Live Attenuated Immersion **Vaccine** to Prevent the Disease Caused by the Infectious Spleen and Kidney Necrosis Virus.
Zeng R, Pan W, Lin Y, Liang M, Fu J, Weng S, He J, Guo C. J Virol. 2023 Jul 27;97(7):e0085723. doi: 10.1128/jvi.00857-23. Epub 2023 Jun 29. PMID: 37382530

Cholera and COVID-19 pandemic prevention in multiple hotspot districts of Uganda: **vaccine** coverage, adverse events following immunization and WASH conditions survey.
Bwire G, Kisakye A, Amulen E, Bwanika JB, Badebye J, Aanyu C, Nakirya BD, Okello A, Okello SA, Bukenya JN, Orach CG. BMC Infect Dis. 2023 Jul 21;23(1):487. doi: 10.1186/s12879-023-08462-y. PMID: 37479986

Live IBD **vaccine** exacerbates disease and pathological effects of Asian lineage H9N2 LPAIV in chickens.
Khalil NW, Elshorbagy MA, Elboraay EM, Helal AM. Avian Pathol. 2023 Jul 26:1-11. doi: 10.1080/03079457.2023.2236994. Online ahead of print. PMID: 37439655

Older adults' acceptance of the COVID-19 **vaccine**: Application of the health belief model.
Ibrahim FM, Fadila DE, Elmawla DAEA. Nurs Open. 2023 Jul 23. doi: 10.1002/nop2.1954. Online ahead of print. PMID: 37485792

Characterization of immune responses to two and three doses of the adenoviral vectored **vaccine** ChAdOx1 nCov-19 and the whole virion inactivated **vaccine** BBV152 in a mix-and-match study in India.
Chaudhary A, Madhavan R, Babji S, Raju R, Syed C, Kumar A, Saravanan P, Sharon Nikitha O, Leander Xavier JV, David Chelladurai JS, Deborah AA, George A, Kang G, Rose W. Vaccine. 2023 Jul 25;41(33):4808-4822. doi: 10.1016/j.vaccine.2023.06.059. Epub 2023 Jun 23. PMID: 37357073

Effects of a complex probiotic preparation, Fengqiang Shengtai and coccidiosis **vaccine** on the performance and intestinal microbiota of broilers challenged with Eimeria spp.
Cai H, Luo S, Liu Q, Zhou Q, Yan Z, Kang Z, Liao S, Li J, Lv M, Lin X, Hu J, Yu S, Zhang J, Qi N, Sun M. Parasit Vectors. 2023 Jul 27;16(1):253. doi: 10.1186/s13071-023-05855-5. PMID: 37501177

PD-1/PD-L1 blockade restores tumor-induced COVID-19 **vaccine** bluntness.
Chen X, Lin Y, Yue S, Yang Y, Yang X, He J, Gao L, Li Z, Hu L, Tang J, Wang Y, Tian Q, Hao Y, Xu L, Huang Q, Cao Y, Ye L. Vaccine. 2023 Jul 31;41(34):4986-4995. doi: 10.1016/j.vaccine.2023.06.053. Epub 2023 Jun 20. PMID: 37400286

Optimizing needle length and site choice for adult immunization.
Mardourian M, Hao KA, Wiggins W, Arias J, King JJ, Wright TW, Wright JO. Vaccine. 2023 Jul 25;41(33):4836-4843. doi: 10.1016/j.vaccine.2023.06.031. Epub 2023 Jun 24. PMID: 37365058

COVID-19: Variants, Immunity, and Therapeutics for Non-Hospitalized Patients.
Lee CYS, Suzuki JB. Biomedicines. 2023 Jul 21;11(7):2055. doi: 10.3390/biomedicines11072055. PMID: 37509694

Generation and characterization of a genetically modified live rabies **vaccine** strain with attenuating mutations in multiple viral proteins and evaluation of its potency in dogs.
Izumi F, Miyamoto S, Masatani T, Sasaki M, Kawakami K, Takahashi T, Fujiwara T, Fujii Y, Okajima M, Nishiyama S, Sawa H, Sugiyama M, Ito N. Vaccine. 2023 Jul 25;41(33):4907-4917. doi: 10.1016/j.vaccine.2023.06.076. Epub 2023 Jul 1. PMID: 37400284

Preclinical evaluation of PHH-1V **vaccine** candidate against SARS-CoV-2 in non-human primates.
Prenafeta A, Bech-Sàbat G, Moros A, Barreiro A, Fernández A, Cañete M, Roca M, González-González L, Garriga C, Confais J, Toussenot M, Contamin H, Pizzorno A, Rosa-Calatrava M, Pradenas E, Marfil S, Blanco J, Rica PC, Sisteré-Oró M, Meyerhans A, Lorca C, Segalés J, Prat T, March R, Ferrer L. iScience. 2023 Jun 28;26(7):107224. doi: 10.1016/j.isci.2023.107224. eCollection 2023 Jul 21. PMID: 37502366

Timely Prenatal and Infant Pertussis **Vaccine** Uptake in an Integrated Health System.
Becerra-Culqui T, Ackerson B, Tseng HF. J Racial Ethn Health Disparities. 2023 Jul 25. doi: 10.1007/s40615-023-01711-5. Online ahead of print. PMID: 37490209

Demographic Disparities in Mpox **Vaccination** Series Completion, by Route of **Vaccine** Administration - California, August 9, 2022-March 31, 2023.
Salih T, Vance J, Quint J, Meza B, McNitt L, Lincoln WU, Schechter R. MMWR Morb Mortal Wkly Rep. 2023 Jul 28;72(30):827-832. doi: 10.15585/mmwr.mm7230a4. PMID: 37498796

COVID-19 **vaccine** safety during pregnancy and breastfeeding in women with autoimmune diseases: results from the COVAD study.
Andreoli L, Lini D, Schreiber K, Parodis I, Sen P, Naveen R, Day J, Joshi M, Jagtap K, Nune A, Nikiphorou E, Agarwal V, Saha S, Tan AL, Shinjo SK, Ziade N, Velikova T, Milchert M, Edgar Gracia-Ramos A, Cavagna L, Kuwana M, Knitza J, Makol A, Patel A, Pauling JD, Wincup C, Barman B, Zamora Tehozol EA, Serrano JR, García-De La Torre I, Colunga-Pedraza IJ, Merayo-Chalico J, Chibuzo OC, Katchamart W, Akarawatcharangura Goo P, Shumnalieva R, Chen YM, Hoff LS, El Kibbi L, Halabi H, Vaidya B, Sazliyana Shaharir S, Hasan ATMT, Dey D, Gutiérrez CET, Caballero-Uribe CV, Lilleker JB, Salim B, Gheita T, Chatterjee T, Saavedra MA, Distler O; COVAD study group; Chinoy GAH, Agarwal V, Aggarwal R, Gupta L. Rheumatology (Oxford). 2023 Jul 28:kead382. doi: 10.1093/rheumatology/kead382. Online ahead of print. PMID: 37505460

Evaluating the Impact of Statin Use on Influenza **Vaccine** Effectiveness and Influenza Infection in Older Adults.
Chung H, Campitelli MA, Buchan SA, Campigotto A, Chen B, Crowcroft NS, Dubey V, Gubbay JB, Karnauchow T, Katz K, McGeer AJ, McNally JD, Mubareka S, Murti M, Richardson DC, Rosella LC,

Schwartz KL, Smieja M, Zahariadis G, Kwong JC. Clin Infect Dis. 2023 Jul 26;77(2):303-311. doi: 10.1093/cid/ciad148. PMID: 36942534

Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus **vaccine** in infants 6-7 months of age: a phase 1/2 randomized trial.
Sáez-Llorens X, Norero X, Mussi-Pinhata MM, Luciani K, Salamanca de la Cueva I, Díez-Domingo J, Lopez-Medina E, Epalza C, Brzostek J, Szymański H, Boucher FD, Cetin BS, De Leon T, Cagri Dinleyici E, Marín Gabriel MÁ, Ince T, Macias-Parra M, Langley JM, Martinón-Torres F, Rämet M, Kuchar E, Pinto J, Puthanakit T, Baquero-Artigao F, Castelli Gattinara G, Merino Arribas JM, Ramos Amador JT, Szenborn L, Tapiero B, Anderson EJ, Campbell JD, Faust SN, Nikic V, Zhou Y, Pu W, Friel D, Dieussaert I, Gonzalez Lopez A, McPhee R, Stoszek SK, Vanhoutte N. J Infect Dis. 2023 Jul 21:jiad271. doi: 10.1093/infdis/jiad271. Online ahead of print. PMID: 37477875

Public opinion on COVID-19 **vaccine** prioritization in Bangladesh: Who gets the **vaccine** and whom do you leave out?
Biswas RK, Afiaz A, Huq S, Farzana M, Kabir E. Vaccine. 2023 Jul 31;41(34):5018-5028. doi: 10.1016/j.vaccine.2023.06.050. Epub 2023 Jun 16. PMID: 37407404

Macrophage-Based Therapeutic Strategies in Hematologic Malignancies.
Khalili S, Zeinali F, Moghadam Fard A, Taha SR, Fazlollahpour Naghibi A, Bagheri K, Shariat Zadeh M, Eslami Y, Fattah K, Asadimanesh N, Azarimatin A, Khalesi B, Almasi F, Payandeh Z. Cancers (Basel). 2023 Jul 22;15(14):3722. doi: 10.3390/cancers15143722. PMID: 37509382

Navigation of Knowledge: the Impact of COVID-19 on Pregnancy-a Bibliometric Analysis.
Wu J, Cao B, Liao J, Li Y, Lu G, Gong F, Lin G, Zhao M. Reprod Sci. 2023 Jul 24. doi: 10.1007/s43032-023-01312-x. Online ahead of print. PMID: 37488404

Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-**vaccinated** SARS survivor.
Chia WN, Tan CW, Tan AWK, Young B, Starr TN, Lopez E, Fibriansah G, Barr J, Cheng S, Yeoh AY, Yap WC, Lim BL, Ng TS, Sia WR, Zhu F, Chen S, Zhang J, Kwek MSS, Greaney AJ, Chen M, Au GG, Paradkar PN, Peiris M, Chung AW, Bloom JD, Lye D, Lok S, Wang LF. Sci Adv. 2023 Jul 28;9(30):eade3470. doi: 10.1126/sciadv.ade3470. Epub 2023 Jul 26. PMID: 37494438

Liquid Metal Nanoplatform Based Autologous Cancer **Vaccines**.
Wang D, Yu Z, Qi Y, Hu K, Zhou T, Liu J, Rao W. ACS Nano. 2023 Jul 25;17(14):13278-13295. doi: 10.1021/acsnano.3c00941. Epub 2023 May 30. PMID: 37253081

Patterns of testing in the extensive Danish national SARS-CoV-2 test set-up.
Gram MA, Steenhard N, Cohen AS, Vangsted AM, Mølbak K, Jensen TG, Hansen CH, Ethelberg S. PLoS One. 2023 Jul 25;18(7):e0281972. doi: 10.1371/journal.pone.0281972. eCollection 2023. PMID: 37490451

Old and new aspects of influenza.
Sanz-Muñoz I, Eiros JM. Med Clin (Barc). 2023 Jul 28:S0025-7753(23)00363-9. doi: 10.1016/j.medcli.2023.06.004. Online ahead of print. PMID: 37517930

Inoculating Against Anti-**Vaccination** Conspiracies.
Banas JA, Bessarabova E, Penkauskas MC, Talbert N. Health Commun. 2023 Jul 25:1-9. doi: 10.1080/10410236.2023.2235733. Online ahead of print. PMID: 37489099

Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a **vaccine** to reduce malaria transmission.
Rausch KM, Barnafo EK, Lambert LE, Muratova O, Gorres JP, Anderson C, Narum DL, Wu Y, Morrison RD, Zaidi I, Duffy PE. iScience. 2023 Jun 22;26(7):107192. doi: 10.1016/j.isci.2023.107192. eCollection 2023 Jul 21. PMID: 37485364

A TLR7/8 agonist increases efficacy of anti-fentanyl **vaccines** in rodent and porcine models.
Crouse B, Miller SM, Muelken P, Hicks L, Vigliaturo JR, Marker CL, Guedes AGP, Pentel PR, Evans JT, LeSage MG, Pravetoni M. NPJ Vaccines. 2023 Jul 24;8(1):107. doi: 10.1038/s41541-023-00697-9. PMID: 37488109

Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants.
Haycroft ER, Davis SK, Ramanathan P, Lopez E, Purcell RA, Tan LL, Pymm P, Wines BD, Hogarth PM, Wheatley AK, Juno JA, Redmond SJ, Gherardin NA, Godfrey DI, Tham WH, Selva KJ, Kent SJ, Chung AW. Med Microbiol Immunol. 2023 Aug;212(4):291-305. doi: 10.1007/s00430-023-00773-w. Epub 2023 Jul 21. PMID: 37477828

Short-Chain Fatty Acids Alleviate Vancomycin-Caused Humoral Immunity Attenuation in Rabies-**Vaccinated** Mice by Promoting the Generation of Plasma Cells via Akt-mTOR Pathway.
Wu Q, Zhang Y, Wang C, Hou Y, He W, Wang L, Xiong J, Ren Z, Wang H, Sui B, Zhou D, Zhou M, Fu ZF, Zhao L. J Virol. 2023 Jul 27;97(7):e0065623. doi: 10.1128/jvi.00656-23. Epub 2023 Jun 20. PMID: 37338411

Attitudes Toward COVID-19 **Vaccination** Among Pregnant Persons in Urban Hospital-Affiliated Practices: Exploring Themes in **Vaccine** Hesitancy.
Gibson A, Rand C, Olson-Chen C. Matern Child Health J. 2023 Jul 24. doi: 10.1007/s10995-023-03752-y. Online ahead of print. PMID: 37486448

Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies.
Wolff ASB, Hansen L, Grytaas MA, Oftedal BE, Breivik L, Zhou F, Hufthammer KO, Sjøgren T, Olofsson JS, Trieu MC, Meager A, Jørgensen AP, Lima K, Greve-Isdahl Mohn K, Langeland N, Cox RJ, Husebye ES. iScience. 2023 Jul 21;26(7):107084. doi: 10.1016/j.isci.2023.107084. Epub 2023 Jun 9. PMID: 37346050

Humoral and cellular immune responses in sheep following administration of different doses of an inactivated phase I **vaccine** against Coxiella burnetii.
Bauer BU, Schwecht KM, Jahnke R, Matthiesen S, Ganter M, Knittler MR. Vaccine. 2023 Jul 25;41(33):4798-4807. doi: 10.1016/j.vaccine.2023.06.061. Epub 2023 Jun 23. PMID: 37357077

Development of toxin-antitoxin self-destructive bacteria, aimed for salmonella **vaccination**.

Gruzdev N, Pitcovski J, Katz C, Ruimi N, Eliahu D, Noach C, Rosenzweig E, Finger A, Shahar E. Vaccine. 2023 Jul 25;41(33):4918-4925. doi: 10.1016/j.vaccine.2023.06.074. Epub 2023 Jul 1. PMID: 37400285

Designing a multi-epitopes subunit **vaccine** against human herpes virus 6A based on molecular dynamics and immune stimulation.
Suleman M, Khan SH, Rashid F, Khan A, Hussain Z, Zaman N, Rehman SU, Zhai J, Xue M, Zheng C. Int J Biol Macromol. 2023 Jul 31;244:125068. doi: 10.1016/j.ijbiomac.2023.125068. Epub 2023 May 26. PMID: 37245745

Genomic epidemiology and multilevel genome typing of *Bordetella pertussis*.
Payne M, Xu Z, Hu D, Kaur S, Octavia S, Sintchenko V, Lan R. Emerg Microbes Infect. 2023 Jul 24:2239945. doi: 10.1080/22221751.2023.2239945. Online ahead of print. PMID: 37483082

Guest Editorial: The inner immune voice: Can we explicitly sense antibody response to Covid-19 **vaccination**?
Lasselin J, Schedlowski M. Biol Psychol. 2023 Jul 21:108638. doi: 10.1016/j.biopsycho.2023.108638. Online ahead of print. PMID: 37482460

BCGitis with aortoiliac aneurysm involvement: Report of two cases and review of the literature.
Raíces Francisco N, Suárez Gil R, Ayuso García B, Romay Lema E, Rivas Domínguez OM, Rodríguez Ameijeiras E, Besteiro Balado Y, Pérez López A, Rabuñal Rey R. Enferm Infecc Microbiol Clin (Engl Ed). 2023 Jul 22:S2529-993X(23)00201-0. doi: 10.1016/j.eimce.2023.07.003. Online ahead of print. PMID: 37487765

Bivalent mRNA **vaccines** against three SARS-CoV-2 variants mediated by new ionizable lipid nanoparticles.
Wang J, Zhang Y, Dong S, Zha W, Liu C, Wang Y, Jiang Y, Xing H, Li X. Int J Pharm. 2023 Jul 25;642:123155. doi: 10.1016/j.ijpharm.2023.123155. Epub 2023 Jul 2. PMID: 37402442

Evaluation of the immunoprotective effects of eight recombinant proteins from Baylisascaris schroederi in mice model.
Xiong L, Chen L, Chen Y, Shen N, Hua R, Yang G. Parasit Vectors. 2023 Jul 28;16(1):254. doi: 10.1186/s13071-023-05886-y. PMID: 37501169

An Intranasal Multivalent Epitope-Based Nanoparticle **Vaccine** Confers Broad Protection against Divergent Influenza Viruses.
Pan J, Wang Q, Qi M, Chen J, Wu X, Zhang X, Li W, Zhang XE, Cui Z. ACS Nano. 2023 Jul 25;17(14):13474-13487. doi: 10.1021/acsnano.3c01829. Epub 2023 Jul 3. PMID: 37395606

Vaccination After SARS-CoV-2 Infection and Post-COVID-19 Condition.
Yang C, Lapp L, Tebbutt SJ. JAMA Intern Med. 2023 Jul 24. doi: 10.1001/jamainternmed.2023.3033. Online ahead of print. PMID: 37486686

Impacts of routine varicella **vaccination** program and COVID-19 pandemic on varicella and herpes zoster incidence and health resource use among children in Japan.

Uda K, Okubo Y, Tsuge M, Tsukahara H, Miyairi I. Vaccine. 2023 Jul 31;41(34):4958-4966. doi: 10.1016/j.vaccine.2023.06.054. Epub 2023 Jun 19. PMID: 37400282

Tracking B cell responses to the SARS-CoV-2 mRNA-1273 **vaccine**.
Lopes de Assis F, Hoehn KB, Zhang X, Kardava L, Smith CD, El Merhebi O, Buckner CM, Trihemasava K, Wang W, Seamon CA, Chen V, Schaughency P, Cheung F, Martins AJ, Chiang CI, Li Y, Tsang JS, Chun TW, Kleinstein SH, Moir S. Cell Rep. 2023 Jul 25;42(7):112780. doi: 10.1016/j.celrep.2023.112780. Epub 2023 Jul 12. PMID: 37440409

COVID-19 Epidemiology during Delta Variant Dominance Period in 45 High-Income Countries, 2020-2021.
Atherstone CJ, Guagliardo SAJ, Hawksworth A, O'Laughlin K, Wong K, Sloan ML, Henao O, Rao CY, McElroy PD, Bennett SD. Emerg Infect Dis. 2023 Jul 26;29(9). doi: 10.3201/eid2909.230142. Online ahead of print. PMID: 37494699

Vaccination Mandates-An Old Public Health Tool Faces New Challenges.
Gostin LO, Reiss D, Mello MM. JAMA. 2023 Jul 24. doi: 10.1001/jama.2023.11059. Online ahead of print. PMID: 37486681

Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy.
Reynolds G, Hall VG, Teh BW. Transpl Infect Dis. 2023 Jul 29:e14109. doi: 10.1111/tid.14109. Online ahead of print. PMID: 37515788

The doctor knows or the evidence shows: An online survey experiment testing the effects of source trust, pro-**vaccine** evidence, and dual-processing in expert messages recommending child COVID-19 **vaccination** to parents.
Kikut AI. PLoS One. 2023 Jul 21;18(7):e0288272. doi: 10.1371/journal.pone.0288272. eCollection 2023. PMID: 37478116

Peptide **Vaccines** as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape.
Lekshmy M, Dhanya CR, Smrithi JS, Sindhurani JA, Vandanamthadathil JJ, Veettil JT, Anila L, Lathakumari VS, Nayar AM, Madhavan M. Pharmaceuticals (Basel). 2023 Jul 24;16(7):1054. doi: 10.3390/ph16071054. PMID: 37513965

COVID-19 **vaccine** uptake before and after a **vaccine** mandate at a major academic hospital: Trends by race/ethnicity and level of patient contact.
Green-McKenzie J, Shofer FS, Kruse G, Momplaisir F, Brennan PJ, Kuter BJ. Vaccine. 2023 Jul 28:S0264-410X(23)00853-8. doi: 10.1016/j.vaccine.2023.07.032. Online ahead of print. PMID: 37517911

Longitudinal study of antimicrobial use patterns, **vaccination** and disease prevalence in British sheep flocks.
Davies PL, Hyde RM, Lovatt FM. Vet Rec. 2023 Jul 22;193(2):e2786. doi: 10.1002/vetr.2786. Epub 2023 Mar 20. PMID: 36938988

Navigating paediatric virology through the COVID-19 era (Review).
Mammas IN, Drysdale SB, Charalampous C, Koletsi P, Papatheodoropoulou A, Koutsaftiki C, Sergentanis T, Merakou K, Kornarou H, Papaioannou G, Kramvis A, Greenough A, Theodoridou M, Spandidos DA. Int J Mol Med. 2023 Sep;52(3):83. doi: 10.3892/ijmm.2023.5286. Epub 2023 Jul 28. PMID: 37503745

SuPAR mediates viral response proteinuria by rapidly changing podocyte function.
Wei C, Datta PK, Siegerist F, Li J, Yashwanth S, Koh KH, Kriho NW, Ismail A, Luo S, Fischer T, Amber KT, Cimbaluk D, Landay A, Endlich N, Rappaport J; Michigan Medicine COVID−19 Investigators; Hayek SS, Reiser J. Nat Commun. 2023 Jul 21;14(1):4414. doi: 10.1038/s41467-023-40165-5. PMID: 37479685

Genomic and geographical structure of human cytomegalovirus.
Charles OJ, Venturini C, Gantt S, Atkinson C, Griffiths P, Goldstein RA, Breuer J. Proc Natl Acad Sci U S A. 2023 Jul 25;120(30):e2221797120. doi: 10.1073/pnas.2221797120. Epub 2023 Jul 17. PMID: 37459519

Evaluating the effectiveness and cost-effectiveness of free influenza **vaccination** policy for older adults in Yinzhou, China: Study protocol of a real-world analyses.
Zhang X, Shen P, Liu J, Ji X, Su K, Hu R, Chen C, Fang H, Jin X, Lin H, Sun Y, Yan LL. Vaccine. 2023 Jul 31;41(34):5045-5052. doi: 10.1016/j.vaccine.2023.06.087. Epub 2023 Jul 5. PMID: 37419850

Comparative effectiveness of heterologous third dose **vaccine** schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses.
Andersson NW, Thiesson EM, Baum U, Pihlström N, Starrfelt J, Faksová K, Poukka E, Lund LC, Hansen CH, Aakjær M, Kjær J, Cohet C, Goossens M, Andersen M, Hallas J, Meijerink H, Ljung R, Hviid A. BMJ. 2023 Jul 24;382:e074325. doi: 10.1136/bmj-2022-074325. PMID: 37487623

Designing Selenium Nanoadjuvant as Universal Agent for Live-Killed Virus-Based **Vaccine**.
Deng B, He X, Wang D, Wang Y, Jiang Y, Chen T, Xu L. Small Methods. 2023 Jul 25:e2300293. doi: 10.1002/smtd.202300293. Online ahead of print. PMID: 37491791

Advances in Chemical Probing Concepts for Chemical Biology Applications.
Arimondo PB, Essig S, Schopfer U, Rufer A. Chembiochem. 2023 Jul 27:e202300319. doi: 10.1002/cbic.202300319. Online ahead of print. PMID: 37501334

Adenovirus vector produced Zika virus-like particles induce a long-lived neutralising antibody response in mice.
Carrera J, Aktepe TE, Earnest L, Christiansen D, Wheatley AK, Tan HX, Chung AW, Collett S, McPherson K, Torresi J, Mackenzie JM, Simmons CP. Vaccine. 2023 Jul 25;41(33):4888-4898. doi: 10.1016/j.vaccine.2023.06.068. Epub 2023 Jun 28. PMID: 37391311

Acceptance of and hesitancy about COVID-19 **vaccination** among nursing students in clinical practice.
Kim S, Lee J, Yang H, Kim H. PLoS One. 2023 Jul 26;18(7):e0286640. doi: 10.1371/journal.pone.0286640. eCollection 2023. PMID: 37494378

Developments in oral enterotoxigenic Escherichia coli **vaccines**.
Svennerholm AM, Lundgren A. Curr Opin Immunol. 2023 Jul 29;84:102372. doi: 10.1016/j.coi.2023.102372. Online ahead of print. PMID: 37523966

Inactivated SARS-CoV-2 booster **vaccine** enhanced immune responses in patients with chronic liver diseases.
Liu Y, Lu J, Zhan H, Yuan W, Li X, Kang H, Li H, Chen Y, Cheng L, Sun X, Zheng H, Wang W, Dai E, Li Y. Virol Sin. 2023 Jul 22:S1995-820X(23)00085-8. doi: 10.1016/j.virs.2023.07.005. Online ahead of print. PMID: 37487943

Impact of peripheral mitochondrial DNA level on immune response after COVID-19 **vaccination**.
Ikezaki H, Nomura H, Shimono N. iScience. 2023 Jul 21;26(7):107094. doi: 10.1016/j.isci.2023.107094. Epub 2023 Jun 10. PMID: 37351502

Estimating the full health and economic benefits of current and future influenza **vaccines**.
Lafond KE, Gharpure R, Dugan VG, Azziz-Baumgartner E. BMC Med. 2023 Jul 27;21(1):273. doi: 10.1186/s12916-023-02995-4. PMID: 37501176

Immunization with lytic polysaccharide monooxygenase CbpD induces protective immunity against *Pseudomonas aeruginosa* pneumonia.
Askarian F, Tsai CM, Cordara G, Zurich RH, Bjånes E, Golten O, Vinther Sørensen H, Kousha A, Meier A, Chikwati E, Bruun JA, Ludviksen JA, Choudhury B, Trieu D, Davis S, Edvardsen PKT, Mollnes TE, Liu GY, Krengel U, Conrad DJ, Vaaje-Kolstad G, Nizet V. Proc Natl Acad Sci U S A. 2023 Jul 25;120(30):e2301538120. doi: 10.1073/pnas.2301538120. Epub 2023 Jul 17. PMID: 37459522

Safety of BA.4-5 or BA.1 bivalent mRNA booster **vaccines**: nationwide cohort study.
Andersson NW, Thiesson EM, Hansen JV, Hviid A. BMJ. 2023 Jul 25;382:e075015. doi: 10.1136/bmj-2023-075015. PMID: 37491031

Henoch-schonlein purpura following exposure to SARS-CoV2 **vaccine** or infection: a systematic review and a case report.
Di Vincenzo F, Ennas S, Pizzoferrato M, Bibbò S, Porcari S, Ianiro G, Cammarota G. Intern Emerg Med. 2023 Jul 27. doi: 10.1007/s11739-023-03366-w. Online ahead of print. PMID: 37500944

Antigen/Adjuvant-Displaying Enveloped Viral Replica as a Self-Adjuvanting Anti-Breast-Cancer **Vaccine** Candidate.
Ito K, Furukawa H, Inaba H, Ohshima S, Kametani Y, Maeki M, Tokeshi M, Huang X, Kabayama K, Manabe Y, Fukase K, Matsuura K. J Am Chem Soc. 2023 Jul 26;145(29):15838-15847. doi: 10.1021/jacs.3c02679. Epub 2023 Jun 21. PMID: 37344812

Understanding factors influencing healthcare workers' intention towards the COVID-19 **vaccine**.
Xie Z, Qalati SA, Limón MLS, Sulaiman MABA, Qureshi NA. PLoS One. 2023 Jul 27;18(7):e0286794. doi: 10.1371/journal.pone.0286794. eCollection 2023. PMID: 37498835

Compulsory **vaccination** protects autonomy.
Gooch G, Graber A. J Med Ethics. 2023 Jul 28:jme-2023-109426. doi: 10.1136/jme-2023-109426. Online ahead of print. PMID: 37507220

Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster **vaccines** among adults aged ≥50 years in Nordic countries: nationwide cohort study.

Andersson NW, Thiesson EM, Baum U, Pihlström N, Starrfelt J, Faksová K, Poukka E, Meijerink H, Ljung R, Hviid A. BMJ. 2023 Jul 25;382:e075286. doi: 10.1136/bmj-2022-075286. PMID: 37491022

Association between duration of SARS-CoV-2 positivity and long COVID.
Pozzi C, Sarti R, Levi R, Mollura M, Azzolini E, Barbieri R, Mantovani A, Rescigno M. Clin Infect Dis. 2023 Jul 22:ciad434. doi: 10.1093/cid/ciad434. Online ahead of print. PMID: 37480344

Canada's role in covid-19 global **vaccine** equity failures.
Houston AR, Liu J, Habibi R, Murthy S, Pai M. BMJ. 2023 Jul 24;382:e075149. doi: 10.1136/bmj-2023-075149. PMID: 37487600

Streamlined and on-demand preparation of mRNA products on a universal integrated platform.
Wei H, Rong Z, Liu L, Sang Y, Yang J, Wang S. Microsyst Nanoeng. 2023 Jul 24;9:97. doi: 10.1038/s41378-023-00538-8. eCollection 2023. PMID: 37492616

Induced protection from a CCHFV-M DNA **vaccine** requires $CD8^+$ T cells.
Golden JW, Fitzpatrick CJ, Suschak JJ, Clements TL, Ricks KM, Sanchez-Lockhart M, Garrison AR. Virus Res. 2023 Jul 24;334:199173. doi: 10.1016/j.virusres.2023.199173. Online ahead of print. PMID: 37459918

The unique COVID-19 experience in Western Australia: lessons learnt.
House CL, Rawlins M, Dyer J, Boan P, Musk M. Intern Med J. 2023 Jul 26. doi: 10.1111/imj.16172. Online ahead of print. PMID: 37493390

Preschool-located influenza **vaccination** and influenza-like illness surveillance: an Italian pilot experience.
Amendola A, Borghi E, Bianchi S, Gori M, Fappani C, Barcellini L, Forlanini F, Garancini N, Nava C, Mari A, Sala A, Gasparini C, Ottaviano E, Colzani D, Biganzoli EM, Tanzi E, Zuccotti GV. Ital J Pediatr. 2023 Jul 21;49(1):91. doi: 10.1186/s13052-023-01481-0. PMID: 37480047

Marketing authorisations for unmet medical needs: A critical appraisal of regulatory pathways in the European Union.
Manellari S, Musazzi UM, Rocco P, Minghetti P. Int J Pharm. 2023 Jul 25;642:123193. doi: 10.1016/j.ijpharm.2023.123193. Epub 2023 Jun 30. PMID: 37394157

Humoral immune response following the inactivated quadrivalent influenza **vaccination** among HIV-infected and HIV-uninfected adults.
Liu Z, Pang C, Deng Y, Guo C, Li J, Li Y, Xin R, Li X, Xu C, Huang C, Lu H, Li J. Vaccine. 2023 Jul 31;41(34):4978-4985. doi: 10.1016/j.vaccine.2023.05.055. Epub 2023 Jun 30. PMID: 37394372

Low prevalence of current and past SARS-CoV-2 infections among visitors and staff members of homelessness services in Amsterdam at the end of the second wave of infections in the Netherlands.
Generaal E, van Santen DKD, Campman SL, Booij MJ, Price D, Buster M, van Dijk C, Boyd A, Bruisten SM, van Dam AP, van der Lubben M, van Duijnhoven YTHP, Prins M. PLoS One. 2023 Jul 25;18(7):e0288610. doi: 10.1371/journal.pone.0288610. eCollection 2023. PMID: 37490469

Quality of routine data for monitoring nutrition and diarrhoea indicators of children under 5 in Mozambique: an ecological study over a 5-year period.
Sambo J, Chicumbe S, de Deus N, Gonçalves L. BMJ Open. 2023 Jul 21;13(7):e073239. doi: 10.1136/bmjopen-2023-073239. PMID: 37479521

Comparison of humoral immune response in heterologous and homologous COVID-19 booster **vaccine** groups using CoronaVac and mRNA-based BNT162b2 **vaccines**.
Atıcı S, Soysal A, Gönüllü E, Aydemir G, Öner N, Alan S, Engin H, Yıldız M, Karaböcüoğlu M. Rev Soc Bras Med Trop. 2023 Jul 24;56:e00462023. doi: 10.1590/0037-8682-0046-2023. eCollection 2023. PMID: 37493731

Measles **vaccination** and reduced child mortality: Prevention of immune amnesia or beneficial non-specific effects of measles **vaccine**?
Benn CS, Aaby P. J Infect. 2023 Jul 22:S0163-4453(23)00382-1. doi: 10.1016/j.jinf.2023.07.010. Online ahead of print. PMID: 37482223

Preparing for Future Pandemics and Public Health Emergencies: An American College of Physicians Policy Position Paper.
Serchen J, Cline K, Mathew S, Hilden D; Health and Public Policy Committee of the American College of Physicians*. Ann Intern Med. 2023 Jul 25. doi: 10.7326/M23-0768. Online ahead of print. PMID: 37487216

Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection.
Lee WS, Tan HX, Reynaldi A, Esterbauer R, Koutsakos M, Nguyen J, Amarasena T, Kent HE, Aggarwal A, Turville SG, Taiaroa G, Kinsella P, Liew KC, Tran T, Williamson DA, Cromer D, Davenport MP, Kent SJ, Juno JA, Khoury DS, Wheatley AK. Sci Adv. 2023 Jul 21;9(29):eadg5301. doi: 10.1126/sciadv.adg5301. Epub 2023 Jul 21. PMID: 37478181

Intramuscular administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infection.
Kim DH, Lee J, Youk S, Jeong JH, Lee DY, Ju HS, Youn HN, Kim JC, Park SB, Park JE, Kim JY, Kim TH, Lee SH, Lee H, Mouhamed Abdallah Amal Abdal L, Lee DH, Park PG, Hong KJ, Song CS. Vaccine. 2023 Jul 25;41(33):4787-4797. doi: 10.1016/j.vaccine.2023.05.071. Epub 2023 Jun 14. PMID: 37355454

Mortality among populations affected by armed conflict in northeast Nigeria, 2016 to 2019.
Checchi F, Jarvis CI, van Zandvoort K, Warsame A. Proc Natl Acad Sci U S A. 2023 Jul 25;120(30):e2217601120. doi: 10.1073/pnas.2217601120. Epub 2023 Jul 19. PMID: 37467271

Phylogenetic analysis and docking study of neuraminidase gene of influenza A/H1N1 viruses circulating in Iran from 2010 to 2019.
Moeini S, Mohebbi A, Farahmand B, Mehrbod P, Fotouhi F. Virus Res. 2023 Jul 26;334:199182. doi: 10.1016/j.virusres.2023.199182. Online ahead of print. PMID: 37490957

Dynamics of anti-RBD (anti-receptor binding domain) levels in diabetes patients following the ChAdOx1 nCoV-19 **vaccine** (AZD1222) in the Thai population.

Sirisreetreerux S, Porntharukchareon T, Dechates B, Rangsrisaeneepitak V, Therawit P, Worawitchawong S, Sornsamdang G, Soonklang K, Tawinprai K. Sci Rep. 2023 Jul 21;13(1):11798. doi: 10.1038/s41598-023-39114-5. PMID: 37479776

Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity.
Jensen JL, Sankhala RS, Dussupt V, Bai H, Hajduczki A, Lal KG, Chang WC, Martinez EJ, Peterson CE, Golub ES, Rees PA, Mendez-Rivera L, Zemil M, Kavusak E, Mayer SV, Wieczorek L, Kannan S, Doranz BJ, Davidson E, Yang ES, Zhang Y, Chen M, Choe M, Wang L, Gromowski GD, Koup RA, Michael NL, Polonis VR, Rolland M, Modjarrad K, Krebs SJ, Joyce MG. J Virol. 2023 Jul 27;97(7):e0159622. doi: 10.1128/jvi.01596-22. Epub 2023 Jul 3. PMID: 37395646

Childhood **vaccine** crusader shares concerns for future.
Cohen J. Science. 2023 Jul 28;381(6656):365. doi: 10.1126/science.adj9567. Epub 2023 Jul 27. PMID: 37499019

Reliability and Comprehensiveness of YouTube Videos About the COVID-19 **Vaccine** in Pregnancy.
Fairchild R, Price M, Craig A, Dotters-Katz SK. Am J Infect Control. 2023 Jul 22:S0196-6553(23)00521-7. doi: 10.1016/j.ajic.2023.07.004. Online ahead of print. PMID: 37487971

Trends and Opportunities: Hepatitis A Virus Infection, Seroprevalence, and **Vaccination** Coverage-United States, 1976-2020.
Hofmeister MG, Yin S, Nelson NP, Weng MK, Gupta N. Public Health Rep. 2023 Jul 21:333549231184007. doi: 10.1177/00333549231184007. Online ahead of print. PMID: 37480244

Estimating the Incidence of First RSV Hospitalization in Children Born in Ontario, Canada.
Buchan SA, Chung H, To T, Daneman N, Guttmann A, Kwong JC, Murti M, Aryal G, Campigotto A, Chakraborty P, Gubbay J, Karnauchow T, Katz K, McGeer AJ, Dayre McNally J, Mubareka S, Richardson D, Richardson SE, Smieja M, Zahariadis G, Deeks SL. J Pediatric Infect Dis Soc. 2023 Jul 31;12(7):421-430. doi: 10.1093/jpids/piad045. PMID: 37335754

Increased innate immune activation induces protective RSV-specific lung-resident memory T cells in neonatal mice.
Malloy AMW, Lu Z, Kehl M, Pena DaMata J, Lau-Kilby AW, Turfkruyer M. Mucosal Immunol. 2023 Jul 21:S1933-0219(23)00047-8. doi: 10.1016/j.mucimm.2023.05.012. Online ahead of print. PMID: 37392972

Sex-based differences in risk of ischaemic stroke or systemic embolism after BNT162b2 or CoronaVac COVID-19 **vaccination** in patients with atrial fibrillation: a self-controlled case series and nested case-control study.
Ye X, Huang C, Yan VKC, Kang W, Fan M, Tsang GKC, Ho CMY, Lip GYH, Yiu KH, Tse HF, Ma T, Qin X, Chui CSL, Lai FTT, Wong CKH, Wan EYF, Li X, Lee CK, Hung IFN, Wong ICK, Chan EWY. Eur Heart J Cardiovasc Pharmacother. 2023 Jul 29;9(5):403-412. doi: 10.1093/ehjcvp/pvad015. PMID: 36918200

Association between SARS-CoV-2 Symptoms, Ct Values, and Serological Response in **Vaccinated** and Unvaccinated Healthcare Personnel.

Farnsworth CW, O'Neil CA, Dalton C, McDonald D, Vogt L, Hock K, Arter O, Wallace MA, Muenks C, Amor M, Alvarado K, Peacock K, Jolani K, Fraser VJ, Burnham CD, Babcock HM, Budge PJ, Kwon JH. J Appl Lab Med. 2023 Jul 21:jfad042. doi: 10.1093/jalm/jfad042. Online ahead of print. PMID: 37478837

Intranasal VLP-RBD **vaccine** adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
Lee KS, Rader NA, Miller-Stump OA, Cooper M, Wong TY, Shahrier Amin M, Barbier M, Bevere JR, Ernst RK, Heath Damron F. Vaccine. 2023 Jul 31;41(34):5003-5017. doi: 10.1016/j.vaccine.2023.06.080. Epub 2023 Jun 28. PMID: 37407405

Activity Relationship of Poly(ethylenimine)-Based Liposomes as Group A *Streptococcus* **Vaccine** Delivery Systems.
Jin S, Zhang J, Nahar UJ, Huang W, Alharbi NA, Shalash AO, Koirala P, Yang J, Kiong JJE, Khalil ZG, Capon RJ, Stephenson RJ, Skwarczynski M, Toth I, Hussein WM. ACS Infect Dis. 2023 Jul 24. doi: 10.1021/acsinfecdis.3c00159. Online ahead of print. PMID: 37489053

Vaccination After SARS-CoV-2 Infection and Post-COVID-19 Condition-In Reply.
Tsampasian V, Vassiliou VS. JAMA Intern Med. 2023 Jul 24. doi: 10.1001/jamainternmed.2023.3036. Online ahead of print. PMID: 37486646

Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 **vaccination**.
Yamamoto S, Yamayoshi S, Ito M, Sakai-Tagawa Y, Nakachi I, Baba R, Kamimoto S, Ogura T, Hagiwara S, Kato H, Nakajima H, Uwamino Y, Yagi K, Sugaya N, Nagai H, Saito M, Adachi E, Koga M, Tsutsumi T, Duong C, Okuda M, Murakami J, Furusawa Y, Ujie M, Iwatsuki-Horimoto K, Yotsuyanagi H, Kawaoka Y. iScience. 2023 Jun 25;26(7):107208. doi: 10.1016/j.isci.2023.107208. eCollection 2023 Jul 21. PMID: 37448563

Free COVID-19 **Vaccinations** on the Way for Uninsured Adults.
Harris E. JAMA. 2023 Jul 26. doi: 10.1001/jama.2023.13133. Online ahead of print. PMID: 37494016

Cationic-nanogel nasal **vaccine** containing the ectodomain of RSV-small hydrophobic protein induces protective immunity in rodents.
Umemoto S, Nakahashi-Ouchida R, Yuki Y, Kurokawa S, Machita T, Uchida Y, Mori H, Yamanoue T, Shibata T, Sawada SI, Ishige K, Hirano T, Fujihashi K, Akiyoshi K, Kurashima Y, Tokuhara D, Ernst PB, Suzuki M, Kiyono H. NPJ Vaccines. 2023 Jul 24;8(1):106. doi: 10.1038/s41541-023-00700-3. PMID: 37488116

Reminders, but not monetary incentives, increase COVID-19 booster uptake.
Chang TY, Jacobson M, Shah M, Kopetsky M, Pramanik R, Shah SB. Proc Natl Acad Sci U S A. 2023 Aug;120(31):e2302725120. doi: 10.1073/pnas.2302725120. Epub 2023 Jul 24. PMID: 37487101

New consensus guidelines on **vaccination** in multiple sclerosis.
Zettl UK, Rommer PS. Nat Rev Neurol. 2023 Jul 25. doi: 10.1038/s41582-023-00854-7. Online ahead of print. PMID: 37491641

Attitudes toward COVID-19 **vaccination** of healthcare workers in Israel and **vaccination** rates during **vaccine** rollout.
Halevi A, Shkalim Zemer V, Embar T, Jacobson E, Reichenberg Y, Yosef N, Shlomi D. Epidemiol Infect. 2023 Jul 24:1-20. doi: 10.1017/S0950268823000961. Online ahead of print. PMID: 37482675

3Rs implementation in veterinary **vaccine** batch-release testing: Current state-of-the-art and future opportunities. A webinar and workshop report.
Viviani L, Balks E, Beken S, Brady AM, Clayton R, Cliquet F, Desmayanti L, Fragoeiro S, Hamtak TJ, John D, Jungbaëck C, Kalaivani M, Kross I, Lang C, Ria Isriyanthi NM, Mallet L, Milne C, Rubbrecht M, Siklódi B, Singh B, Srinivas GB, Stickings P, Stirling C, Sundram P, Szabó M, Thomas A, van den Berg M, Walker A, Philippe C, Vandeputte J. Biologicals. 2023 Jul 27;83:101695. doi: 10.1016/j.biologicals.2023.101695. Online ahead of print. PMID: 37516084

An intranasal **vaccine** comprising SARS-CoV-2 spike receptor-binding domain protein entrapped in mannose-conjugated chitosan nanoparticle provides protection in hamsters.
Tabynov K, Solomadin M, Turebekov N, Babayeva M, Fomin G, Yadagiri G, Sankar R, Yerubayev T, Petrovsky N, Renukaradhya GJ, Tabynov K. Sci Rep. 2023 Jul 26;13(1):12115. doi: 10.1038/s41598-023-39402-0. PMID: 37495639

Influenza **vaccination** from the perspective of health care workers at university hospitals.
Rykowska D, Sobierajski T, Okarska-Napierała M, Wanke-Rytt M, Kuchar E. PLoS One. 2023 Jul 21;18(7):e0288470. doi: 10.1371/journal.pone.0288470. eCollection 2023. PMID: 37478110

Prophylactic and early outpatient treatment of COVID-19 in patients with kidney disease: considerations from the Immunonephrology Working Group of the European Renal Association (ERA-IWG).
Hilhorst M, Bemelman FJ, Bruchfeld A, Fernandez-Juarez GM, Floege J, Frangou E, Goumenos D, van Kooten C, Kronbichler A, Stevens KI, Turkmen K, Wiersinga WJ, Anders HJ. Nephrol Dial Transplant. 2023 Jul 31;38(8):1807-1816. doi: 10.1093/ndt/gfad044. PMID: 36881727

The Utilization and Development of Viral Vectors in **Vaccines** as a Prophylactic Treatment Against Ebola Virus as an Emerging and Zoonotic Infectious Disease.
Garcia A, Grundmann O. Mini Rev Med Chem. 2023 Jul 25. doi: 10.2174/1389557523666230725115324. Online ahead of print. PMID: 37489781

Influenza and pneumococcal **vaccination** coverage and associated factors in patients hospitalized with acute exacerbations of COPD in China: Findings from the real-world data.
He R, Ren X, Huang K, Lei J, Niu H, Li W, Dong F, Li B, Wang Y, Yang T, Wang C. Chin Med J (Engl). 2023 Jul 24. doi: 10.1097/CM9.0000000000002790. Online ahead of print. PMID: 37488669

Potent Zinc(II)-Based Immunogenic Cell Death Inducer Triggered by ROS-Mediated ERS and Mitochondrial Ca^{2+} Overload.
Liao LS, Chen Y, Hou C, Liu YH, Su GF, Liang H, Chen ZF. J Med Chem. 2023 Jul 27. doi: 10.1021/acs.jmedchem.3c00603. Online ahead of print. PMID: 37498080

Excess Death Rates for Republican and Democratic Registered Voters in Florida and Ohio During the COVID-19 Pandemic.

Wallace J, Goldsmith-Pinkham P, Schwartz JL. JAMA Intern Med. 2023 Jul 24:e231154. doi: 10.1001/jamainternmed.2023.1154. Online ahead of print. PMID: 37486680

Preparing student-pharmacists to utilize motivational interviewing techniques to address COVID-19 **vaccine** hesitancy in underrepresented racial/ethnic patient populations.
Jackson J, Guirguis E, Sourial M, Pirmal S, Pinder L. Curr Pharm Teach Learn. 2023 Jul 21:S1877-1297(23)00184-3. doi: 10.1016/j.cptl.2023.07.008. Online ahead of print. PMID: 37482494

The prevalence of and factors related to reinfection with COVID-19 in Ahvaz, Iran: A comparative cross-sectional study.
Abedi P, Afshari P, Ansari S, Alavi SM, Dashtpayma S, Amiri H. Health Sci Rep. 2023 Jul 21;6(7):e1420. doi: 10.1002/hsr2.1420. eCollection 2023 Jul. PMID: 37492272

A Single Oral Immunization with a Replication-Competent Adenovirus-Vectored **Vaccine** Protects Mice from Influenza Respiratory Infection.
Goffin E, Du X, Hemmi S, Machiels B, Gillet L. J Virol. 2023 Jul 27;97(7):e0013523. doi: 10.1128/jvi.00135-23. Epub 2023 Jun 20. PMID: 37338377

Biodistribution assessment of cationic pullulan nanogel, a nasal **vaccine** delivery system, in mice and non-human primates.
Yuki Y, Harada N, Sawada SI, Uchida Y, Nakahashi-Ouchida R, Mori H, Yamanoue T, Machita T, Kanazawa M, Fukumoto D, Ohba H, Miyazaki T, Akiyoshi K, Fujihashi K, Kiyono H. Vaccine. 2023 Jul 31;41(34):4941-4949. doi: 10.1016/j.vaccine.2023.06.065. Epub 2023 Jun 27. PMID: 37385890

Evolution and Phylodynamics of the Hemagglutinin Protein of Influenza A/(H1N1)pdm09 Virus Isolates from India from 2009 to 2020.
Ramesh K, Ethiraj K, Srinivasan S, Krishnasamy K, Rajendran K, Selvaraj G, Padmanaban P. Jpn J Infect Dis. 2023 Jul 24;76(4):219-225. doi: 10.7883/yoken.JJID.2022.453. Epub 2023 Feb 28. PMID: 36858600

Justifying a morally permissible breach of contract: kantian ethics, nozickian justice, and **vaccine** patents.
Cordeiro-Rodrigues L. Med Health Care Philos. 2023 Jul 21. doi: 10.1007/s11019-023-10165-9. Online ahead of print. PMID: 37479910

Timeliness of routine childhood **vaccination** among 12-35 months old children in The Gambia: Analysis of national immunisation survey data, 2019-2020.
Wariri O, Utazi CE, Okomo U, Sogur M, Murray KA, Grundy C, Fofanna S, Kampmann B. PLoS One. 2023 Jul 21;18(7):e0288741. doi: 10.1371/journal.pone.0288741. eCollection 2023. PMID: 37478124

Probiotics formulation and cancer nanovaccines show synergistic effect in immunotherapy and prevention of colon cancer.
Xu X, Zhang M, Liu X, Chai M, Diao L, Ma L, Nie S, Xu M, Wang Y, Mo F, Liu M. iScience. 2023 Jun 19;26(7):107167. doi: 10.1016/j.isci.2023.107167. eCollection 2023 Jul 21. PMID: 37456845

Genetic characterization and molecular evolution of type 3 **vaccine**-derived polioviruses from an immunodeficient patient in China.

Guo Q, Zhu S, Wang D, Li X, Zhu H, Song Y, Liu X, Xiao F, Zhao H, Lu H, Xiao J, Yu L, Wang W, He Y, Liu Y, Li J, Zhang Y, Xu W, Yan D. Virus Res. 2023 Jul 24;334:199177. doi: 10.1016/j.virusres.2023.199177. Online ahead of print. PMID: 37479187

Impact of the SARS-CoV-2 nucleocapsid 203K/204R mutations on the inflammatory immune response in COVID-19 severity.
Shuaib M, Adroub S, Mourier T, Mfarrej S, Zhang H, Esau L, Alsomali A, Alofi FS, Ahmad AN, Shamsan A, Khogeer A, Hashem AM, Almontashiri NAM, Hala S, Pain A. Genome Med. 2023 Jul 21;15(1):54. doi: 10.1186/s13073-023-01208-0. PMID: 37475040

Development of Nanopackaging for Storage and Transport of Loaded Lipid Nanoparticles.
Kaur A, Darvill D, Xiang S, Heng JYY, Petrov PK, Hoye RLZ, Chen R. Nano Lett. 2023 Jul 26;23(14):6760-6767. doi: 10.1021/acs.nanolett.3c01271. Epub 2023 Jun 6. PMID: 37279451

Differences between DNA **vaccine** and single-cycle viral **vaccine** in the ability of cross-protection against viral hemorrhagic septicemia virus (VHSV) and infectious hematopoietic necrosis virus (IHNV).
Kim SY, Lee KM, Kim KH. Vaccine. 2023 Jul 28:S0264-410X(23)00889-7. doi: 10.1016/j.vaccine.2023.07.058. Online ahead of print. PMID: 37517909

Influenza **vaccine** effectiveness in preventing hospital encounters for laboratory-confirmed infection among Italian adults, 2022/23 season.
Domnich A, Orsi A, Ogliastro M, Trombetta CS, Scarpaleggia M, Stefanelli F, Panatto D, Bruzzone B, Icardi G. Vaccine. 2023 Jul 25;41(33):4861-4866. doi: 10.1016/j.vaccine.2023.06.072. Epub 2023 Jun 28. PMID: 37385889

Safety and immunogenicity of 15-valent pneumococcal conjugate **vaccine** in Japanese healthy infants: A phase III study (V114-033).
Suzuki H, Fujita H, Iwai K, Kuroki H, Taniyama K, Shizuya T, Kishino H, Igarashi R, Shirakawa M, Sawata M. Vaccine. 2023 Jul 31;41(34):4933-4940. doi: 10.1016/j.vaccine.2023.05.064. Epub 2023 Jun 19. PMID: 37344262

Thyroid disturbances after COVID-19 and the effect of **vaccination** in children: a prospective tri-center registry analysis.
Herczeg V, Garai R, Takács J, Kovács F, Luczay A, Hrapka E, Krivácsy P, Hosszú É, Beniczky NJ, Németh Á, Szilágyi ES, Pécsi A, Szabó Z, Szabó AJ, Tóth-Heyn P. Eur J Pediatr. 2023 Jul 25. doi: 10.1007/s00431-023-05097-8. Online ahead of print. PMID: 37488409

Efficacy and safety of tixagevimab-cilgavimab (Evusheld®) in people with Multiple Sclerosis on Ocrelizumab: preliminary evidence.
Altieri M, Melisi RD, Conte M, Capuano R, Donnarumma G, Grimaldi E, Coppola N, De Pascalis S, Risi M, d'Ambrosio A, Bisecco A, Gallo A. Neurol Sci. 2023 Jul 27. doi: 10.1007/s10072-023-06975-7. Online ahead of print. PMID: 37498399

Vector-based SARS-CoV-2 **vaccination** is associated with improved T-cell responses in hematological neoplasia.

Engelmann R, Jaekel N, Jotschke S, Ludwig-Kraus B, Kraus FB, Kumari N, Schulze S, Hecker M, Zahn C, Al-Ali HK, Junghanss C, Böttcher S. Blood Adv. 2023 Jul 25;7(14):3403-3415. doi: 10.1182/bloodadvances.2022009054. PMID: 36947191

Counter-stereotypical messaging and partisan cues: Moving the needle on **vaccines** in a polarized United States.
Larsen BJ, Ryan TJ, Greene S, Hetherington MJ, Maxwell R, Tadelis S. Sci Adv. 2023 Jul 21;9(29):eadg9434. doi: 10.1126/sciadv.adg9434. Epub 2023 Jul 19. PMID: 37467319

Differences in Coronavirus disease - 19 **vaccination** related side effects in patients with ulcerative colitis and Crohn'**s** disease in Japan.
Miyazaki H, Watanabe D, Ito Y, Ikeda S, Okamoto N, Tokunaga E, Ku Y, Ooi M, Hoshi N, Kodama Y. Indian J Gastroenterol. 2023 Jul 28. doi: 10.1007/s12664-023-01386-0. Online ahead of print. PMID: 37505394

Vaccination against COVID-19 and potential protective effects on seizure recurrence in children with epilepsy: A cross-sectional survey.
Chen C, Chen N, Xie L, Luo Y, Ma J, Li T. Epilepsia Open. 2023 Jul 22. doi: 10.1002/epi4.12794. Online ahead of print. PMID: 37483062

Lc-pPG-612-OmpU-CTB: A promising oral **vaccine** for protecting Carassius auratus against Vibrio mimicus infection.
Yang BT, Zhao T, Li HJ, Liang ZL, Cong W, Kang YH. Fish Shellfish Immunol. 2023 Jul 21;140:108973. doi: 10.1016/j.fsi.2023.108973. Online ahead of print. PMID: 37481101

Specific mRNA lipid nanoparticles and acquired resistance to ticks.
Matias J, Cui Y, Tang X, Sajid A, Arora G, Wu MJ, DePonte K, Muramatsu H, Tam YK, Narasimhan S, Pardi N, Weissman D, Fikrig E. Vaccine. 2023 Jul 31;41(34):4996-5002. doi: 10.1016/j.vaccine.2023.06.081. Epub 2023 Jul 6. PMID: 37407406

The Role of Children in Household Transmission of SARS-CoV-2 Across Four Waves of the Pandemic.
Fuller TL, Bastos L, Carvalho MS, Resende PC, Damasceno L, Cruz OG, Medeiros F, Calvet G, Guaraldo L, Nielsen-Saines K, Whitworth J, Smith C, Siqueira M, Brasil P. J Pediatric Infect Dis Soc. 2023 Jul 31;12(7):413-420. doi: 10.1093/jpids/piad044. PMID: 37327193

Preclinical evaluation of general toxicity and safety pharmacology of a receptor-binding domain-based COVID-19 subunit **vaccine** in various animal models.
Park SJ, Jang MS, Lim KH, Seo JW, Im WJ, Han KH, Kim SE, Jang E, Park D, Kim YB. Arch Toxicol. 2023 Jul 25. doi: 10.1007/s00204-023-03549-6. Online ahead of print. PMID: 37491472

Compliance Trajectory and Patterns of COVID-19 Preventive Measures, Japan, 2020-2022.
Kusama T, Takeuchi K, Tamada Y, Kiuchi S, Osaka K, Tabuchi T. Emerg Infect Dis. 2023 Jul 24;29(9). doi: 10.3201/eid2909.221754. Online ahead of print. PMID: 37487165

"Figuring stuff out myself" - a qualitative study on maternal **vaccination** in socially and ethnically diverse areas in England.

Berendes S, Mounier-Jack S, Ojo-Aromokudu O, Ivory A, Tucker JD, Larson HJ, Free C. BMC Public Health. 2023 Jul 21;23(1):1408. doi: 10.1186/s12889-023-16317-z. PMID: 37480010

Interseason waning of **vaccine**-induced hemagglutination inhibition antibody titers and contributing factors to pre-existing humoral immunity against influenza in community-dwelling older adults 75 years and older.
Wunderlich B, Laskow T, Li H, Zhang L, Abrams E, Tian J, Yu J, Chen Y, Tavenier J, Huang Y, Talaat K, Bream JH, Xue QL, Pawelec G, Leng SX. Immun Ageing. 2023 Jul 31;20(1):38. doi: 10.1186/s12979-023-00362-8. PMID: 37525151

Veteran influenza **vaccination** acceptance rates after completion of the COVID-19 **vaccination** series among historical influenza **vaccine** refusers.
Patel UC, Schultz T, Schmidt J. Vaccine. 2023 Jul 25;41(33):4782-4786. doi: 10.1016/j.vaccine.2023.06.090. Epub 2023 Jul 3. PMID: 37414694

Vaccination schedule for adolescents. Consensus of the AEV, CAV-AEP and SEMA.
García FJÁ, Tejada AMG, Heras IG, de Arce AI, Llop FM, Herreros FN, Martín JJP, Marchuet PS, Rodríguez JV. An Pediatr (Engl Ed). 2023 Jul 22:S2341-2879(23)00162-X. doi: 10.1016/j.anpede.2023.07.004. Online ahead of print. PMID: 37487775

Elevated serum levels of T cell immunoglobulin and mucin-domain containing molecule 3 in patients with systemic inflammation following COVID-19 **vaccination**.
Hsieh MC, Yu WC, Weng CC, Chen WJ, Chen CK, Lee YC, Chen MH. J Chin Med Assoc. 2023 Jul 24. doi: 10.1097/JCMA.0000000000000969. Online ahead of print. PMID: 37481764

Gonococcal microparticle **vaccine** in dissolving microneedles induced immunity and enhanced bacterial clearance in infected mice.
Bagwe P, Bajaj L, Menon I, Braz Gomes K, Kale A, Patil S, Vijayanand S, Gala R, D'Souza MJ, Zughaier SM. Int J Pharm. 2023 Jul 25;642:123182. doi: 10.1016/j.ijpharm.2023.123182. Epub 2023 Jun 25. PMID: 37369287

Improved HIV-1 neutralization breadth and potency of V2-apex antibodies by in silico design.
Holt GT, Gorman J, Wang S, Lowegard AU, Zhang B, Liu T, Lin BC, Louder MK, Frenkel MS, McKee K, O'Dell S, Rawi R, Shen CH, Doria-Rose NA, Kwong PD, Donald BR. Cell Rep. 2023 Jul 25;42(7):112711. doi: 10.1016/j.celrep.2023.112711. Epub 2023 Jul 11. PMID: 37436900

Microbiota perturbation by anti-microbiota **vaccine** reduces the colonization of Borrelia afzelii in Ixodes ricinus.
Wu-Chuang A, Mateos-Hernandez L, Maitre A, Rego ROM, Šíma R, Porcelli S, Rakotobe S, Foucault-Simonin A, Moutailler S, Palinauskas V, Aželytė J, Sĭmo L, Obregon D, Cabezas-Cruz A. Microbiome. 2023 Jul 24;11(1):151. doi: 10.1186/s40168-023-01599-7. PMID: 37482606

Reasons patients cite to their healthcare provider for not initiating or completing HPV **vaccination**.
Chido-Amajuoyi OG, Osaghae I, Shete S. JNCI Cancer Spectr. 2023 Jul 21:pkad047. doi: 10.1093/jncics/pkad047. Online ahead of print. PMID: 37478343

Incidence of diabetes following COVID-19 **vaccination** and SARS-CoV-2 infection in Hong Kong: A population-based cohort study.

Xiong X, Lui DTW, Chung MSH, Au ICH, Lai FTT, Wan EYF, Chui CSL, Li X, Cheng FWT, Cheung CL, Chan EWY, Lee CH, Woo YC, Tan KCB, Wong CKH, Wong ICK. PLoS Med. 2023 Jul 24;20(7):e1004274. doi: 10.1371/journal.pmed.1004274. Online ahead of print. PMID: 37486927

An electronic medical record reminder is independently associated with improved opportunistic influenza **vaccination** rates for older inpatients.
Chapman L, Kelly M, Piggott RS, Carr B, Courtney G, McDonagh R, O'Connell B, Bannan C, Cunningham C, Briggs R. J R Coll Physicians Edinb. 2023 Jul 25:14782715231187763. doi: 10.1177/14782715231187763. Online ahead of print. PMID: 37491778

Nephrotic syndrome caused by IgA vasculitis flare up following COVID-19 **vaccination**.
Horino T, Osakabe Y, Ishihara M, Nakajima K, Terada Y. QJM. 2023 Jul 28;116(7):556-558. doi: 10.1093/qjmed/hcad040. PMID: 36919781

Identification of an optimized Receptor-Binding Domain Subunit **Vaccine** against SARS-CoV-2.
Yu H, Worrall LJ, Berger T, Petric M, Lin BH, Vuckovic M, Robb CS, Le Q, Kenward C, Dai C, Wakeham A, Liu S, Snow B, Tobin C, Budylowski P, Guvenc F, You-Ten A, Haight J, Silvester J, Singh RP, Ahn SK, Sultana A, Poon B, Lam J, Christie-Holmes N, Ostrowski M, Gray-Owen SD, Kubli S, Mak T, Strynadka NCJ, Brunham RC. J Immunol. 2023 Jul 26:ji2300282. doi: 10.4049/jimmunol.2300282. Online ahead of print. PMID: 37493438

Pemphigus vulgaris after the second dose of COVID-19 **vaccination**: a case report.
Khalayli N, Omar A, Kudsi M. J Med Case Rep. 2023 Jul 27;17(1):322. doi: 10.1186/s13256-023-04055-0. PMID: 37496035

Use of Information and Communication Technology Strategies to Increase **Vaccination** Coverage in Older Adults: A Systematic Review.
Buja A, Grotto G, Taha M, Cocchio S, Baldo V. Vaccines (Basel). 2023 Jul 21;11(7):1274. doi: 10.3390/vaccines11071274. PMID: 37515089

Non-specific benefit of seasonal influenza **vaccine** on respiratory syncytial virus-hospitalisations in children: An instrumental variable approach using population-based data.
Le H, de Klerk N, Blyth CC, Gidding H, Fathima P, Moore HC. Vaccine. 2023 Jul 31;41(34):5029-5036. doi: 10.1016/j.vaccine.2023.06.085. Epub 2023 Jul 6. PMID: 37407408

A step forward for Plasmodium falciparum malaria transmission-blocking **vaccines**.
Beeson JG, Chan JA. Lancet Infect Dis. 2023 Jul 24:S1473-3099(23)00288-8. doi: 10.1016/S1473-3099(23)00288-8. Online ahead of print. PMID: 37499677

Correspondence: Clinical Course of Adverse Effects after COVID-19 **Vaccination**.
Kleebayoon A, Wiwanitkit V. Korean J Fam Med. 2023 Jul 24. doi: 10.4082/kjfm.23.0020. Online ahead of print. PMID: 37482648

Severity of Prior COVID-19 is Associated with Postoperative Outcomes Following Major Inpatient Surgery.
Verhagen NB, SenthilKumar G, Jaraczewski T, Koerber NK, Merrill JR, Flitcroft MA, Szabo A, Banerjee A, Yang X, Taylor BW, Figueroa Castro CE, Yen TWF, Clarke CN, Lauer K, Pfeifer KJ, Gould JC, Kothari AN;

N3C Consortium. Ann Surg. 2023 Jul 21. doi: 10.1097/SLA.0000000000006035. Online ahead of print. PMID: 37476995

Incidence and Determinants of Symptomatic and Asymptomatic SARS-CoV-2 Breakthrough Infections After Booster Dose in a Large European Multicentric Cohort of Health Workers-ORCHESTRA Project.
Porru S, Monaco MGL, Spiteri G, Carta A, Caliskan G, Violán C, Torán-Monserrat P, Vimercati L, Tafuri S, Boffetta P, Violante FS, Sala E, Sansone E, Gobba F, Casolari L, Wieser A, Janke C, Tardon A, Rodriguez-Suarez MM, Liviero F, Scapellato ML, dell'Omo M, Murgia N, Mates D, Calota VC, Strhársky J, Mrázová M, Pira E, Godono A, Magnano GC, Negro C, Verlato G; Orchestra WP5 Working Group. J Epidemiol Glob Health. 2023 Jul 22. doi: 10.1007/s44197-023-00139-8. Online ahead of print. PMID: 37480426

GB Virus B and Hepatitis C Virus, Distantly Related Hepaciviruses, Share an Entry Factor, Claudin-1.
Toon K, Kalemera MD, Palor M, Rose NJ, Takeuchi Y, Grove J, Mattiuzzo G. J Virol. 2023 Jul 27;97(7):e0046923. doi: 10.1128/jvi.00469-23. Epub 2023 Jun 13. PMID: 37310242

Immunoinformatics-Based Identification of the Conserved Immunogenic Peptides Targeting of Zika Virus Precursor Membrane Protein.
Gupta Y, Baranwal M, Chudasama B. Viral Immunol. 2023 Jul 24. doi: 10.1089/vim.2023.0015. Online ahead of print. PMID: 37486711

Effectiveness of inactivated influenza and COVID-19 **vaccines** in hospitalized children in 2022/23 season in Japan - The first season of co-circulation of influenza and COVID-19.
Shinjoh M, Furuichi M, Tsuzuki S, Iqbal A, Fukushima N, Soen S, Fukushima H, Kobayashi K, Yamada G, Narabayashi A, Tsunematsu K, Maeda N, Shimoyamada M, Yoshida M, Kuramochi Y, Shibata A, Yamaguchi Y, Yaginuma M, Takahashi T, Ishikane M, Sugaya N; Keio Pediatric Influenza Research Group. Vaccine. 2023 Jul 25;41(33):4777-4781. doi: 10.1016/j.vaccine.2023.06.082. Epub 2023 Jun 30. PMID: 37419851

Monoclonal antibody levels and protection from COVID-19.
Stadler E, Burgess MT, Schlub TE, Khan SR, Chai KL, McQuilten ZK, Wood EM, Polizzotto MN, Kent SJ, Cromer D, Davenport MP, Khoury DS. Nat Commun. 2023 Jul 28;14(1):4545. doi: 10.1038/s41467-023-40204-1. PMID: 37507368

Use of Respiratory Syncytial Virus **Vaccines** in Older Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, Havers FP. MMWR Morb Mortal Wkly Rep. 2023 Jul 21;72(29):793-801. doi: 10.15585/mmwr.mm7229a4. PMID: 37471262

A review of foot-and-mouth disease status and control measures in Botswana.
Kabelo TI, Fana EM, Hyera JM, Lebani K. Trop Anim Health Prod. 2023 Jul 28;55(4):278. doi: 10.1007/s11250-023-03674-5. PMID: 37500989

Evaluation of the live-attenuated intranasal respiratory syncytial virus (RSV) **vaccine** RSV/6120/ΔNS2/1030s in RSV-seronegative young children.

Karron RA, Luongo C, Woods S, Oliva J, Collins PL, Buchholz UJ; RSVPed Team. J Infect Dis. 2023 Jul 26:jiad281. doi: 10.1093/infdis/jiad281. Online ahead of print. PMID: 37493269

Infant Health Care Disruptions by Race and Ethnicity, Income, and Insurance During the COVID-19 Pandemic.
Eliason EL, Agostino J, Vivier P. Acad Pediatr. 2023 Jul 22:S1876-2859(23)00270-X. doi: 10.1016/j.acap.2023.07.005. Online ahead of print. PMID: 37487800

Translating the COVID-19 experience in widening the HPV **vaccination** campaign for cervical cancer in India.
Ghose A, Agarwal A, Sirohi B, Nag S, Chuang L, Mitra S. Gynecol Oncol Rep. 2023 Jul 21;48:101247. doi: 10.1016/j.gore.2023.101247. eCollection 2023 Aug. PMID: 37492441

Protection against genotype VII Newcastle disease virus by a mucosal subunit **vaccination** based on bacterium-like particles bearing the F or HN antigen.
Wang J, Lan Q, Zong X, Zhu G, Yang R, Yang G, Jiang Y, Yang W, Huang H, Shi C, Zeng Y, Wang N, Cao X, Wang C. Int J Biol Macromol. 2023 Jul 31;244:125293. doi: 10.1016/j.ijbiomac.2023.125293. Epub 2023 Jun 12. PMID: 37315677

Infectious Complications of Lung Transplant for Coronavirus Disease 2019-Associated Lung Injury: A Single-Center Case-Control Cohort Study.
Osborn R, Alamri M, Tomic R, Ison MG. Clin Infect Dis. 2023 Jul 26;77(2):220-228. doi: 10.1093/cid/ciad160. PMID: 36942560

Combined Infection Control Interventions Protect Essential Food Workers from Occupational Exposures to SARS-CoV-2 in the Agricultural Environment.
Cooper DK, Sobolik JS, Kovacevic J, Rock CM, Sajewski ET, Guest JL, Lopman BA, Jaykus LA, Leon JS. Appl Environ Microbiol. 2023 Jul 26;89(7):e0012823. doi: 10.1128/aem.00128-23. Epub 2023 Jun 13. PMID: 37310232

Factors associated with perceived fear of future pandemics and/or epidemics: a cross-sectional study in Cyprus.
Alexandrou R, Kyprianidou M, Photiou G, Kassianos AP, Giannakou K. Sci Rep. 2023 Jul 27;13(1):12194. doi: 10.1038/s41598-023-39381-2. PMID: 37500807

A case of anti-LGI1 encephalitis after mRNA COVID-19 **vaccination**.
Lewis A, Wisely H, Bayuk T, Ma Y. QJM. 2023 Jul 28;116(7):582-583. doi: 10.1093/qjmed/hcad060. PMID: 37067518

Condition-Dependent and Dynamic Impacts of Indoor Masking Policies for Coronavirus Disease 2019 Mitigation: A Nationwide, Interrupted Time-Series Analysis.
Ertem Z, Nelson RE, Schechter-Perkins EM, Al-Amery A, Zhang X, Branch-Elliman W. Clin Infect Dis. 2023 Jul 26;77(2):203-211. doi: 10.1093/cid/ciad115. PMID: 37072937

Impact of COVID-19 and effects of booster **vaccination** with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron.

Di Fusco M, Sun X, Moran MM, Coetzer H, Zamparo JM, Alvarez MB, Puzniak L, Tabak YP, Cappelleri JC. J Patient Rep Outcomes. 2023 Jul 24;7(1):77. doi: 10.1186/s41687-023-00616-5. PMID: 37486567

Effects of School-Based Preventive Measures on COVID-19 Incidence, Hong Kong, 2022.
Tsang TK, Huang X, Fong MW, Wang C, Lau EHY, Wu P, Cowling BJ. Emerg Infect Dis. 2023 Jul 25;29(9). doi: 10.3201/eid2909.221897. Online ahead of print. PMID: 37490926

A highly potent human neutralizing antibody prevents vertical transmission of Rift Valley fever virus in a rat model.
McMillen CM, Chapman NS, Hoehl RM, Skvarca LB, Schwarz MM, Handal LS, Crowe JE Jr, Hartman AL. Nat Commun. 2023 Jul 26;14(1):4507. doi: 10.1038/s41467-023-40187-z. PMID: 37495594

Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T-cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2.
Becerra-Artiles A, Nanaware PP, Muneeruddin K, Weaver GC, Shaffer SA, Calvo-Calle JM, Stern LJ. PLoS Pathog. 2023 Jul 27;19(7):e1011032. doi: 10.1371/journal.ppat.1011032. Online ahead of print. PMID: 37498934

Unravelling disparity in age-specific acceptance of COVID-19 **vaccination**: the contextual and psychosocial influences.
Yuan J, Lam WWT, Xiao J, Cowling BJ, Ni MY, Dong M, Liao Q. Psychol Health. 2023 Jul 25:1-20. doi: 10.1080/08870446.2023.2239279. Online ahead of print. PMID: 37491766

Thrombotic microangiopathy concurrent with disseminated intravascular coagulation after SARS-CoV-2 **vaccination**.
Wen YK. Clin Nephrol. 2023 Jul 24. doi: 10.5414/CN111208. Online ahead of print. PMID: 37485884

Immunization, not **vaccination**: monoclonal antibodies for infant RSV prevention and the US **vaccines** for children program.
Sevilla JP. J Med Econ. 2023 Jul 27:1-24. doi: 10.1080/13696998.2023.2242169. Online ahead of print. PMID: 37498791

Safety and efficacy of COVID-19 **vaccines** in patients on dialysis: a multicentre cohort study in Italy.
Menniti-Ippolito F, Mele A, Da Cas R, De Masi S, Chiarotti F, Fabiani M, Baglio G, Traversa G, Colavita F, Castilletti C, Salomone M, Zoccali C, Messa P; COVIDVaxDia Study Group. J Nephrol. 2023 Jul 25. doi: 10.1007/s40620-023-01708-7. Online ahead of print. PMID: 37490271

Hepatitis a **Vaccine** as Opportunity of Primary Prevention for Food Handlers: A Narrative Review.
Fallucca A, Restivo V, Sgariglia MC, Roveta M, Trucchi C. Vaccines (Basel). 2023 Jul 21;11(7):1271. doi: 10.3390/vaccines11071271. PMID: 37515087

Safety of Inactivated SARS-CoV-2 **Vaccines** Among Adults with Experience of Allergies to Food or Medicines.
Jin Y, Zheng M, He S, Chen M, Cao C. Int J Gen Med. 2023 Jul 21;16:3105-3113. doi: 10.2147/IJGM.S422337. eCollection 2023. PMID: 37496598

Boost immunizations with NA-derived peptide conjugates achieve induction of NA inhibition antibodies and heterologous influenza protections.
Liu DJ, Liu CC, Zhong XQ, Wu X, Zhang HH, Lu SW, Shen ZL, Song WW, Zhao SL, Peng YS, Zheng HP, Wan MY, Chen YQ, Deng L. Cell Rep. 2023 Jul 25;42(7):112766. doi: 10.1016/j.celrep.2023.112766. Epub 2023 Jul 7. PMID: 37421618

Evidence for positive long- and short-term effects of **vaccinations** against COVID-19 in wearable sensor metrics.
Wiedermann M, Rose AH, Maier BF, Kolb JJ, Hinrichs D, Brockmann D. PNAS Nexus. 2023 Jul 25;2(7):pgad223. doi: 10.1093/pnasnexus/pgad223. eCollection 2023 Jul. PMID: 37497048

Protective effect of **vaccination** on the risk of cardiovascular disease after SARS-CoV-2 infection.
Song J, Choi S, Jeong S, Chang JY, Park SJ, Oh YH, Kim JS, Cho Y, Byeon K, Choi JY, Lee S, Park SM. Clin Res Cardiol. 2023 Jul 31. doi: 10.1007/s00392-023-02271-8. Online ahead of print. PMID: 37522901

Building resilient cervical cancer prevention through gender-neutral HPV **vaccination**.
Man I, Georges D, Sankaranarayanan R, Basu P, Baussano I. Elife. 2023 Jul 24;12:e85735. doi: 10.7554/eLife.85735. PMID: 37486822

Is **vaccine** response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?
Jeantin L, Abdi B, Soulié C, Sterlin D, Maillart E, Beigneux Y, Hippolyte A, Belin L, Marcelin AG, Pourcher V, Louapre C. J Neurol Neurosurg Psychiatry. 2023 Jul 21:jnnp-2023-331770. doi: 10.1136/jnnp-2023-331770. Online ahead of print. PMID: 37479463

Intralesional human papillomavirus **vaccine** for the treatment of recalcitrant cutaneous warts.
Bar-Ilan E, Bar J, Baniel A, Slodownik D, Artzi O, Samuelov L, Sprecher E, Mashiah J. J Dermatol. 2023 Jul 27. doi: 10.1111/1346-8138.16905. Online ahead of print. PMID: 37501372

Optimising DTwP-containing **vaccine** infant immunisation schedules (OptImms) - a protocol for two parallel, open-label, randomised controlled trials.
Kelly S, Liu X, Theiss-Nyland K, Voysey M, Murphy S, Li G, Nyantaro M, Gurung M, Basnet S, Pokhrel B, Bijukchhe SM, Eordogh A, Gombe B, Kakande A, Kerridge S, Kimbugwe G, Kusemererwa S, Lubyayi L, Luzze H, Mazur O, Mujadidi YF, Nabukenya S, Nagumo WR, Nareeba T, Noristani R, O'Reilly P, Roberts A, Shah G, Shrestha S, Shrestha LP, Thapa SB, Kibengo FM, Sharma AK, Elliott A, Shrestha S, Pollard AJ. Trials. 2023 Jul 21;24(1):465. doi: 10.1186/s13063-023-07477-9. PMID: 37480110

Use of Interferon Gamma Release Assays in Children <2 Years Old.
Turner NA, Ahmed A, Haley CA, Starke JR, Stout JE. J Pediatric Infect Dis Soc. 2023 Jul 21:piad053. doi: 10.1093/jpids/piad053. Online ahead of print. PMID: 37478309

Omicron BA.4/5 Neutralization and T-Cell Responses in Organ Transplant Recipients After Booster Messenger RNA **Vaccine**: A Multicenter Cohort Study.
Ferreira VH, Ierullo M, Mavandadnejad F, Kurtesi A, Hu Q, Hardy WR, Hall VG, Pinzon N, Yotis D, Gingras AC, Belga S, Shalhoub S, Hébert MJ, Humar A, Kabbani D, Kumar D. Clin Infect Dis. 2023 Jul 26;77(2):229-236. doi: 10.1093/cid/ciad175. PMID: 36975097

How to model the impact of **vaccines** for policymaking when the characteristics are uncertain: A case study in Thailand prior to the **vaccine** rollout during the COVID-19 pandemic.
Luangasanatip N, Painter C, Pan-Ngum W, Saralamba S, Wichaita T, White L, Aguas R, Clapham H, Wang Y, Isaranuwatchai W, Teerawattananon Y. Vaccine. 2023 Jul 25;41(33):4854-4860. doi: 10.1016/j.vaccine.2023.06.055. Epub 2023 Jun 20. PMID: 37365059

Clostridium tetani infection in a geriatric patient: don't let your guard off!
Piscitelli A, Cacciatore S, Ambrosio F, Ragozzino R, Pasquini FM, Incordino F, D'Angelo E, Gerardino L, Maggi L, Landi F. Ann Geriatr Med Res. 2023 Jul 24. doi: 10.4235/agmr.23.0067. Online ahead of print. PMID: 37482408

Limited benefit of post-exposure prophylaxis with VSV-EBOV in Ebola virus-infected rhesus macaques.
Bushmaker T, Feldmann F, Lovaglio J, Saturday G, Griffin AJ, O'Donnell KL, Strong JE, Sprecher A, Kobinger G, Geisbert TW, Marzi A, Feldmann H. J Infect Dis. 2023 Jul 21:jiad280. doi: 10.1093/infdis/jiad280. Online ahead of print. PMID: 37474155

An Immunoinformatics-Based Study of Mycobacterium tuberculosis Region of Difference-2 Uncharacterized Protein (Rv1987) as a Potential Subunit **Vaccine** Candidate for Preliminary Ex Vivo Analysis.
Arega AM, Dhal AK, Pattanaik KP, Nayak S, Mahapatra RK. Appl Biochem Biotechnol. 2023 Jul 27. doi: 10.1007/s12010-023-04658-9. Online ahead of print. PMID: 37498378

Development of conserved multi-epitopes based hybrid **vaccine** against SARS-CoV-2 variants: an immunoinformatic approach.
Yaseen AR, Suleman M, Qadri AS, Asghar A, Arshad I, Khan DM. In Silico Pharmacol. 2023 Jul 27;11(1):18. doi: 10.1007/s40203-023-00156-2. eCollection 2023. PMID: 37519944

Reverse-zoonoses of 2009 H1N1 pandemic influenza A viruses and evolution in United States swine results in viruses with zoonotic potential.
Markin A, Ciacci Zanella G, Arendsee ZW, Zhang J, Krueger KM, Gauger PC, Vincent Baker AL, Anderson TK. PLoS Pathog. 2023 Jul 27;19(7):e1011476. doi: 10.1371/journal.ppat.1011476. eCollection 2023 Jul. PMID: 37498825

Rational social distancing in epidemics with uncertain **vaccination** timing.
Schnyder SK, Molina JJ, Yamamoto R, Turner MS. PLoS One. 2023 Jul 21;18(7):e0288963. doi: 10.1371/journal.pone.0288963. eCollection 2023. PMID: 37478107

A numerical study of spatio-temporal COVID-19 **vaccine** model via finite-difference operator-splitting and meshless techniques.
Khan AA, Ullah S, Altanji M, Amin R, Haider N, Alshehri A, Riaz MB. Sci Rep. 2023 Jul 26;13(1):12108. doi: 10.1038/s41598-023-38925-w. PMID: 37495630

Spatiotemporal dynamics of confirmed case distribution during the COVID-19 pandemic in China: data comparison between 2020/04-2020/08 and 2021/04-2021/08.
Fu LT, Qu ZL, Zeng X, Li LZ, Lan R, Zhou Y. Sci Rep. 2023 Jul 23;13(1):11896. doi: 10.1038/s41598-023-39139-w. PMID: 37482580

A structure and knowledge-based combinatorial approach to engineering universal scFv antibodies against influenza M2 protein.
Kumar U, Goyal P, Madni ZK, Kamble K, Gaur V, Rajala MS, Salunke DM. J Biomed Sci. 2023 Jul 25;30(1):56. doi: 10.1186/s12929-023-00950-2. PMID: 37491224

Analysis of qualification for post-exposure prophylaxis against rabies in children in Poland.
Ostrowska A, Susło A, Zabłocka K, Bieńkowski C, Pokorska-Śpiewak M. Paediatr Int Child Health. 2023 Jul 23:1-6. doi: 10.1080/20469047.2023.2236480. Online ahead of print. PMID: 37482764

Nonhuman Primates in Public Health: Between Biological Standardization, Conservation and Care.
Druglitrø T. J Hist Biol. 2023 Jul 21. doi: 10.1007/s10739-023-09721-z. Online ahead of print. PMID: 37477736

In-depth cellular and humoral dynamics of the response to COVID-19 **vaccine** booster in patients with chronic B-cell neoplasms.
Ayers E, Canderan G, Williams ME, Keshavarz B, Portell CA, Wilson JM, Woodfolk JA. Blood Cancer J. 2023 Jul 26;13(1):114. doi: 10.1038/s41408-023-00884-w. PMID: 37495573

Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein **Vaccine** in Children and Adolescents in India: A Phase 2-3 Randomized Clinical Trial.
Gunale B, Kapse D, Kar S, Bavdekar A, Kohli S, Lalwani S, Meshram S, Raut A, Kulkarni P, Samuel C, Munshi R, Gupta M, Plested JS, Cloney-Clark S, Zhu M, Pryor M, Hamilton S, Thakar M, Shete A, Dharmadhikari A, Bhamare C, Shaligram U, Poonawalla CS, Mallory RM, Glenn GM, Kulkarni PS; COVOVAX-Ped study group. JAMA Pediatr. 2023 Jul 31. doi: 10.1001/jamapediatrics.2023.2552. Online ahead of print. PMID: 37523166

Safety evaluation of immune-cell therapy for malignant tumor in the Cancer Immune-cell Therapy Evaluation Group (CITEG).
Takimoto R, Kamigaki T, Ito H, Saito M, Takizawa K, Soejima K, Yasuda H, Ohgino K, Terai H, Tomita K, Miura M, Mizukoshi E, Miyashita T, Nakamoto Y, Hayashi K, Miwa S, Kitahara M, Takeuchi A, Kimura H, Mochizuki T, Sugie H, Seino KI, Yamada T, Takeuchi S, Makita K, Naitoh K, Yasumoto K, Yoshida Y, Inoue H, Kotake K, Ohshima K, Noda SE, Okamoto M, Yoshimoto Y, Okada S, Ibe H, Oguma E, Goto S; CITEG. Cytotherapy. 2023 Jul 22:S1465-3249(23)00984-2. doi: 10.1016/j.jcyt.2023.06.007. Online ahead of print. PMID: 37486281

Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
Stępień A, Pogoda-Wesołowska A, Tokarz-Kupczyk E, Słowik A, Puz P, Adamczyk-Sowa M, Kurkowska-Jastrzębska I, Kułakowska A, Chorąży M, Piasecka-Stryczyńska K, Jamróz-Wiśniewska A, Bartosik-Psujek H, Rejdak K. Neurol Neurochir Pol. 2023 Jul 25. doi: 10.5603/PJNNS.a2023.0050. Online ahead of print. PMID: 37490356

The position of Spy Tag/Catcher system in hepatitis B core protein particles affects the immunogenicity and stability of the synthetic **vaccine**.
Sheng Y, Li Z, Lin X, Ma Y, Ren Y, Su Z, Ma G, Zhang S. Vaccine. 2023 Jul 25;41(33):4867-4878. doi: 10.1016/j.vaccine.2023.06.070. Epub 2023 Jun 28. PMID: 37391312

The ghost of polio haunts us once again. The appeal of the scientific community is clear: "**Vaccinate** your kids today!".
Martini M, Orsini D. Vaccine. 2023 Jul 24:S0264-410X(23)00850-2. doi: 10.1016/j.vaccine.2023.07.029. Online ahead of print. PMID: 37495489

Effectiveness of COVID-19 **vaccines** against infection in Japan: A test-negative study from the VENUS study.
Tamada Y, Takeuchi K, Kusama T, Maeda M, Murata F, Osaka K, Fukuda H. Vaccine. 2023 Jul 22:S0264-410X(23)00856-3. doi: 10.1016/j.vaccine.2023.07.035. Online ahead of print. PMID: 37487845

Nanoadjuvants Produced by Advanced Nanochelating Technology in the Inactivated-Severe Acute Respiratory Syndrome Coronavirus-2 **Vaccine** Formulation: Preliminary Results on Cytokines and IgG Responses.
Kalanaky S, Fakharzadeh S, Karimi P, Hafizi M, Jamaati H, Hassanzadeh SM, Khorasani A, Mahdavi M, Nazaran MH. Viral Immunol. 2023 Jul 28. doi: 10.1089/vim.2023.0001. Online ahead of print. PMID: 37506342

Retraction statement: Impact of COVID-19 pandemic on **vaccination** coverage of children and adolescents: A systematic review.
[No authors listed] Health Sci Rep. 2023 Jul 26;6(7):e1452. doi: 10.1002/hsr2.1452. eCollection 2023 Jul. PMID: 37502116

Ionizable Amino Lipids Distribution and Effects on DSPC/Cholesterol Membranes: Implications for Lipid Nanoparticle Structure.
Dehghani-Ghahnaviyeh S, Smith M, Xia Y, Dousis A, Grossfield A, Sur S. J Phys Chem B. 2023 Jul 27. doi: 10.1021/acs.jpcb.3c01296. Online ahead of print. PMID: 37498794

SARS CoV-2 spike protein-guided exosome isolation facilitates detection of potential miRNA biomarkers in COVID-19 infections.
Mimmi S, Zimbo AM, Rotundo S, Cione E, Nisticò N, Aloisio A, Maisano D, Tolomeo AM, Dattilo V, Lionello R, Fioravanti A, Di Loria A, Quirino A, Marascio N, Russo A, Trecarichi EM, Matera G, Quinto I, Torti C, Iaccino E. Clin Chem Lab Med. 2023 Mar 27;61(8):1518-1524. doi: 10.1515/cclm-2022-1286. Print 2023 Jul 26. PMID: 36972680

The Prospects of Phytomedicines and Nanomedicines to Treat Leishmaniasis: A Comprehensive Review.
Aggarwal K, Swami R. Curr Drug Res Rev. 2023 Jul 25. doi: 10.2174/2589977515666230725105141. Online ahead of print. PMID: 37489778

Characterization, Directed Evolution, and Targeting of DNA Virus-Encoded RNA Capping Enzymes Using Phenotypic Yeast Platforms.
Ornelas MY, Thomas AY, Johnson Rosas LI, Medina GN, Mehta AP. ACS Chem Biol. 2023 Jul 27. doi: 10.1021/acschembio.3c00243. Online ahead of print. PMID: 37498174

Serum anti-Spike immunoglobulin G levels in random blood donors in Italy: High-titre convalescent plasma is easier than ever to procure.

Focosi D, Meschi S, Coen S, Iorio MC, Franchini M, Lanza M, Maggi F. Vox Sang. 2023 Jul 25. doi: 10.1111/vox.13498. Online ahead of print. PMID: 37489640

Hospital length of stay throughout bed pathways and factors affecting this time: A non-concurrent cohort study of Colombia COVID-19 patients and an unCoVer network project.
Ruiz Galvis LM, Pérez Aguirre CA, Pérez Bedoya JP, Mendoza Cardozo OI, Barengo NC, Sánchez Escudero JP, Cardona Jiménez J, Diaz Valencia PA. PLoS One. 2023 Jul 26;18(7):e0278429. doi: 10.1371/journal.pone.0278429. eCollection 2023. PMID: 37494381

A cohort study reveals different dynamics of SARS-CoV-2-specific antibody formation after Comirnaty and Vaxzevria **vaccination**.
Augustyniak A, Szymański T, Porzucek F, Mieloch AA, Semba JA, Hubert KA, Grajek D, Krela R, Rogalska Z, Zalc-Budziszewska E, Wysocki S, Sobczak K, Kuczyński L, Rybka JD. Vaccine. 2023 Jul 31;41(34):5037-5044. doi: 10.1016/j.vaccine.2023.06.008. Epub 2023 Jun 21. PMID: 37407407

Development of a Naturalness Preference Scale.
Bayerman SF, Li M, Syed A, Scherer L. Med Decis Making. 2023 Jul 31:272989X231189494. doi: 10.1177/0272989X231189494. Online ahead of print. PMID: 37522395

Ascaridia galli - An old problem that requires new solutions.
Höglund J, Daş G, Tarbiat B, Geldhof P, Jansson DS, Gauly M. Int J Parasitol Drugs Drug Resist. 2023 Jul 24;23:1-9. doi: 10.1016/j.ijpddr.2023.07.003. Online ahead of print. PMID: 37516026

Cytotoxicity of human antibodies targeting the circumsporozoite protein is amplified by 3D substrate and correlates with protection.
Aguirre-Botero MC, Wang LT, Formaglio P, Aliprandini E, Thiberge JM, Schön A, Flores-Garcia Y, Mathis-Torres S, Flynn BJ, da Silva Pereira L, Le Duff Y, Hurley M, Nacer A, Bowyer PW, Zavala F, Idris AH, Francica JR, Seder RA, Amino R. Cell Rep. 2023 Jul 25;42(7):112681. doi: 10.1016/j.celrep.2023.112681. Epub 2023 Jun 28. PMID: 37389992

Malaria transmission-blocking **vaccines** Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial.
Sagara I, Healy SA, Assadou MH, Kone M, Swihart BJ, Kwan JL, Fintzi J, Sissoko K, Kamate B, Samake Y, Guindo MA, Doucoure M, Niaré K, Dolo A, Diarra B, Rausch KM, Narum DL, Jones DS, MacDonald NJ, Zhu D, Gorres JP, Imeru A, Mohan R, Thera I, Zaidi I, Salazar-Miralles F, Duan J, Neal J, Morrison RD, Muratova O, Sylla D, O'Connell EM, Wu Y, Hume JCC, Coulibaly MB, Anderson CF, Traore SF, Doumbo OK, Duffy PE. Lancet Infect Dis. 2023 Jul 24:S1473-3099(23)00276-1. doi: 10.1016/S1473-3099(23)00276-1. Online ahead of print. PMID: 37499679

B and T cell responses to the BNT162b2 COVID-19 mRNA **vaccine** are not impaired in germ-free or antibiotic-treated mice.
Norton T, Lynn MA, Rossouw C, Abayasingam A, Perkins G, Hissaria P, Bull RA, Lynn DJ. Gut. 2023 Jul 27:gutjnl-2023-329810. doi: 10.1136/gutjnl-2023-329810. Online ahead of print. PMID: 37500502

Case report: Granulomatosis with polyangiitis (GPA) and facial paralysis after COVID-19 **vaccination**.
Saiz LC, Villanueva Alcojol M. Med Clin (Barc). 2023 Jul 21;161(2):84-85. doi: 10.1016/j.medcli.2023.03.018. Epub 2023 Apr 5. PMID: 37164829

Frequency of B-Cell Subpopulations in Low Responders in Comparison with High Responders to Hepatitis B **Vaccine** Among Health Care Workers.
Saleh Z, Mehdipour F, Ataollahi MR, Ali-Hassanzadeh M, Kabelitz D, Kalantar K. Curr Microbiol. 2023 Jul 24;80(9):296. doi: 10.1007/s00284-023-03367-0. PMID: 37488238

Transcription factor expression repertoire basis for epigenetic and transcriptional subtypes of colorectal cancers.
Bhandari YR, Krishna V, Powers R, Parmar S, Thursby SJ, Gupta E, Kulak O, Gokare P, Reumers J, Van Wesenbeeck L, Bachman KE, Baylin SB, Easwaran H. Proc Natl Acad Sci U S A. 2023 Aug;120(31):e2301536120. doi: 10.1073/pnas.2301536120. Epub 2023 Jul 24. PMID: 37487069

Nanoencapsulated all-*trans* retinoic acid as an adjuvant for mucosal **vaccines**.
Borges GS, Lages EB, Goulart GA, Ferreira LA. Nanomedicine (Lond). 2023 Jul 28. doi: 10.2217/nnm-2023-0144. Online ahead of print. PMID: 37503732

Integrated COVID-19 Interventions in a Native American Community: Arizona, December 25, 2021-January 31, 2022.
Van Dyne EA, Jentoft C, Boone T, Close RM. Am J Public Health. 2023 Jul 27:e1-e4. doi: 10.2105/AJPH.2023.307364. Online ahead of print. PMID: 37499203

Formulation of Recombinant H1N1 Hemagglutinin in MF59 and Alum Adjuvants: A Comparison of the **Vaccines** Potency and Efficacy in BALB/C Mice.
Sepasi A, Ghafourian M, Taghizadeh M, Mahdavi M. Viral Immunol. 2023 Jul 27. doi: 10.1089/vim.2023.0003. Online ahead of print. PMID: 37504965

Association Between COVID-19 **Vaccination** and Mortality after Major Operations.
Sharath SE, Kougias P, Daviú-Molinari T, Faridmoayer E, Berger DH. Ann Surg. 2023 Jul 27. doi: 10.1097/SLA.0000000000006051. Online ahead of print. PMID: 37497640

Expedited Evaluation of Conformational Stability-Heterogeneity Associations for Crude Polyclonal Antibodies in Response to Conjugate **Vaccines**.
Zheng Z, Ma M, Jia Y, Cui Y, Zhao R, Li S, Wenthur C, Li L, Li G. Anal Chem. 2023 Jul 25;95(29):10895-10902. doi: 10.1021/acs.analchem.3c00223. Epub 2023 Jul 11. PMID: 37433088

Exploring COVID-19 **vaccine** uptake among healthcare workers in Zimbabwe: A mixed methods study.
Taruvinga T, Chingono RS, Marambire E, Larsson L, Olaru ID, Sibanda S, Nzvere F, Redzo N, Ndhlovu CE, Rusakaniko S, Mujuru H, Sibanda E, Chonzi P, Siamuchembu M, Chikodzore R, Mahomva A, Ferrand RA, Dixon J, Kranzer K. medRxiv. 2023 Jul 23:2023.07.17.23292791. doi: 10.1101/2023.07.17.23292791. Preprint. PMID: 37503278

COVID-19 **vaccine** registry for pregnant women: policy to control complications of **vaccination** in pregnant women in 2021-2022.

Asadi F, Shakiba R, Rabiei R, Emami H, Sabahi A. BMC Pregnancy Childbirth. 2023 Jul 27;23(1):542. doi: 10.1186/s12884-023-05856-3. PMID: 37501112

Outcomes of **vaccinated** versus unvaccinated COVID-19 patients in Israel during the Omicron and Delta waves-A retrospective cohort study.
Poran I, Mokh AA, Vronsky D, Drozdinsky G, Basharim B, Eliakim-Raz N. Med Clin (Barc). 2023 Jul 21;161(2):59-61. doi: 10.1016/j.medcli.2023.04.003. Epub 2023 Apr 11. PMID: 37248130

Evaluation of an inducible knockout system in insect cells based on co-infection and CRISPR/Cas9.
Hausjell CS, Klausberger M, Ernst W, Grabherr R. PLoS One. 2023 Jul 27;18(7):e0289178. doi: 10.1371/journal.pone.0289178. eCollection 2023. PMID: 37498808

Effect of COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation.
Mariottini A, Lotti A, Innocenti C, Repice AM, Nozzoli C, Boncompagni R, Fainardi E, Saccardi R, Massacesi L. Eur J Neurol. 2023 Jul 22. doi: 10.1111/ene.15989. Online ahead of print. PMID: 37483174

Computational analysis of spike protein of SARS-CoV-2 (Omicron variant) for development of peptide-based therapeutics and diagnostics.
Pritam M, Dutta S, Medicherla KM, Kumar R, Singh SP. J Biomol Struct Dyn. 2023 Jul 27:1-19. doi: 10.1080/07391102.2023.2239932. Online ahead of print. PMID: 37498146

This Fall**'s** COVID-19 **Vaccines** Will Target Omicron XBB Subvariants, but Who Needs Them Remains to Be Seen.
Rubin R. JAMA. 2023 Jul 25;330(4):299-301. doi: 10.1001/jama.2023.10053. PMID: 37405757

Dendritic cell ICAM-1 strengthens synapses with CD8 T cells but is not required for their early differentiation.
Sapoznikov A, Kozlovski S, Levi N, Feigelson SW, Regev O, Davidzohn N, Ben-Dor S, Haffner-Krausz R, Feldmesser E, Wigoda N, Petrovich-Kopitman E, Biton M, Alon R. Cell Rep. 2023 Jul 25;42(8):112864. doi: 10.1016/j.celrep.2023.112864. Online ahead of print. PMID: 37494182

Establishing immunogenicity and safety of needle-free intradermal delivery by nanoporous ceramic skin patch of mRNA SARS-CoV-2 **vaccine** as a revaccination strategy in healthy volunteers.
Prins MLM, Prins C, de Vries JJC, Visser LG, Roukens AHE. Virus Res. 2023 Jul 21;334:199175. doi: 10.1016/j.virusres.2023.199175. Online ahead of print. PMID: 37473964

The US Federal Retail Pharmacy Program: Optimizing COVID-19 **Vaccine** Delivery Through a Strategic Public-Private Partnership.
Kim C, Guo A, Yassanye D, Link-Gelles R, Yates K, Duggar C, Moore L, El Kalach R, Jones-Jack N, Walker C, Gibbs Scharf L, Pillai SK, Patel A. Public Health Rep. 2023 Jul 28:333549231186606. doi: 10.1177/00333549231186606. Online ahead of print. PMID: 37503697

A case of anti-MDA5 antibody-positive dermatomyositis with severe necrosis on limbs after COVID-19 **vaccination**.

Nakanishi M, Mizutani K, Sugioka K, Nishimura M, Habe K, Yamanaka K. J Dermatol. 2023 Jul 24. doi: 10.1111/1346-8138.16906. Online ahead of print. PMID: 37485592

Generation of whole tumor cell **vaccine** for on-demand manipulation of immune responses against cancer under near-infrared laser irradiation.
Meng J, Lv Y, Bao W, Meng Z, Wang S, Wu Y, Li S, Jiao Z, Tian Z, Ma G, Wei W. Nat Commun. 2023 Jul 26;14(1):4505. doi: 10.1038/s41467-023-40207-y. PMID: 37495590

Development of Shigella conjugate **vaccines** targeting Shigella flexneri 2a and **S**. flexneri 3a using a simple platform-approach conjugation by squaric acid chemistry.
Kelly M, Mandlik A, Charles RC, Verma S, Calderwood SB, Leung DT, Biswas R, Islam K, Kamruzzaman M, Chowdhury F, Khanam F, Vann WF, Khan AI, Bhuiyan TR, Qadri F, Vortherms AR, Kaminski R, Kováč P, Xu P, Ryan ET. Vaccine. 2023 Jul 31;41(34):4967-4977. doi: 10.1016/j.vaccine.2023.06.052. Epub 2023 Jul 1. PMID: 37400283

Progress Toward Hepatitis B Control and Elimination of Mother-to-Child Transmission of Hepatitis B Virus - World Health Organization African Region, 2016-2021.
Kabore HJ, Li X, Alleman MM, Manzengo CM, Mumba M, Biey J, Paluku G, Bwaka AM, Impouma B, Tohme RA. MMWR Morb Mortal Wkly Rep. 2023 Jul 21;72(29):782-787. doi: 10.15585/mmwr.mm7229a2. PMID: 37471264

The WUR0000125 PRRS resilience SNP had no apparent effect on pigs' infectivity and susceptibility in a novel transmission trial.
Chase-Topping M, Plastow G, Dekkers J, Li Y, Fang Y, Gerdts V, Van Kessel J, Harding J, Opriessnig T, Doeschl-Wilson A. Genet Sel Evol. 2023 Jul 24;55(1):51. doi: 10.1186/s12711-023-00824-z. PMID: 37488481

Use of antibiotics in hospitalized patients with COVID-19: evolving concepts in a highly dynamic antimicrobial stewardship scenario.
Bassetti M, Brucci G, Vena A, Giacobbe DR. Expert Opin Pharmacother. 2023 Jul 23:1-6. doi: 10.1080/14656566.2023.2239154. Online ahead of print. PMID: 37466425

HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide.
Wang S, Matassoli F, Zhang B, Liu T, Shen CH, Bylund T, Johnston T, Henry AR, Teng IT, Tripathi P, Becker JE, Changela A, Chaudhary R, Cheng C, Gaudinski M, Gorman J, Harris DR, Lee M, Morano NC, Novik L, O'Dell S, Olia AS, Parchment DK, Rawi R, Roberts-Torres J, Stephens T, Tsybovsky Y, Wang D, Van Wazer DJ, Zhou T, Doria-Rose NA, Koup RA, Shapiro L, Douek DC, McDermott AB, Kwong PD. Cell Rep. 2023 Jul 25;42(7):112755. doi: 10.1016/j.celrep.2023.112755. Epub 2023 Jul 11. PMID: 37436899

Identifying barriers and facilitators to COVID-19 **vaccination** uptake among People Who Use Drugs in Canada: a National Qualitative Study.
Ali F, Kaura A, Russell C, Bonn M, Bruneau J, Dasgupta N, Imtiaz S, Martel-Laferrière V, Rehm J, Shahin R, Elton-Marshall T. Harm Reduct J. 2023 Jul 29;20(1):99. doi: 10.1186/s12954-023-00826-6. PMID: 37516836

Medics as influencers: a historical analysis of British Army military medical exercises in Kenya over two decades.
Falconer Hall P, Falconer Hall T, Bailey Z, Horne ST. BMJ Mil Health. 2023 Jul 25:e002442. doi: 10.1136/military-2023-002442. Online ahead of print. PMID: 37491138

Protocol: carrageenan for the prevention of oral HPV infection - a feasibility randomised clinical trial.
Alli BY, Madathil S, Tran SD, Nicolau B. BMJ Open. 2023 Jul 27;13(7):e074498. doi: 10.1136/bmjopen-2023-074498. PMID: 37500273

Response of antibody titers to SARS-CoV-2 **vaccination** and clinical outcomes during the predominance of the Omicron variant in Colombia.
Montero C, Torres R, Reina M, Flechas J, Andrade D, Moreno S, Granados C, Yomayusa N. SAGE Open Med. 2023 Jul 21;11:20503121231187754. doi: 10.1177/20503121231187754. eCollection 2023. PMID: 37489136

An immuno-informatics approach for annotation of hypothetical proteins and multi-epitope **vaccine** designed against the Mpox virus.
Ahmed MH, Samia NSN, Singh G, Gupta V, Mishal MFM, Hossain A, Suman KH, Raza A, Dutta AK, Labony MA, Sultana J, Faysal EH, Alnasser SM, Alam P, Azam F. J Biomol Struct Dyn. 2023 Jul 31:1-20. doi: 10.1080/07391102.2023.2239921. Online ahead of print. PMID: 37519185

Application of microneedles combined with dendritic cell-targeted nanovaccine delivery system in percutaneous immunotherapy for triple-negative breast cancer.
Weng J, Yang J, Wang W, Wen J, Fang M, Zheng G, Xie J, Zheng X, Yan Q, Feng L. Nanotechnology. 2023 Jul 21. doi: 10.1088/1361-6528/ace97b. Online ahead of print. PMID: 37478829

Development of a multi-epitope **vaccine** candidate against *Pseudomonas aeruginosa* causing urinary tract infection and evaluation of its immunoreactivity in a rabbit model.
Kalantari H, Habibi M, Ferdousi A, Asadi Karam MR, Mohammadian T. J Biomol Struct Dyn. 2023 Jul 24:1-16. doi: 10.1080/07391102.2023.2239915. Online ahead of print. PMID: 37489041

Evidence of Mpox Virus Infection Among Persons Without Characteristic Lesions or Rash Presenting for First Dose of JYNNEOS **Vaccine**-District of Columbia, August 2022.
Ogale YP, Baird N, Townsend MB, Berry I, Griffin I, Lee M, Ashley P, Rhodes T, Notigan T, Wynn N, Kling C, Smith T, Priyamvada L, Carson WC, Navarra T, Dawson P, Weidle PJ, Willut C, Mangla AT, Satheshkumar PS, Hutson CL, Jackson DA, Waltenburg MA; DC Mpox Response Project Team. Clin Infect Dis. 2023 Jul 26;77(2):298-302. doi: 10.1093/cid/ciad145. PMID: 36916132

Recognition of Arboviruses by the Mosquito Immune System.
Prince BC, Walsh E, Torres TZB, Rückert C. Biomolecules. 2023 Jul 21;13(7):1159. doi: 10.3390/biom13071159. PMID: 37509194

Emergency Regulatory Procedures, Pharmaceutical Regulatory Politics, and the Political Economy of **Vaccine** Regulation in the COVID-19 Pandemic.
Nachlis H, Thomson K. J Health Polit Policy Law. 2023 Jul 31:10910278. doi: 10.1215/03616878-10910278. Online ahead of print. PMID: 37522337

Target Protein Expression on Tetrahymena thermophila Cell Surface Using the Signal Peptide and GPI Anchor Sequences of the Immobilization Antigen of Cryptocaryon irritans.
Watanabe Y, Asada M, Inokuchi M, Kotake M, Yoshinaga T. Mol Biotechnol. 2023 Jul 22. doi: 10.1007/s12033-023-00824-w. Online ahead of print. PMID: 37480447

Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA **Vaccines** after Intramuscular Injection.
Takanashi A, Pouton CW, Al-Wassiti H. Mol Pharm. 2023 Jul 26. doi: 10.1021/acs.molpharmaceut.2c01024. Online ahead of print. PMID: 37491979

Novel pneumococcal capsule type 33E results from the inactivation of glycosyltransferase WciE in **vaccine** type 33F.
Ganaie FA, Saad JS, Lo SW, McGee L, van Tonder AJ, Hawkins PA, Calix JJ, Bentley SD, Nahm MH. J Biol Chem. 2023 Jul 24:105085. doi: 10.1016/j.jbc.2023.105085. Online ahead of print. PMID: 37495106

The Rabies Free Burkina Faso initiative: an example of how one health-oriented civil society organizations can contribute towards the achievement of the rabies zero by 30 goal.
Savadogo M, Dahourou LD, Ilboudo AK, Ilboudo SG, Zangré H, Tarnagda G, Souli Z, Combari AHB, Diarra R, Bidima M, Traoré MGB, Mandé CD, Sondo KA, de Balogh K. One Health Outlook. 2023 Jul 21;5(1):9. doi: 10.1186/s42522-023-00086-1. PMID: 37480134

Establishment of a CPER reverse genetics system for Powassan virus defines attenuating NS1 glycosylation sites and an infectious NS1-GFP11 reporter virus.
Conde JN, Himmler GE, Mladinich MC, Setoh YX, Amarilla AA, Schutt WR, Saladino N, Gorbunova EE, Salamango DJ, Benach J, Kim HK, Mackow ER. mBio. 2023 Jul 25:e0138823. doi: 10.1128/mbio.01388-23. Online ahead of print. PMID: 37489888

Systematic genomic analysis of SARS-CoV-2 co-infections throughout the pandemic and segregation of the strains involved.
Peñas-Utrilla D, Pérez-Lago L, Molero-Salinas A, Estévez A, Sanz A, Herranz M, Martínez-Laperche C, Andrés-Zayas C, Veintimilla C, Catalán P, Alonso R, Muñoz P, García de Viedma D; Gregorio Marañón Microbiology-ID COVID 19 Study Group. Genome Med. 2023 Jul 24;15(1):57. doi: 10.1186/s13073-023-01198-z. PMID: 37488638

Assessing How Risk Communication Surveillance Prompts COVID-19 **Vaccine** Acceptance Among Internet Users by Applying the Situational Theory of Problem Solving: Cross-Sectional Study.
Jin Q, Raza SH, Yousaf M, Zaman U, Ogadimma EC, Shah AA, Core R, Malik A. JMIR Form Res. 2023 Jul 26;7:e43628. doi: 10.2196/43628. PMID: 37315198

COVID-19 in patients with liver disease and liver transplant: clinical implications, prevention, and management.
Perreault G, Ching C, Nobel YR. Therap Adv Gastroenterol. 2023 Jul 25;16:17562848231188586. doi: 10.1177/17562848231188586. eCollection 2023. PMID: 37521085

Efficacy of a 4-Antigen Staphylococcus aureus **Vaccine** in Spinal Surgery: The STaphylococcus aureus suRgical Inpatient **Vaccine** Efficacy (STRIVE) Randomized Clinical Trial.

Hassanzadeh H, Baber J, Begier E, Noriega DC, Konishi H, Yato Y, Wang MY, Le Huec JC, Patel V, Varga P, Liljenqvist U, Conly J, Sabharwal C, Munjal I, Cooper D, Radley D, Jaques A, Patton M, Gruber WC, Jansen KU, Anderson AS, Gurtman A; STaphylococcus aureus suRgical Inpatient Vaccine Efficacy Investigator Team. Clin Infect Dis. 2023 Jul 26;77(2):312-320. doi: 10.1093/cid/ciad218. PMID: 37125490

Letter to the Editor: Anti-SARS-CoV-2 **Vaccination**-Related Polyradiculitis Requires Early Diagnosis and Treatment to Improve the Outcome.
Finsterer J. Pulm Ther. 2023 Jul 24. doi: 10.1007/s41030-023-00237-9. Online ahead of print. PMID: 37486562

A prospective cohort study protocol: monitoring and surveillance of adverse events following heterologous booster doses of Oxford AstraZeneca COVID-19 **vaccine** in previous recipients of two doses of Sinopharm or Sputnik V **vaccines** in Iran.
Soltani S, Matin BK, Gouya MM, Zahraei SM, Moradi G, Chehri O, Soofi M, Moradinazar M, Shadmani FK, Kalantari M, Khajeha H, Emamian MH, Najafi F. BMC Public Health. 2023 Jul 24;23(1):1415. doi: 10.1186/s12889-023-16265-8. PMID: 37488541

Liquid nitrogen frozen cells for chemotherapy drug delivery and **vaccination** of melanoma.
Wu M, Xiao Y, Huang J, Wang Y, Zhang Y, Xu J, Dai H, Lv C, Hu Y, Chen B, Fu Q, Le W, Xue C. J Cancer Res Clin Oncol. 2023 Jul 31. doi: 10.1007/s00432-023-05117-y. Online ahead of print. PMID: 37522925

Factors associated with COVID-19 **vaccination** hesitancy in South Korea: A cross-sectional study.
Chung SJ, Han K, Kim C, Kim J. Nurs Health Sci. 2023 Jul 27. doi: 10.1111/nhs.13031. Online ahead of print. PMID: 37497789

Immune vulnerabilities of mutant KRAS in pancreatic cancer.
Cheng NC, Vonderheide RH. Trends Cancer. 2023 Jul 29:S2405-8033(23)00131-0. doi: 10.1016/j.trecan.2023.07.004. Online ahead of print. PMID: 37524642

Public perspectives on strays and companion animal management in Malaysia.
Munir SMI, Mokhtar MI, Arham AF. BMC Public Health. 2023 Jul 26;23(1):1428. doi: 10.1186/s12889-023-16276-5. PMID: 37495958

Outcomes After Decompressive Surgery for Severe Cerebral Venous Sinus Thrombosis Associated or Not Associated with **Vaccine**-Induced Immune Thrombosis with Thrombocytopenia: A Multicenter Cohort Study.
Pelz JO, Kenda M, Alonso A, Etminan N, Wittstock M, Niesen WD, Lambeck J, Güresir E, Wach J, Lampmannn T, Dziewas R, Wiedmann M, Schneider H, Bayas A, Christ M, Mengel A, Poli S, Brämer D, Lindner D, Pfrepper C, Roth C, Salih F, Günther A, Michalski D; IGNITE Study Group. Neurocrit Care. 2023 Jul 27. doi: 10.1007/s12028-023-01782-6. Online ahead of print. PMID: 37498459

Evaluation of the interest to combine a CD4 Th1-inducer cancer **vaccine** derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).

Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat E, Hammel P, Rosmorduc O, Stouvenot M, Allaire M, Bouattour M, Regnault H, Fratte S, Raymond E, Soularue E, Husson-Wetzel S, Di Martino V, Muller A, Clairet AL, Fagnoni-Legat C, Adotevi O, Meurisse A, Vernerey D, Borg C. BMC Cancer. 2023 Jul 29;23(1):710. doi: 10.1186/s12885-023-11065-0. PMID: 37516867

Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted **vaccine** used as booster in healthy adults.
Pasquevich KA, Coria LM, Ceballos A, Mazzitelli B, Rodriguez JM, Demaría A, Pueblas Castro C, Bruno L, Saposnik L, Salvatori M, Varese A, González S, González Martínez VV, Geffner J, Álvarez D; Laboratorio Pablo Cassará R&D and CMC for ARVAC CG consortium; Feleder E, Halabe K, Perez Lera PE, de Oca FM, Vega JC, Lombardo M, Yerino GA, Fló J, Cassataro J. Nat Commun. 2023 Jul 28;14(1):4551. doi: 10.1038/s41467-023-40272-3. PMID: 37507392

IFITM1 inhibits trophoblast invasion and is induced in placentas associated with IFN-mediated pregnancy diseases.
Degrelle SA, Buchrieser J, Dupressoir A, Porrot F, Loeuillet L, Schwartz O, Fournier T. iScience. 2023 Jun 15;26(7):107147. doi: 10.1016/j.isci.2023.107147. eCollection 2023 Jul 21. PMID: 37434700

Risk of Worsening Heart Failure and All-Cause Mortality Following COVID-19 **Vaccination** in Patients With Heart Failure: A Nationwide Real-World Safety Study.
Sindet-Pedersen C, Michalik F, Strange JE, Christensen DM, Nouhravesh N, Gerds TA, Andersson C, Folke F, Biering-Sørensen T, Fosbøl E, Torp-Pedersen C, Gislason GH, Køber L, Schou M. Circ Heart Fail. 2023 Jul 28:e010617. doi: 10.1161/CIRCHEARTFAILURE.123.010617. Online ahead of print. PMID: 37503624

Prevalence and predictors of COVID-19 **vaccination** hesitancy among healthcare workers in Sub-Saharan Africa: A systematic review and meta-analysis.
Kigongo E, Kabunga A, Tumwesigye R, Musinguzi M, Izaruku R, Acup W. PLoS One. 2023 Jul 28;18(7):e0289295. doi: 10.1371/journal.pone.0289295. eCollection 2023. PMID: 37506132

A joint Bayesian hierarchical model for estimating SARS-CoV-2 genomic and subgenomic RNA viral dynamics and seroconversion.
Dong TQ, Brown ER. Biostatistics. 2023 Jul 25:kxad016. doi: 10.1093/biostatistics/kxad016. Online ahead of print. PMID: 37490631

Impact of a clinical pharmacist'**s** intervention on pneumococcal **vaccination** in a population of at- risk hospitalized patients: The IP-VAC study.
Chiappin M, Leguelinel-Blache G, Roux-Marson C, Kinowski JM, Dubois F. Infect Dis Now. 2023 Jul 25:104765. doi: 10.1016/j.idnow.2023.104765. Online ahead of print. PMID: 37499757

Quality Improvement Initiative to Improve Time and Adherence to Revaccination after Hematopoietic Cell Transplantation: Implementation of a Revaccination Clinic within the HCT program.
Elgarten CW, Wohlschlaeger A, Levy EA, Tadley K, Wang L, Atkinson M, Roberson H, Olson TS, Bunin NJ, Heimall J, Fisher BT, Grupp SJ, Freedman JL. Transplant Cell Ther. 2023 Jul 28:S2666-6367(23)01432-X. doi: 10.1016/j.jtct.2023.07.020. Online ahead of print. PMID: 37517611

Beyond the numbers: An in-depth look at Cameroon's fifth national COVID-19 **vaccination** campaign through geographical and gender lenses.
Amani A, Njoh AA, Atuhebwe P, Ndoula S, Nembot R, Mbossou F, Tsague L, Adisso L, Bita Fouda AA, Gonese E, Perrault N, Habimana P, Saidu Y, Mirza I, Ntakarutimana D, Balde T, Mihigo R, Chaiban T, Gueye AS. Vaccine. 2023 Jul 29:S0264-410X(23)00905-2. doi: 10.1016/j.vaccine.2023.07.062. Online ahead of print. PMID: 37524630

Association of **vaccine** stockout with immunisation coverage in low-income and middle-income countries: a retrospective cohort study.
Lee D, Lavayen MC, Kim TT, Legins K, Seidel M. BMJ Open. 2023 Jul 31;13(7):e072364. doi: 10.1136/bmjopen-2023-072364. PMID: 37524556

Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment.
Maldonado MDM, Schlom J, Hamilton DH. Cancer Immunol Immunother. 2023 Jul 28. doi: 10.1007/s00262-023-03496-2. Online ahead of print. PMID: 37505292

Expertise as a Response to Limited Multilateralism: The Case of South Korea's **Vaccine** Procurement Task Force for COVID-19 **Vaccines** amid Unequal Access via the COVAX Facility.
Park J. J Health Polit Policy Law. 2023 Jul 31:10910224. doi: 10.1215/03616878-10910224. Online ahead of print. PMID: 37522333

Bioinformatics-based design of a fusion **vaccine** with CTLA-4 variable region to combat Brucella.
Guo WH, Zhu YJ, Haimiti G, Xie XR, Niu C, Li M, Shi J, Yin ZW, Yu MK, Ding JB, Zhang FB. Braz J Med Biol Res. 2023 Jul 21;56:e12938. doi: 10.1590/1414-431X2023e12938. eCollection 2023. PMID: 37493775

Development of monoclonal antibodies to target the large surface protein of hepatitis B virus and their use in therapeutic and diagnostic applications.
Paul SS, Patwa SM, Tan YJ. J Viral Hepat. 2023 Jul 31. doi: 10.1111/jvh.13880. Online ahead of print. PMID: 37525419

Correction to: Relative Effectiveness of Coronavirus Disease 2019 **Vaccination** and Booster Dose Combinations Among 18.9 Million **Vaccinated** Adults During the Early Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Period-United States, 1 January 2022 to 31 March 2022.
[No authors listed] Clin Infect Dis. 2023 Jul 26;77(2):334. doi: 10.1093/cid/ciad256. PMID: 37253067

Construction of Fosmid-based SARS-CoV-2 replicons for antiviral drug screening and replication analyses in biosafety level 2 facilities.
Takazawa S, Kotaki T, Nakamura S, Utsubo C, Kameoka M. Virus Res. 2023 Jul 22;334:199176. doi: 10.1016/j.virusres.2023.199176. Online ahead of print. PMID: 37473963

Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

Levitt JE, Hedlin H, Duong S, Lu D, Lee J, Bunning B, Elkarra N, Pinsky BA, Heffernan E, Springman E, Moss RB, Bonilla HF, Parsonnet J, Zamanian RT, Langguth JJ, Bollyky J, Khosla C, Nicolls MR, Desai M, Rogers AJ. Clin Infect Dis. 2023 Jul 26;77(2):186-193. doi: 10.1093/cid/ciad187. PMID: 36996150

Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and **Vaccination** Status: A Multicenter Cross-Sectional Study.
Kahlert CR, Strahm C, Güsewell S, Cusini A, Brucher A, Goppel S, Möller E, Möller JC, Ortner M, Ruetti M, Stocker R, Vuichard-Gysin D, Besold U, McGeer A, Risch L, Friedl A, Schlegel M, Vernazza P, Kuster SP, Kohler P; SURPRISE (SURveillance of infectious diseases among health PRofessionals In SwitzErland) Study Group. Clin Infect Dis. 2023 Jul 26;77(2):194-202. doi: 10.1093/cid/ciad143. PMID: 36905145

Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset.
Chebbi P, Shobha V, Rao VK, Haridas V, Janardana R, Pinto B, Kumar S, Patil A, Tekkatte R, Salanke M, Mahendranath KM. BMC Rheumatol. 2023 Jul 26;7(1):22. doi: 10.1186/s41927-023-00345-8. PMID: 37496101

Understanding Stakeholders' Perspectives to Increase COVID-19 **Vaccine** and Booster Uptake: Response to Comment.
Ezeh N, Sirek G, Ulysse SN, Ramsey-Goldman R, Feldman CH. Arthritis Care Res (Hoboken). 2023 Jul 27. doi: 10.1002/acr.25206. Online ahead of print. PMID: 37501323

Insights into the Structure of Comirnaty Covid-19 **Vaccine**: A Theory on Soft, Partially Bilayer-Covered Nanoparticles with Hydrogen Bond-Stabilized mRNA-Lipid Complexes.
Szebeni J, Kiss B, Bozó T, Turjeman K, Levi-Kalisman Y, Barenholz Y, Kellermayer M. ACS Nano. 2023 Jul 25;17(14):13147-13157. doi: 10.1021/acsnano.2c11904. Epub 2023 Jul 7. PMID: 37417667

Skin diseases in a 19th century English workhouse: analysis of the admission book for the Wakefield Workhouse Infirmary, 1826-1857.
Labbouz S, Manley AL, Gawkrodger DJ. Clin Exp Dermatol. 2023 Jul 21;48(8):916-919. doi: 10.1093/ced/llad140. PMID: 37070391

Plasmablasts in previously immunologically naïve COVID-19 patients express markers indicating mucosal homing and secrete antibodies cross-reacting with SARS-CoV-2 variants and other beta-coronaviruses.
Lundgren A, Leach S, Axelsson H, Isakson P, Nyström K, Scharf L, Andersson BA, Miron N, Marklund E, Andersson LM, Gisslén M, Angeletti D, Bemark M. Clin Exp Immunol. 2023 Jul 21;213(2):173-189. doi: 10.1093/cei/uxad044. PMID: 37071584

Dosing interval regimen shapes potency and breadth of antibody repertoire after **vaccination** of SARS-CoV-2 RBD protein subunit **vaccine**.
Guo S, Zheng Y, Gao Z, Duan M, Liu S, Du P, Xu X, Xu K, Zhao X, Chai Y, Wang P, Zhao Q, Gao GF, Dai L. Cell Discov. 2023 Jul 28;9(1):79. doi: 10.1038/s41421-023-00585-5. PMID: 37507370

Inborn Errors of Immunity in Children With Invasive Pneumococcal Disease: A Multicenter Prospective Study.

Phuong LK, Cheung A, Agrawal R, Butters C, Buttery J, Clark J, Connell T, Curtis N, Daley AJ, Dobinson HC, Frith C, Hameed NS, Hernstadt H, Krieser DM, Loke P, Ojaimi S, McMullan B, Pinzon-Charry A, Sharp EG, Sinnappurajar P, Templeton T, Wen S, Cole T, Gwee A. Pediatr Infect Dis J. 2023 Jul 31. doi: 10.1097/INF.0000000000004004. Online ahead of print. PMID: 37463351

Current Status of Epidemiology, Diagnosis, Therapeutics, and **Vaccines** for the Re-emerging Human Monkeypox Virus.
Lee W, Kim YJ, Lee SJ, Ahn DG, Kim SJ. J Microbiol Biotechnol. 2023 Jul 25;33(12):1-7. doi: 10.4014/jmb.2306.06033. Online ahead of print. PMID: 37519276

Long-term results of **vaccination** with adjuvanted recombinant varicella zoster glycoprotein E during initial Bruton tyrosine kinase inhibitors therapy for chronic lymphocytic leukemia or lymphoplasmacytic lymphoma.
Brady MT, Laniewski N, Strawderman M, Chu CC, Kanagaiah P, Sangster MY, Topham DJ, Friedberg JW, Zent CS. Am J Hematol. 2023 Jul 23. doi: 10.1002/ajh.27038. Online ahead of print. PMID: 37483138

Time- and cost-effective production of untagged recombinant MVA by flow virometry and direct virus sorting.
Daniela B, Panigada M, Di Terlizzi S, Romanò M, Canonico E, Villa C, Minici C, van Anken E, Soprana E, Siccardi AG. J Transl Med. 2023 Jul 23;21(1):495. doi: 10.1186/s12967-023-04353-7. PMID: 37482614

EXPRESS: Potential Reduction of Post-Acute Sequelae of SARS-COV2 Symptoms Via **Vaccination**.
Vanichkachorn GS, Gilman E, Ganesh R, Mueller M, Swift M, Breeher L, Murad MH. J Investig Med. 2023 Jul 27:10815589231191812. doi: 10.1177/10815589231191812. Online ahead of print. PMID: 37497990

Diphtheria in two Nigerian Hospitals: What is New and the Implications for Control.
Oyedeji OA, Olagunju FA, Ayinde JB, Osundare YJ, Ologun BG. West Afr J Med. 2023 Jul 28;40(7):769-772. PMID: 37516937

Affinity-matured homotypic interactions induce spectrum of PfCSP structures that influence protection from malaria infection.
Martin GM, Torres JL, Pholcharee T, Oyen D, Flores-Garcia Y, Gibson G, Moskovitz R, Beutler N, Jung DD, Copps J, Lee WH, Gonzalez-Paez G, Emerling D, MacGill RS, Locke E, King CR, Zavala F, Wilson IA, Ward AB. Nat Commun. 2023 Jul 28;14(1):4546. doi: 10.1038/s41467-023-40151-x. PMID: 37507365

Alarming decline in **vaccine** update must be tackled, say MPs.
Limb M. BMJ. 2023 Jul 27;382:p1741. doi: 10.1136/bmj.p1741. PMID: 37500115

Adverse effect of VEGFR-2 (rs1870377) polymorphism on the clinical course of COVID-19 in females and males in an age-dependent manner.
Sayin Kocakap DB, Kaygusuz S, Aksoy E, Şahin Ö, Baççioğlu A, Ekici A, Kalpaklioğlu AF, Ekici MS, Gül S, Kaçmaz B, Ayaşlioğlu Açikgöz E, Alyilmaz Bekmez S, Rouse BT, Kürşat Azkur A. Microbes Infect. 2023 Jul 25:105188. doi: 10.1016/j.micinf.2023.105188. Online ahead of print. PMID: 37499788

Adjuvant effects of combination monophosphoryl lipid A and poly I:C on antigen-specific immune responses and protective efficacy of influenza **vaccines**.

Le CTT, Ahn SY, Ho TL, Lee J, Lee DH, Hwang HS, Kang SM, Ko EJ. Sci Rep. 2023 Jul 28;13(1):12231. doi: 10.1038/s41598-023-39210-6. PMID: 37507413

"EvoVax" - A rationally designed inactivated Salmonella Typhimurium **vaccine** induces strong and long-lasting immune responses in pigs.
Lentsch V, Aslani S, Echtermann T, Preet S, Cappio Barazzone E, Hoces D, Moresi C, Kümmerlen D, Slack E. Vaccine. 2023 Jul 28:S0264-410X(23)00890-3. doi: 10.1016/j.vaccine.2023.07.059. Online ahead of print. PMID: 37517910

International adaptation and validation of the Pro-VC-Be: measuring the psychosocial determinants of **vaccine** confidence in healthcare professionals in European countries.
Garrison A, Karlsson L, Fressard L, Fasce A, Rodrigues F, Schmid P, Taubert F, Holford D, Lewandowsky S, Nynäs P, Anderson EC, Gagneur A, Dubé E, Soveri A, Verger P. Expert Rev Vaccines. 2023 Jul 28. doi: 10.1080/14760584.2023.2242479. Online ahead of print. PMID: 37507356

Arboviral **vaccines** for use in pregnant travelers.
Hills SL, Wong JM, Staples JE. Travel Med Infect Dis. 2023 Jul 28:102624. doi: 10.1016/j.tmaid.2023.102624. Online ahead of print. PMID: 37517630

Balancing Intelectual Property Protection and Legal Risk Assessment in Registration of Covid-19 **Vaccines** in Malaysia.
Ahamat H, Sa'ban H, Manap NA. Health Care Anal. 2023 Jul 21. doi: 10.1007/s10728-023-00465-9. Online ahead of print. PMID: 37477838

Nirmatrelvir plus ritonavir remains effective in **vaccinated** patients at risk of progression with COVID-19: A systematic review and meta-analysis.
Li H, Xiang H, He B, Zhang Q, Peng W. J Glob Health. 2023 Jul 21;13:06032. doi: 10.7189/jogh.13.06032. PMID: 37469290

The Double Democratic Bind: Challenges to Enacting Mandates and Combating Misinformation.
Boräng F, Carlitz R. J Health Polit Policy Law. 2023 Jul 31:10910233. doi: 10.1215/03616878-10910233. Online ahead of print. PMID: 37522334

Dissecting the Protective Effect of CD8$^+$ T Cells in Response to SARS-CoV-2 mRNA **Vaccination** and the Potential Link with Lymph Node CD8$^+$ T Cells.
Chen M, Venturi V, Munier CML. Biology (Basel). 2023 Jul 22;12(7):1035. doi: 10.3390/biology12071035. PMID: 37508464

The potential impact of a **vaccine** on Neisseria gonorrhoeae prevalence among heterosexuals living in a high prevalence setting.
Padeniya TN, Hui BB, Wood JG, Seib KL, Regan DG. Vaccine. 2023 Jul 28:S0264-410X(23)00879-4. doi: 10.1016/j.vaccine.2023.07.048. Online ahead of print. PMID: 37517908

Effect of immune responses on breath methane dynamics.
Polag D, Keppler F. J Breath Res. 2023 Jul 24. doi: 10.1088/1752-7163/ace9f2. Online ahead of print. PMID: 37487488

Targeted **vaccine** development against Bilophila wadsworthia to curb colon diseases: A multiepitope approach based on reverse vaccinology and computational analysis.
Khan S, Aziz S, Waqas M, Kakar MA, Ahmad S. Int J Biol Macromol. 2023 Jul 26:126002. doi: 10.1016/j.ijbiomac.2023.126002. Online ahead of print. PMID: 37506789

Investigating the mechanism of action of DNA-loaded PEGylated lipid nanoparticles.
Digiacomo L, Renzi S, Quagliarini E, Pozzi D, Amenitsch H, Ferri G, Pesce L, De Lorenzi V, Matteoli G, Cardarelli F, Caracciolo G. Nanomedicine. 2023 Jul 26:102697. doi: 10.1016/j.nano.2023.102697. Online ahead of print. PMID: 37507061

Public Anxiety, Attitudes, and Practices towards COVID-19 Infection in the Eastern Province of Saudi Arabia: A Cross-Sectional Study.
Berekaa MM, AlMulla AA, AlMoslem MM, AlSahli KS, AlJassim MT, AlSaif AS, AlQuwayi SA. Healthcare (Basel). 2023 Jul 21;11(14):2083. doi: 10.3390/healthcare11142083. PMID: 37510523

Population-Level Disparities in Exposure to COVID-19 Mitigation Policies, April 2020-April 2021.
Douglas MD, Li C, Josiah Willock R, Baltrus P, Caplan L, Immergluck L, McKinney T, Hopkins J, Mack D, Gaglioti AH. J Public Health Manag Pract. 2023 Jul 26. doi: 10.1097/PHH.0000000000001777. Online ahead of print. PMID: 37498523

Neurological symptoms after COVID-19 **vaccination**: a report on the clinical presentation of the first 50 patients.
Gerhard A, Raeder V, Pernice HF, Boesl F, Schroeder M, Richter J, Endres M, Prüß H, Hahn K, Audebert HJ, Franke C. J Neurol. 2023 Jul 29. doi: 10.1007/s00415-023-11895-9. Online ahead of print. PMID: 37515731

COVID-19 transmission dynamics and the impact of **vaccination**: modelling, analysis and simulations.
Malinzi J, Juma VO, Madubueze CE, Mwaonanji J, Nkem GN, Mwakilama E, Mupedza TV, Chiteri VN, Bakare EA, Moyo IL, Campillo-Funollet E, Nyabadza F, Madzvamuse A. R Soc Open Sci. 2023 Jul 26;10(7):221656. doi: 10.1098/rsos.221656. eCollection 2023 Jul. PMID: 37501660

Correspondence on outcomes following COVID-19 **vaccination** and associated factors among healthcare professionals.
Sriwijitalai W, Wiwanitkit V. Hum Vaccin Immunother. 2023 Jul 21:2219180. doi: 10.1080/21645515.2023.2219180. Online ahead of print. PMID: 37477213

An educational intervention in the emergency department seeking to improve COVID-19 **vaccination** rates among unvaccinated patients aged 20-64.
DeWaard S, Dewyer Z, Al Assil T, Gallap R, Patrick L, Fukuda N, Ford M. Infect Dis Health. 2023 Jul 29:S2468-0451(23)00040-8. doi: 10.1016/j.idh.2023.07.001. Online ahead of print. PMID: 37524612

Vaccine adjuvant-elicited CD8+ T cell immunity is co-dependent on T-bet and FOXO1.
Ivanova DL, Thompson SB, Klarquist J, Harbell MG, Kilgore AM, Lasda EL, Hesselberth JR, Hunter CA, Kedl RM. Cell Rep. 2023 Jul 28;42(8):112911. doi: 10.1016/j.celrep.2023.112911. Online ahead of print. PMID: 37516968

The safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus **vaccine** among patients undergoing elective surgery for closed fractures: A randomized, double-blind, placebo-controlled, multicenter phase 2 clinical trial.
Jiang XY, Gong MQ, Zhang HJ, Peng AQ, Xie Z, Sun D, Liu L, Zhou SQ, Chen H, Yang XF, Song JF, Yu B, Jiang Q, Ma X, Gu J, Yang F, Zeng H, Zou QM. Vaccine. 2023 Jul 27:S0264-410X(23)00878-2. doi: 10.1016/j.vaccine.2023.07.047. Online ahead of print. PMID: 37516573

Perspectives on the current diphtheria outbreak among asylum seekers in the UK.
Ryan R, Eisen S, Patel D, Longley N. J Travel Med. 2023 Jul 24:taad095. doi: 10.1093/jtm/taad095. Online ahead of print. PMID: 37486727

Fabrication and characterization of nanodelivery platform based on chitosan to improve the anticancer outcome of sorafenib in hepatocellular carcinoma.
Albalawi F, Hussein MZ, Fakurazi S, Masarudin MJ. Sci Rep. 2023 Jul 27;13(1):12180. doi: 10.1038/s41598-023-38054-4. PMID: 37500670

mRNA **vaccines** do not stop with COVID-19.
Zhou J, Zhang Y, Mo K, Newbert H, Song X. Lancet. 2023 Jul 27:S0140-6736(23)01514-3. doi: 10.1016/S0140-6736(23)01514-3. Online ahead of print. PMID: 37517411

Retinal Changes After COVID-19 Infection and COVID-19 **Vaccination**.
Leite J, Abreu AC, Furtado MJ, Lume M. Int Med Case Rep J. 2023 Jul 24;16:433-442. doi: 10.2147/IMCRJ.S408306. eCollection 2023. PMID: 37519404

Widespread Reassortment Contributes to Antigenic Shift in Bluetongue Viruses from South Africa.
Van Schalkwyk A, Coetzee P, Ebersohn K, Von Teichman B, Venter E. Viruses. 2023 Jul 23;15(7):1611. doi: 10.3390/v15071611. PMID: 37515297

WT1 and PRAME RNA-loaded dendritic cell **vaccine** as maintenance therapy in de novo AML after intensive induction chemotherapy.
Fløisand Y, Remberger M, Bigalke I, Josefsen D, Vålerhaugen H, Inderberg EM, Olaussen RW, Gjertsen BT, Goedkoop R, Geiger C, Prinz PU, Schnorfeil FM, Pinkernell K, Schendel DJ, Kvalheim G. Leukemia. 2023 Jul 28. doi: 10.1038/s41375-023-01980-3. Online ahead of print. PMID: 37507426

Population structure and antimicrobial resistance patterns of *Salmonella* Typhi and Paratyphi A amid a phased municipal **vaccination** campaign in Navi Mumbai, India.
da Silva KE, Date K, Hirani N, LeBoa C, Jayaprasad N, Borhade P, Warren J, Shimpi R, Hoffman SA, Mikoleit M, Bhatnagar P, Cao Y, Haldar P, Harvey P, Zhang C, Daruwalla S, Dharmapalan D, Gavhane J, Joshi S, Rai R, Rathod V, Shetty K, Warrier DS, Yadav S, Chakraborty D, Bahl S, Katkar A, Kunwar A, Yewale V, Dutta S, Luby SP, Andrews JR. mBio. 2023 Jul 28:e0117923. doi: 10.1128/mbio.01179-23. Online ahead of print. PMID: 37504577

Predictors of Pediatric COVID-19 **vaccination**: a case-control study in Tabriz, Iran.
Sarbakhsh P, Jafari N, Salemi S, Akbarnejad R. BMC Pediatr. 2023 Jul 31;23(1):379. doi: 10.1186/s12887-023-04202-y. PMID: 37525177

The impact of hybrid immunity on immune responses after SARS-CoV-2 **vaccination** in persons with multiple sclerosis treated with disease modifying therapies.
Rabenstein M, Thomas OG, Carlin G, Khademi M, Högelin KA, Malmeström C, Axelsson M, Brandt AF, Gafvelin G, Grönlund H, Kockum I, Piehl F, Lycke J, Olsson T, Hessa T. Eur J Neurol. 2023 Jul 31. doi: 10.1111/ene.16015. Online ahead of print. PMID: 37522464

Modulation of type I interferon responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus macaques.
Viox EG, Hoang TN, Upadhyay AA, Nchioua R, Hirschenberger M, Strongin Z, Tharp GK, Pino M, Nguyen K, Harper JL, Gagne M, Marciano S, Boddapati AK, Pellegrini KL, Pradhan A, Tisoncik-Go J, Whitmore LS, Karunakaran KA, Roy M, Kirejczyk S, Curran EH, Wallace C, Wood JS, Connor-Stroud F, Voigt EA, Monaco CM, Gordon DE, Kasturi SP, Levit RD, Gale M Jr, Vanderford TH, Silvestri G, Busman-Sahay K, Estes JD, Vaccari M, Douek DC, Sparrer KMJ, Johnson RP, Kirchhoff F, Schreiber G, Bosinger SE, Paiardini M. Sci Immunol. 2023 Jul 28;8(85):eadg0033. doi: 10.1126/sciimmunol.adg0033. Epub 2023 Jul 28. PMID: 37506197

Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic **vaccination**.
Duran-Castells C, Prats A, Oriol-Tordera B, Llano A, Galvez C, Martinez-Picado J, Ballana E, Garcia-Vidal E, Clotet B, Muñoz-Moreno JA, Hanke T, Moltó J, Mothe B, Brander C, Ruiz-Riol M. EBioMedicine. 2023 Jul 26;95:104732. doi: 10.1016/j.ebiom.2023.104732. Online ahead of print. PMID: 37506557

Long-term immunoprotection after live attenuated measles-mumps-rubella booster **vaccination** in children with juvenile idiopathic arthritis.
Hamad Saied M, van Straalen JW, de Roock S, de Joode-Smink GCJ, Verduyn Lunel FM, Swart JF, Wulffraat NM, Jansen MHA. Vaccine. 2023 Jul 27:S0264-410X(23)00883-6. doi: 10.1016/j.vaccine.2023.07.052. Online ahead of print. PMID: 37516575

Empathic Engagement With the COVID-19 **Vaccine** Hesitant in Private Facebook Groups: A Randomized Trial.
Abroms LC, Koban D, Krishnan N, Napolitano M, Simmens S, Caskey B, Wu TC, Broniatowski DA. Health Educ Behav. 2023 Jul 30:10901981231188313. doi: 10.1177/10901981231188313. Online ahead of print. PMID: 37519038

Long COVID-19 and Insulin Autoimmune Syndrome: A Case Report.
Corona-Meraz FI, Quintero-Castillo BP, Hernández-Palma LA, Machado-Sulbaran AC. Clin Ther. 2023 Jul 29:S0149-2918(23)00250-3. doi: 10.1016/j.clinthera.2023.06.026. Online ahead of print. PMID: 37524570

Effects of Sulforaphane on SARS-CoV-2 infection and NF-κB dependent expression of genes involved in the COVID-19 'cytokine storm'.
Gasparello J, Marzaro G, Papi C, Gentili V, Rizzo R, Zurlo M, Scapoli C, Finotti A, Gambari R. Int J Mol Med. 2023 Sep;52(3):76. doi: 10.3892/ijmm.2023.5279. Epub 2023 Jul 21. PMID: 37477130

COVID-19 **Vaccination** Personas in Yemen: Insights from Three Rounds of a Cross-Sectional Survey.
Nikoloski Z, Chimenya D, Alshehari A, Hassan H, Bain R, Menchini L, Gillespie A. Vaccines (Basel). 2023 Jul 21;11(7):1272. doi: 10.3390/vaccines11071272. PMID: 37515086

The treatment of mild upper respiratory tract infections - a position paper with recommendations for best practice.
Smith A, Kardos P, Pfaar O, Randerath W, Estrada Riolobos G, Braido F, Sadofsky L. Drugs Context. 2023 Jul 25;12:2023-4-2. doi: 10.7573/dic.2023-4-2. eCollection 2023. PMID: 37521107

Poly(vinyl pyrrolidone) derivatives as PEG alternatives for stealth, non-toxic and less immunogenic siRNA-containing lipoplex delivery.
Berger M, Toussaint F, Djemaa SB, Laloy J, Pendeville H, Evrard B, Jerôme C, Lechanteur A, Mottet D, Debuigne A, Piel G. J Control Release. 2023 Jul 21:S0168-3659(23)00455-8. doi: 10.1016/j.jconrel.2023.07.031. Online ahead of print. PMID: 37482343

Unveiling the interplay between evidence, values and cognitive biases. The case of the failure of the AstraZeneca COVID-19 **vaccine**.
Amoretti MC, Lalumera E. J Eval Clin Pract. 2023 Jul 29. doi: 10.1111/jep.13903. Online ahead of print. PMID: 37515407

Horizon scanning: what next for bovine TB control in England?
McCormack J. Ir Vet J. 2023 Jul 31;76(Suppl 1):18. doi: 10.1186/s13620-023-00242-z. PMID: 37525221

Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A **vaccine** candidate: a randomised, double-blind, placebo-controlled, phase 2a trial.
Leroux-Roels I, Willems P, Waerlop G, Janssens Y, Tourneur J, De Boever F, Bruhwyler J, Alhatemi A, Jacobs B, Nicolas F, Leroux-Roels G, Le Vert A. Lancet Infect Dis. 2023 Jul 27:S1473-3099(23)00351-1. doi: 10.1016/S1473-3099(23)00351-1. Online ahead of print. PMID: 37517422

Molecular and serological survey of bovine viral diarrhea virus infection in cattle in Kazakhstan.
Zhigailov AV, Perfilyeva YV, Ostapchuk YO, Kan SA, Lushova AV, Kuligin AV, Ivanova KR, Kuatbekova SA, Abdolla N, Naizabayeva DA, Maltseva ER, Berdygulova ZA, Mashzhan AS, Zima YA, Nizkorodova AS, Skiba YA, Mamadaliyev SM. Res Vet Sci. 2023 Jul 24;162:104965. doi: 10.1016/j.rvsc.2023.104965. Online ahead of print. PMID: 37516041

Testing Efficacy of a Conserved Polypeptide from the Bm86 Protein against *Rhipicephalus microplus* in the Mexican Tropics.
Coate R, Alonso-Díaz MÁ, Martínez-Velázquez M, Castro-Saines E, Hernández-Ortiz R, Lagunes-Quintanilla R. Vaccines (Basel). 2023 Jul 21;11(7):1267. doi: 10.3390/vaccines11071267. PMID: 37515082

Erythema multiforme reactions following Pfizer/BioNTech (tozinameran) **vaccination**: two case-reports with positive rechallenge and review of the literature.
Charfi O, Lakhoua G, Berrim K, Kastalli S, Aouinti I, Badri T, Daghfous R, Zaiem A, El Aidli S. Curr Drug Saf. 2023 Jul 25. doi: 10.2174/1574886318666230725101846. Online ahead of print. PMID: 37489779

Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium.
Shaw D, Abad R, Amin-Chowdhury Z, Bautista A, Bennett D, Broughton K, Cao B, Casanova C, Choi EH, Chu YW, Claus H, Coelho J, Corcoran M, Cottrell S, Cunney R, Cuypers L, Dalby T, Davies H, de Gouveia

L, Deghmane AE, Demczuk W, Desmet S, Domenech M, Drew R, du Plessis M, Duarte C, Erlendsdóttir H, Fry NK, Fuursted K, Hale T, Henares D, Henriques-Normark B, Hilty M, Hoffmann S, Humphreys H, Ip M, Jacobsson S, Johnson C, Johnston J, Jolley KA, Kawabata A, Kozakova J, Kristinsson KG, Krizova P, Kuch A, Ladhani S, Lâm TT, León ME, Lindholm L, Litt D, Maiden MCJ, Martin I, Martiny D, Mattheus W, McCarthy ND, Meehan M, Meiring S, Mölling P, Morfeldt E, Morgan J, Mulhall R, Muñoz-Almagro C, Murdoch D, Murphy J, Musilek M, Mzabi A, Novakova L, Oftadeh S, Perez-Argüello A, Pérez-Vázquez M, Perrin M, Perry M, Prevost B, Roberts M, Rokney A, Ron M, Sanabria OM, Scott KJ, Sheppard C, Siira L, Sintchenko V, Skoczyńska A, Sloan M, Slotved HC, Smith AJ, Steens A, Taha MK, Toropainen M, Tzanakaki G, Vainio A, van der Linden MPG, van Sorge NM, Varon E, Vohrnova S, von Gottberg A, Yuste J, Zanella R, Zhou F, Brueggemann AB. Lancet Digit Health. 2023 Jul 27:S2589-7500(23)00108-5. doi: 10.1016/S2589-7500(23)00108-5. Online ahead of print. PMID: 37516557

Pediatric Hospitalizations and ICU Admissions Due to COVID-19 and Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 in England.
Ward JL, Harwood R, Kenny S, Cruz J, Clark M, Davis PJ, Draper ES, Hargreaves D, Ladhani SN, Gent N, Williams HE, Luyt K, Turner S, Whittaker E, Bottle A, Fraser LK, Viner RM. JAMA Pediatr. 2023 Jul 31. doi: 10.1001/jamapediatrics.2023.2357. Online ahead of print. PMID: 37523172

Pre-emptively tackling **vaccine** misinformation for a successful large-scale roll-out of malaria **vaccines** in Africa.
Titanji BK, Mekone I, Scales D, Ndoula ST, Seungue J, Gorman S. Lancet Infect Dis. 2023 Jul 25:S1473-3099(23)00453-X. doi: 10.1016/S1473-3099(23)00453-X. Online ahead of print. PMID: 37506727

Immunization of sheep with a recombinant **vaccine** containing immunogenic nontoxic domains of Clostridium perfringens alpha and beta toxins.
Rodrigues Rodrigues R, Alves Ferreira MR, Moreira Júnior C, Ferreira Alves ML, Costa AV, Andrade Bilhalva M, Amaral Donassolo R, Freitas Motta J, Cancela Galvão C, Silva Martins FM, Masiero Salvarani F, Rochedo Conceição F. Microb Pathog. 2023 Jul 27:106269. doi: 10.1016/j.micpath.2023.106269. Online ahead of print. PMID: 37516212

Cefoperazone targets D-alanyl-D-alanine carboxypeptidase (DAC) to control *Morganella morganii*-mediated infection: a subtractive genomic and molecular dynamics approach.
Ahmad V, Jamal A, Khan MI, Alzahrani FA, Albiheyri R, Jamal QMS. J Biomol Struct Dyn. 2023 Jul 22:1-14. doi: 10.1080/07391102.2023.2238088. Online ahead of print. PMID: 37480259

Quadrivalent HPV **vaccine** effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
Nygård S, Nygård M, Orumaa M, Hansen BT. Vaccine. 2023 Jul 27:S0264-410X(23)00852-6. doi: 10.1016/j.vaccine.2023.07.031. Online ahead of print. PMID: 37516572

Vaccine Nationalism: How China**'s** State Media Misinform about Western **Vaccines** and Highlight the Successes of Chinese **Vaccines** to Different Audiences.
Chester PJ, Shih V. J Health Polit Policy Law. 2023 Jul 31:10910260. doi: 10.1215/03616878-10910260. Online ahead of print. PMID: 37522356

Evaluation of Haematological and Immunological Parameters of the ASFV Lv17/WB/Rie1 Strain and Its Derived Mutant Lv17/WB/Rie1/d110-11L against ASFV Challenge Infection in Domestic Pigs.
Franzoni G, Petrini S, Mészáros I, Dei Giudici S, Righi C, Olasz F, Zinellu S, Tamás V, Pela M, Gallardo C, Zádori Z, Oggiano A, Feliziani F. Vaccines (Basel). 2023 Jul 24;11(7):1277. doi: 10.3390/vaccines11071277. PMID: 37515092

Epidemiological evidence of acute transmission of Zika virus infection in dengue suspected patients in Sri-Lanka.
Ngwe Tun MM, Raini SK, Fernando L, Gunawardene Y, Inoue S, Takamatsu Y, Urano T, Muthugala R, Hapugoda M, Morita K. J Infect Public Health. 2023 Jul 23;16(9):1435-1442. doi: 10.1016/j.jiph.2023.07.014. Online ahead of print. PMID: 37517370

Operationalizing the Centers for Disease Control and Prevention'**s Vaccinate** With Confidence Framework During the COVID-19 Emergency Response in the United States.
Holmes K, Gutierrez-Nkomo M, Donovan J, Manns BJ, Griswold S, Edwards R, Flores SA, Parker Fiebelkorn A. Health Promot Pract. 2023 Jul 31:15248399231188106. doi: 10.1177/15248399231188106. Online ahead of print. PMID: 37525454

A Response Letter to: Letter to the Editor Regarding "Anti-SARS-CoV-2 **Vaccination** Related Polyradiculitis Requires Early Diagnosis and Treatment to Improve the Outcome: Facts and Challenges During COVID-19 Pandemic".
Duong-Quy S. Pulm Ther. 2023 Jul 24. doi: 10.1007/s41030-023-00236-w. Online ahead of print. PMID: 37488403

Effectiveness of thirteen-valent pneumococcal conjugate **vaccine** to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada.
Deceuninck G, Brousseau N, Lefebvre B, Quach C, Tapiero B, Bui YG, Desjardins M, De Wals P. Vaccine. 2023 Jul 29:S0264-410X(23)00880-0. doi: 10.1016/j.vaccine.2023.07.049. Online ahead of print. PMID: 37524629

A rare mutation causing autosomal dominant STAT1 deficiency in a South African multiplex kindred with disseminated BCG infection.
Greybe L, Leung D, Wieselthaler N, le Roux DM, Chan KW, Lau YL, Eley B. BMC Pediatr. 2023 Jul 29;23(1):378. doi: 10.1186/s12887-023-04206-8. PMID: 37516851

A Personalized Cancer Nanovaccine that Enhances T-Cell Responses and Efficacy through Dual Interactions with Dendritic Cells and T Cells.
Go S, Jung M, Lee S, Moon S, Hong J, Kim C, Chung Y, Kim BS. Adv Mater. 2023 Jul 29:e2303979. doi: 10.1002/adma.202303979. Online ahead of print. PMID: 37515819

Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo.
Hansen L, McMahon M, Turner HL, Zhu X, Turner JS, Ozorowski G, Stadlbauer D, Vahokoski J, Schmitz AJ, Rizk AA, Alsoussi WB, Strohmeier S, Yu W, Choreño-Parra JA, Jiménez-Alvarez L, Cruz-Lagunas A, Zúñiga J, Mudd PA, Cox RJ, Wilson IA, Ward AB, Ellebedy AH, Krammer F. Immunity. 2023 Jul 25:S1074-7613(23)00317-5. doi: 10.1016/j.immuni.2023.07.004. Online ahead of print. PMID: 37506693

Predictors of Tetanus **Vaccine** Uptake among Pregnant Women in Khartoum State, Sudan: A Hospital-Based Cross-Sectional Study.
Ibrahim ZA, Sabahelzain MM, Elhadi YAM, Malande OO, Babiker S. Vaccines (Basel). 2023 Jul 21;11(7):1268. doi: 10.3390/vaccines11071268. PMID: 37515083

Estimation of the relationship between meteorological factors and measles using spatiotemporal Bayesian model in Shandong Province, China.
Jia Y, Xu Q, Zhu Y, Li C, Qi C, She K, Liu T, Zhang Y, Li X. BMC Public Health. 2023 Jul 25;23(1):1422. doi: 10.1186/s12889-023-16350-y. PMID: 37491220

Correlates of protection for booster doses of the SARS-CoV-2 **vaccine** BNT162b2.
Hertz T, Levy S, Ostrovsky D, Oppenheimer H, Zismanov S, Kuzmina A, Friedman LM, Trifkovic S, Brice D, Chun-Yang L, Cohen-Lavi L, Shemer-Avni Y, Cohen-Lahav M, Amichay D, Keren-Naus A, Voloshin O, Weber G, Najjar-Debbiny R, Chazan B, McGargill MA, Webby R, Chowers M, Novack L, Novack V, Taube R, Nesher L, Weinstein O. Nat Commun. 2023 Jul 29;14(1):4575. doi: 10.1038/s41467-023-39816-4. PMID: 37516771

Successful adult **vaccine** drives must centre disability inclusion.
Rotenberg S, Downer M. Lancet. 2023 Jul 29;402(10399):369-370. doi: 10.1016/S0140-6736(23)01305-3. PMID: 37516538

Clinical Characteristics of Myasthenia Gravis Patients with COVID-19 in Guangxi, China: A Case-Control Study.
Zhou S, Wen Y, Liu C, Zhong J, Liang M, Wu Y, Lv S, Gong Z, Lao D, Li T, Lu T, Tang J, Mo X, Huang W. J Inflamm Res. 2023 Jul 26;16:3157-3168. doi: 10.2147/JIR.S419307. eCollection 2023. PMID: 37525635

Knowledge levels and community guidance of doctors working in family health centers on HPV screening and HPV **vaccination**.
Yetik I, Tanoglu FB, Pasin O, Cetin C, Ozcan P. J Obstet Gynaecol Res. 2023 Jul 29. doi: 10.1111/jog.15750. Online ahead of print. PMID: 37515522

The immediate treatment outcomes and cost estimate for managing clinical measles in children admitted at Mulago Hospital: A retrospective cohort study.
Namugga B, Malande O, Kitonsa J, Manirakiza L, Banura C, Mupere E. PLOS Glob Public Health. 2023 Jul 21;3(7):e0001523. doi: 10.1371/journal.pgph.0001523. eCollection 2023. PMID: 37478055

Gender-Related Health Care Discrimination and Human Papillomavirus **Vaccination** Among Transgender and Nonbinary Young Adults in the United States.
Agénor M, Lett E, Murchison GR, Tabaac AR, Dowshen N, Gordon AR. Transgend Health. 2023 Jul 28;8(4):389-395. doi: 10.1089/trgh.2021.0077. eCollection 2023 Aug. PMID: 37525839

Evolution of preferences for COVID-19 **vaccine** throughout the pandemic - The choice experiment approach.
Daziano R, Budziński W. Soc Sci Med. 2023 Jul 21;332:116093. doi: 10.1016/j.socscimed.2023.116093. Online ahead of print. PMID: 37515953

A Rebalancing of Financial Valuations and Expectations Moving Forward in the Telehealth Sector as the United States Moves Toward a Post-COVID-19 Reality.
Bettencourt N, Wilson CJ, Johnson PJ, D'Souza F. J Med Internet Res. 2023 Jul 31;25:e35857. doi: 10.2196/35857. PMID: 37523216

Draft genome sequences of two strains of *Staphylococcus aureus* isolated from mastitis-infected camel in Kajiado County, Kenya.
Mwangi K, Gachogo R, Masila E, Ogali I, Langat N, Onywera R, Malonza V, Wesonga H, Maichomo M, Murungi E. Microbiol Resour Announc. 2023 Jul 27:e0025423. doi: 10.1128/MRA.00254-23. Online ahead of print. PMID: 37498084

COVID-19 and **Vaccination**: Knowledge, Attitudes and Practices of People Working on Illegal Gold Mining Sites in French Guiana.
Durand P, Basurko C, Vreden S, Nacher M, Douine M. Vaccines (Basel). 2023 Jul 21;11(7):1265. doi: 10.3390/vaccines11071265. PMID: 37515080

Re-**vaccination** For Hepatitis B in Previous Non-Responders Following Hepatitis C Eradication.
Powell JG, Goble SR, Debes JD. J Infect Dis. 2023 Jul 31:jiad301. doi: 10.1093/infdis/jiad301. Online ahead of print. PMID: 37523757

Post-marketing Safety Surveillance of a Hexavalent **Vaccine** in the **Vaccine** Adverse Event Reporting System.
Moro PL, Zhang B, Marquez P, Reich J. J Pediatr. 2023 Jul 28:113643. doi: 10.1016/j.jpeds.2023.113643. Online ahead of print. PMID: 37517652

Characterization of *Brucella abortus* Mutant A19mut2, a Potential DIVA **Vaccine** Candidate with a Modification on Lipopolysaccharide.
Abdelgawad HA, Lian Z, Yin Y, Fang T, Tian M, Yu S. Vaccines (Basel). 2023 Jul 21;11(7):1273. doi: 10.3390/vaccines11071273. PMID: 37515088

Prevalence of SARS-CoV-2 Variants and Disease Outcome of COVID-19 Patients in the Amazonas Region of Peru.
Campos CJ, Pajuelo-Reyes C, Rojas LM, De La Cruz-Vargas JA, Tejedo JR, Tapia-Limonchi R, Tsukayama P, Chenet SM. Am J Trop Med Hyg. 2023 Jul 31:tpmd220739. doi: 10.4269/ajtmh.22-0739. Online ahead of print. PMID: 37524331

Detection of HPV DNA, E6/E7 mRNA, and p16INK4a in lung cancer: A systematic review and meta-analysis.
Li X, Ling Y, Hu L, Zhang L, Lin S, Zhang X, Zang S. J Infect Dis. 2023 Jul 28:jiad295. doi: 10.1093/infdis/jiad295. Online ahead of print. PMID: 37506267

Humoral Response After 6 or More Successive Doses of SARS-CoV-2 mRNA **Vaccines** in Kidney Transplant Recipients-Should We Keep **Vaccinating**?
Åsberg A, Hovd M, Kjellevold SA, Stenehjem AE, Wien TN, Broch LU, Reier-Nielsen M, Qvale TH, Marti HP, Heldal K, Bitter J, Hagelsteen Kvien E, Vaage JT, Lund-Johansen F, Midtvedt K. Transplantation. 2023 Jul 27. doi: 10.1097/TP.0000000000004732. Online ahead of print. PMID: 37496122

Natural Killer Cells in SARS-CoV-2-**Vaccinated** Subjects with Increased Effector Cytotoxic $CD56^{dim}$ Cells and Memory-Like $CD57^{+}NKG2C^{+}CD56^{dim}$ Cells.
Gentili V, Bortolotti D, Morandi L, Rizzo S, Schiuma G, Beltrami S, Casciano F, Papi A, Contoli M, Zauli G, Rizzo R. Front Biosci (Landmark Ed). 2023 Jul 31;28(7):156. doi: 10.31083/j.fbl2807156. PMID: 37525920

QuickStats: Percentage* of Adults Aged ≥18 Years who Received an Influenza **Vaccination** in the Past 12 Months,† by Race and Ethnicity§ and Family Income¶ - National Health Interview Survey, United States, 2021.
[No authors listed] MMWR Morb Mortal Wkly Rep. 2023 Jul 28;72(30):836. doi: 10.15585/mmwr.mm7230a7. PMID: 37498799

Prevalence of Post COVID-19 **Vaccination** Side Effects amongst Corp Members in an NYSC Orientation Camp in North Central Nigeria.
Udeogu KE, Kuza PB, Hauwa YY, Shehu N, Akpan WS, Usman AM. West Afr J Med. 2023 Jul 28;40(7):742-747. PMID: 37516926

Trust, but verify: a new potential association between food allergy and asthma in children.
Greenhawt M, Phipatanakul W. Lancet Child Adolesc Health. 2023 Jul 24:S2352-4642(23)00150-5. doi: 10.1016/S2352-4642(23)00150-5. Online ahead of print. PMID: 37506716

Effects of previous infection, **vaccination**, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study.
Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, Al-Khatib HA, Al Thani AA, Coyle P, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. EBioMedicine. 2023 Jul 27;95:104734. doi: 10.1016/j.ebiom.2023.104734. Online ahead of print. PMID: 37515986

Physicochemical significance of Topological indices: Importance in drug discovery research.
Bhatia KS, Kumar Gupta A, Saxena AK. Curr Top Med Chem. 2023 Jul 31. doi: 10.2174/1568026623666230731103309. Online ahead of print. PMID: 37519204

Pharmacist telehealth in an underserved urban population with type 2 diabetes mellitus.
Mukherjee SM, DelDotto D, Patel A, Silva MA. Res Social Adm Pharm. 2023 Jul 23:S1551-7411(23)00328-5. doi: 10.1016/j.sapharm.2023.07.010. Online ahead of print. PMID: 37507339

Epidemiology of hand, foot and mouth disease and genomic surveillance of coxsackievirus A10 circulating in Zhejiang Province, China during 2017 to 2022.
Sun Y, Cai J, Mao H, Gong L, Chen Y, Yan H, Shi W, Lou X, Su L, Wang X, Zhou B, Pei Z, Cao Y, Ge Q, Zhang Y. J Clin Virol. 2023 Jul 23;166:105552. doi: 10.1016/j.jcv.2023.105552. Online ahead of print. PMID: 37523938

Studies on immunopathological changes induced by commercial IBD live **vaccines** in poultry birds.
Kajal S, Narang G, Jangir BL, Kundu P, Lather D, Chhabra R. Sci Rep. 2023 Jul 31;13(1):12379. doi: 10.1038/s41598-023-39017-5. PMID: 37524771

Urine shedding patterns of pathogenic Leptospira spp. in dairy cows.
Monti G, Montes V, Tortosa P, Tejeda C, Salgado M. Vet Res. 2023 Jul 31;54(1):64. doi: 10.1186/s13567-023-01190-w. PMID: 37525220

Identification of Spatial Clusters of Undervaccination Patterns Among Children Aged <24 Months Using Immunization Information System Data, Montana, 2015-2019.
Newcomer SR, Graham J, Irish K, Freeman RE, Leary CS, Wehner BK, Daley MF. Public Health Rep. 2023 Jul 28:333549231186603. doi: 10.1177/00333549231186603. Online ahead of print. PMID: 37503702

BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass **vaccination** campaign in southern Brazil: A prospective test-negative design study.
Rosa RG, Falavigna M, Manfio JL, de Araujo CLP, Cohen M, do Valle Barbosa GRG, de Souza AP, Romeiro Silva FK, Sganzerla D, da Silva MMD, Ferreira D, de Oliveira Rodrigues C, de Souza EM, de Oliveira JC, Gradia DF, Brandalize APC, Royer CA, Luiz RM, Kucharski GA, Pedrotti F, Valluri SR, Srivastava A, Julião VW, Melone OC, Allen KE, Kyaw MH, Spinardi J, Del Carmen Morales Castillo G, McLaughlin JM; Toledo BNT16b2 Study Group Investigators. Vaccine. 2023 Jul 26:S0264-410X(23)00869-1. doi: 10.1016/j.vaccine.2023.07.038. Online ahead of print. PMID: 37507274

Comment: Detection of **Vaccine** Adverse Events Before Package Insert Revisions Using a Japanese Spontaneous Reporting System.
Noguchi Y, Yoshimura T. J Clin Pharmacol. 2023 Jul 28. doi: 10.1002/jcph.2324. Online ahead of print. PMID: 37504515

New-onset severe eosinophilic granulomatosis with polyangiitis following the third dose of mRNA COVID-19 **vaccine**: A case report.
Mahdi S, Joudeh AI, Raman KS, Faqih SA, Alhatou MI, Wadiwala MF, Akhtar M, Lutf AQA. Mod Rheumatol Case Rep. 2023 Jul 25:rxad043. doi: 10.1093/mrcr/rxad043. Online ahead of print. PMID: 37525576

Tandem mass tag (TMT) labeling-based quantitative proteomic analysis reveals the cellular protein characteristics of 16HBE cells infected with coxsackievirus A10 and the potential effect of HMGB1 on viral replication.
Song J, Zhao G, Li H, Yang Y, Yu Y, Hu Y, Li Y, Li J, Hu Y. Arch Virol. 2023 Jul 31;168(8):217. doi: 10.1007/s00705-023-05821-7. PMID: 37524962

Strategies to Promote **Vaccine** Uptake in the COVID-19 Pandemic: Exploring the "Ladder of Intrusiveness" in Three Countries.
Cacace M, Castelli M, Toth F. J Health Polit Policy Law. 2023 Jul 31:10910251. doi: 10.1215/03616878-10910251. Online ahead of print. PMID: 37522380

Market Failure, State Failure: The Political Economy of Supply Chain Strengthening to Ensure Equitable Access to **Vaccines** and Medicines in Low- and Middle-Income Countries.
Fox A. J Health Polit Policy Law. 2023 Jul 31:10910242. doi: 10.1215/03616878-10910242. Online ahead of print. PMID: 37522368

The Screening of the Protective Antigens of *Aeromonas hydrophila* Using the Reverse Vaccinology Approach: Potential Candidates for Subunit **Vaccine** Development.
Zhang T, Zhang M, Xu Z, He Y, Zhao X, Cheng H, Chen X, Xu J, Ding Z. Vaccines (Basel). 2023 Jul 21;11(7):1266. doi: 10.3390/vaccines11071266. PMID: 37515081

Rescue of a Live-Attenuated Porcine Epidemic Diarrhea Virus HSGP Strain Using a Virulent Strain and a Partially Attenuated Strain.
Song S, Park GN, Shin J, Kim KS, An BH, Choe S, Kim SY, Hyun BH, An DJ. Viruses. 2023 Jul 21;15(7):1601. doi: 10.3390/v15071601. PMID: 37515287

Protocol for analyzing antibody responses to glycoprotein antigens using electron-microscopy-based polyclonal epitope mapping.
Turner HL, Jackson AM, Richey ST, Sewall LM, Antanasijevic A, Hangartner L, Ward AB. STAR Protoc. 2023 Jul 28;4(3):102476. doi: 10.1016/j.xpro.2023.102476. Online ahead of print. PMID: 37516970

Potent cross-neutralization of respiratory syncytial virus and human metapneumovirus through a structurally conserved antibody recognition mode.
Wen X, Suryadevara N, Kose N, Liu J, Zhan X, Handal LS, Williamson LE, Trivette A, Carnahan RH, Jardetzky TS, Crowe JE Jr. Cell Host Microbe. 2023 Jul 26:S1931-3128(23)00298-6. doi: 10.1016/j.chom.2023.07.002. Online ahead of print. PMID: 37516111

Incremental effectiveness of 23-valent pneumococcal polysaccharide **vaccine** against pneumonia hospitalisation among Australian Indigenous children: A record linkage study.
Kabir A, Randall D, Newall AT, Moore HC, Jayasinghe S, Fathima P, Liu B, McIntyre P, Gidding HF. Vaccine. 2023 Jul 26:S0264-410X(23)00873-3. doi: 10.1016/j.vaccine.2023.07.042. Online ahead of print. PMID: 37507273

Investigation of airborne spread of COVID-19 using a hybrid agent-based model: a case study of the UK.
Rahaman H, Barik D. R Soc Open Sci. 2023 Jul 26;10(7):230377. doi: 10.1098/rsos.230377. eCollection 2023 Jul. PMID: 37501658

Robust immunogenicity of a third BNT162b2 **vaccination** against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort.
Lavender B, Hooker C, Frampton C, Williams M, Carson S, Paterson A, McGregor R, Moreland NJ, Gell K, Priddy FH, Wiig K, Le Gros G, Ussher JE, Brewerton M. Vaccine. 2023 Jul 27:S0264-410X(23)00882-4. doi: 10.1016/j.vaccine.2023.07.051. Online ahead of print. PMID: 37516574

Antibody response to inactivated COVID-19 **vaccine** in patients with type 2 diabetes mellitus after the booster immunization.
Li H, Wang Y, Li X, Wang S, Feng X, Xiao X, Li Y. J Diabetes. 2023 Jul 30. doi: 10.1111/1753-0407.13448. Online ahead of print. PMID: 37518861

Histopathological Pulmonary Lesions in 1st-Day Newborn Piglets Derived from PRRSV-1 MLV **Vaccinated** Sows at the Last Stage of Gestation.

Papakonstantinou GI, Psalla D, Pourlis A, Stylianaki I, Athanasiou LV, Tzika E, Meletis E, Kostoulas P, Maragkakis G, Christodoulopoulos G, Papaioannou N, Papatsiros VG. Life (Basel). 2023 Jul 23;13(7):1609. doi: 10.3390/life13071609. PMID: 37511984

Assessment of Risk Perception of COVID-19 Post **Vaccination** amongst the General Population of Riyadh Region.
Al-Shouli ST, AlAfaleq NO, Almansour M, Alsadhan M, Alsalem N, Alqahtani M, Aldahash N, Almazyad L, Alhazmi S, Aljerian K. Vaccines (Basel). 2023 Jul 24;11(7):1276. doi: 10.3390/vaccines11071276. PMID: 37515091

Comparative effectiveness of four COVID-19 **vaccines**, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection.
Liu B, Stepien S, Qian J, Gidding H, Nicolopoulos K, Amin J, Cheng A, Macartney K. Vaccine. 2023 Jul 29:S0264-410X(23)00881-2. doi: 10.1016/j.vaccine.2023.07.050. Online ahead of print. PMID: 37524631

Clinical assessment of a point-of-care assay to determine protective **vaccinal** antibody titers to canine viral diseases.
Ad Y, Halperin IM, Olstad EC, Gershwin LJ, Sullivan L, Reagan KL. Vet J. 2023 Jul 29:106017. doi: 10.1016/j.tvjl.2023.106017. Online ahead of print. PMID: 37524148

Adaptation and Formative Evaluation of Online Decision Support to Implement Evidence-Based Strategies to Increase HPV **Vaccination** Rates in Pediatric Clinics.
Shegog R, Savas LS, Frost EL, Thormaehlen LC, Teague T, Steffy J, Healy CM, Shay LA, Preston S, Vernon SW. Vaccines (Basel). 2023 Jul 21;11(7):1270. doi: 10.3390/vaccines11071270. PMID: 37515085

The Political Economy of **Vaccines** During the COVID-19 Pandemic.
Jarman H, da Fonsec EM, King EJ. J Health Polit Policy Law. 2023 Jul 31:10910797. doi: 10.1215/03616878-10910797. Online ahead of print. PMID: 37522345

A promising candidate for a universal influenza **vaccine**.
Isakova-Sivak I, Rudenko L. Lancet Infect Dis. 2023 Jul 27:S1473-3099(23)00366-3. doi: 10.1016/S1473-3099(23)00366-3. Online ahead of print. PMID: 37517421

Benefit of repeated COVID-19 **vaccination** for patients with B-cell malignancies.
Bacher U, Shumilov E, Pabst T. Br J Haematol. 2023 Jul 30. doi: 10.1111/bjh.19005. Online ahead of print. PMID: 37519052

First case of rapidly fatal mpox from secondary (household) transmission in a kidney transplant recipient.
Fuller R, Cederroth T, Patel G, Reidy J, Patiño LH, Ramírez JD, Bassily-Marcus A, Paniz-Mondolfi A. Am J Transplant. 2023 Jul 27:S1600-6135(23)00594-4. doi: 10.1016/j.ajt.2023.07.017. Online ahead of print. PMID: 37516244

Genetic Diversity of Newcastle Disease Virus Involved in the 2021 Outbreaks in Backyard Poultry Farms in Tanzania.
Amoia CF, Hakizimana JN, Duggal NK, Chengula AA, Rohaim MA, Munir M, Weger-Lucarelli J, Misinzo G. Vet Sci. 2023 Jul 21;10(7):477. doi: 10.3390/vetsci10070477. PMID: 37505881

Safety, tolerability, and pharmacokinetics of half-life extended SARS-CoV-2-neutralizing monoclonal antibodies AZD7442 (tixagevimab/cilgavimab) in healthy Japanese adults.
Okada H, Ishikawa K, Itoh Y, Noda Y, Eto T, Reddy VP, Chen CC, Gibbs M, Johnsson E. J Infect Chemother. 2023 Jul 29:S1341-321X(23)00181-2. doi: 10.1016/j.jiac.2023.07.014. Online ahead of print. PMID: 37524201

Synergistic Antitumor Effect of Combined Radiotherapy and Engineered *Salmonella typhimurium* in an Intracranial Sarcoma Mouse Model.
Liu Z, Lim SH, Min JJ, Jung S. Vaccines (Basel). 2023 Jul 23;11(7):1275. doi: 10.3390/vaccines11071275. PMID: 37515090

Association of Prior COVID-19 **Vaccination** With SARS-CoV-2 Infection and Death in Children and Young Persons During the Omicron Variant Period in Brazil.
Oliveira EA, Oliveira MCL, Simões E Silva AC, Colosimo EA, Mak RH, Pinhati CC, Martelli H Jr. JAMA Pediatr. 2023 Jul 31. doi: 10.1001/jamapediatrics.2023.2584. Online ahead of print. PMID: 37523191

Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.**S**.
Struyf F, Hardt K, Van Rampelbergh R, Shukarev G, Inamdar A, Ruiz-Guiñazú J, van Paassen V, Anaya-Velarde L, Diba C, Ceuppens M, Cardenas V, Soff GA, Pragalos A, Sadoff J, Douoguih M. Vaccine. 2023 Jul 28:S0264-410X(23)00825-3. doi: 10.1016/j.vaccine.2023.07.013. Online ahead of print. PMID: 37517912

Cardiovascular Assessment up to One Year After COVID-19 **Vaccine**-Associated Myocarditis.
Yu CK, Tsao S, Ng CW, Chua GT, Chan KL, Shi J, Chan YY, Ip P, Kwan MY, Cheung YF. Circulation. 2023 Aug;148(5):436-439. doi: 10.1161/CIRCULATIONAHA.123.064772. Epub 2023 Jul 31. PMID: 37523760

Successful adult **vaccine** drives must centre disability inclusion - Authors' reply.
Agus DB, Nguyen A, Bell J. Lancet. 2023 Jul 29;402(10399):370. doi: 10.1016/S0140-6736(23)01306-5. PMID: 37516540

Clinical outcomes of COVID-19 in Mycosis Fungoides and Sezary Syndrome.
Levy Yurkovski I, Rokach L, Melamed G, Alapi H, Gazit S, Patalon T, Tadmor T. Acta Haematol. 2023 Jul 29. doi: 10.1159/000531831. Online ahead of print. PMID: 37517402

Cohort profile: The Corona Behavioral Unit cohort, a longitudinal mixed-methods study on COVID-19-related behavior, well-being and policy support in the Netherlands.
van den Boom W, van Dijk M, Snijders B, Luijben G, van der Laan J, Euser S, Sanders JG, Buitenhuis AH, Spruijt P, Kroese F, Lambooij M, Muhren Y, Tak N, van der Swaluw K, van Rossum C, Nielen T, Elberse J, Renes RJ, Leurs M, de Bruin M. PLoS One. 2023 Jul 31;18(7):e0289294. doi: 10.1371/journal.pone.0289294. eCollection 2023. PMID: 37523360

Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2.
Chiang HL, Liang KH, Lu RM, Kuo TW, Lin YL, Wu HC. J Biomed Sci. 2023 Jul 31;30(1):59. doi: 10.1186/s12929-023-00955-x. PMID: 37525188

Missed opportunity for routine **vaccination** and associated factors among children aged 0-23 months in public health facilities of Jimma Town.
Abatemam H, Wordofa MA, Worku BT. PLOS Glob Public Health. 2023 Jul 25;3(7):e0001819. doi: 10.1371/journal.pgph.0001819. eCollection 2023. PMID: 37490474

Modulation of Cystatin F in Human Macrophages Impacts Cathepsin-Driven Killing of Multidrug-Resistant *Mycobacterium tuberculosis*.
Mandal M, Pires D, Catalão MJ, Azevedo-Pereira JM, Anes E. Microorganisms. 2023 Jul 24;11(7):1861. doi: 10.3390/microorganisms11071861. PMID: 37513033

Patients with Hashimoto'**s** thyroiditis present higher immune response to COVID-19 mRNA **vaccine** compared to normal individuals.
Polymeris A, Papapetrou PD, Psachna S, Ioannidis D, Lilis D, Drakou M, Vaiopoulos A, Polymerou V, Spanos G. Hormones (Athens). 2023 Jul 29. doi: 10.1007/s42000-023-00470-6. Online ahead of print. PMID: 37515710

T4 bacteriophage nanoparticles engineered through CRISPR provide a versatile platform for rapid development of flu mucosal **vaccines**.
Li M, Chen C, Wang X, Guo P, Feng H, Zhang X, Zhang W, Gu C, Zhu J, Wen G, Feng Y, Xiao L, Peng G, Rao VB, Tao P. Antiviral Res. 2023 Jul 27:105688. doi: 10.1016/j.antiviral.2023.105688. Online ahead of print. PMID: 37516153

Peptide **vaccine** turns up the heat in ALK-positive cancers.
Eccleston A. Nat Rev Drug Discov. 2023 Jul 31. doi: 10.1038/d41573-023-00123-8. Online ahead of print. PMID: 37524810

Exploring the Potential of a Genome-Reduced *Escherichia coli* Strain for Plasmid DNA Production.
Nguyen TT, Bui LM, Byun JY, Cho BK, Kim SC. Int J Mol Sci. 2023 Jul 21;24(14):11749. doi: 10.3390/ijms241411749. PMID: 37511505

Effects of Tannic Acid Supplementation on the Intestinal Health, Immunity, and Antioxidant Function of Broilers Challenged with Necrotic Enteritis.
Xu H, Zhang X, Li P, Luo Y, Fu J, Gong L, Lv Z, Guo Y. Antioxidants (Basel). 2023 Jul 24;12(7):1476. doi: 10.3390/antiox12071476. PMID: 37508014

Turkish airline cabin crew members' attitudes towards protection from infectious diseases in the context of their health responsibilities and health perceptions.
Gökçay G, Çevirme A. Travel Med Infect Dis. 2023 Jul 25:102623. doi: 10.1016/j.tmaid.2023.102623. Online ahead of print. PMID: 37499775

Modification of the antigenicity of cancer cells by conjugates consisting of hyaluronic acid and foreign antigens.
Ogata S, Tsuji R, Moritaka A, Ito S, Mochizuki S. Biomater Sci. 2023 Jul 31. doi: 10.1039/d3bm00439b. Online ahead of print. PMID: 37522638

Autoantibodies against an immunodominant epitope from apolipoprotein B and risk of cardiovascular events in subjects with type 2 diabetes.
Sant'Anna VAR, Izar MCO, Gidlund M, Fonseca HAR; Vaccine Heart Group. Eur J Intern Med. 2023 Jul 26:S0953-6205(23)00245-5. doi: 10.1016/j.ejim.2023.07.018. Online ahead of print. PMID: 37507264

Intellectual Property and the Politics of Public Good in COVID-19: Framing Law, Institutions, and Ideas during TRIPS Waiver Negotiations at the WTO.
Fischer SE, Vitale L, Agutu AL, Kavanagh MM. J Health Polit Policy Law. 2023 Jul 31:10910269. doi: 10.1215/03616878-10910269. Online ahead of print. PMID: 37522338

Efficacy of inactivated SARS-CoV-2 **vaccination** in pediatric hematology/oncology patients: a real-world study.
Miao J, Zhang JY, Liang J, Zhao FY, Song H, Xu WQ, Tang YM, Xu XJ, Shu Q. World J Pediatr. 2023 Jul 31. doi: 10.1007/s12519-023-00737-3. Online ahead of print. PMID: 37525069

Continued Circulation of Highly Pathogenic H5 Influenza Viruses in Vietnamese Live Bird Markets in 2018-2021.
Guan L, Babujee L, Browning VL, Presler R, Pattinson D, Nguyen HLK, Hoang VMP, Le MQ, van Bakel H, Neumann G, Kawaoka Y. Viruses. 2023 Jul 21;15(7):1596. doi: 10.3390/v15071596. PMID: 37515281

A tale of two cities: A retrospective observational cohort study of the impact of COVID-19 on acute stroke presentation, timing, and outcomes.
Brown GG, Foroughi R, Bandela S, Cardentey A, Clark KL, Dula AN. J Stroke Cerebrovasc Dis. 2023 Jul 26;32(9):107274. doi: 10.1016/j.jstrokecerebrovasdis.2023.107274. Online ahead of print. PMID: 37506542

A study of anti-SARS-CoV-2 antibody positivity in Duhok City, Iraq.
Hussein NR, Shahab GH, Rasheed NA, Ahmed AN, Salih RS, Mahdi AS, Mansour SA, Mahdi S, Naqid IA, Ibrahim N, Musa DH, Saleem ZS. J Infect Dev Ctries. 2023 Jul 27;17(7):937-943. doi: 10.3855/jidc.17518. PMID: 37515796

Africa needs to boost HPV **vaccine** uptake to stem rise in cervical cancer.
Senior K. Lancet Oncol. 2023 Jul 27:S1470-2045(23)00380-7. doi: 10.1016/S1470-2045(23)00380-7. Online ahead of print. PMID: 37517408

Reply to: Comment: Detection of **Vaccine** Adverse Events Before Package Insert Revisions Using a Japanese Spontaneous Reporting System.
Suzuki S, Imai S, Mitsuboshi S, Kizaki H, Hashiguchi M, Hori S. J Clin Pharmacol. 2023 Jul 29. doi: 10.1002/jcph.2323. Online ahead of print. PMID: 37515403

High uptake of **vaccination** against mpox in men who have sex with men (MSM) on HIV pre-exposure prophylaxis (PrEP) in Paris, France.
Palich R, Jedrzejewski T, Schneider L, Qatib N, Orriere T, Gosset D, Grunemwald T, Pataut D, Ohayon M, Katlama C. Sex Transm Infect. 2023 Jul 28:sextrans-2023-055885. doi: 10.1136/sextrans-2023-055885. Online ahead of print. PMID: 37507222

Exposing and exploiting host-parasite arms race clues in SARS-CoV-2: a principally new method for improved T cell immunogenicity prediction.
Flegr J, Králová Lesná I, Zahradník D. Biol Methods Protoc. 2023 Jul 25;8(1):bpad011. doi: 10.1093/biomethods/bpad011. eCollection 2023. PMID: 37497282

Anti/Vax: Reframing the **Vaccine** Controversy, by Bernice L. Hausman : Ithaca, NY: ILR Press, an imprint of Cornell University Press, 2019.
Larson HJ. J Med Humanit. 2023 Jul 29. doi: 10.1007/s10912-023-09815-z. Online ahead of print. PMID: 37507624

Elimination of cervical cancer in Latin America (Project ECHO-ELA): lessons from phase one of implementation.
Batman S, Varon ML, San Miguel-Majors SL, Benitez Majano S, Pontremoli Salcedo M, Montealegre J, Arrossi S, Oliveira MTDC, Oliveira LH, Luciani S, Milan J, Trimble EL, Schmeler KM, Maza M. Rev Panam Salud Publica. 2023 Jul 24;47:e113. doi: 10.26633/RPSP.2023.113. eCollection 2023. PMID: 37489237

Factors associated with Pap test screening among South Korean women aged 20 to 39 years.
Seo YA, Kim YA. Medicine (Baltimore). 2023 Jul 28;102(30):e34539. doi: 10.1097/MD.0000000000034539. PMID: 37505160

The role of wastewater-based epidemiology for SARS-CoV-2 in developing countries: Cumulative evidence from South Africa supports sentinel site surveillance to guide public health decision-making.
Iwu-Jaja C, Ndlovu NL, Rachida S, Yousif M, Taukobong S, Macheke M, Mhlanga L, van Schalkwyk C, Pulliam J, Moultrie T, le Roux W, Schaefer L, Pockock G, Coetzee L, Mans J, Bux F, Pillay L, de Villiers D, du Toit AP, Jambo D, Gomba A, Groenink S, Madgewick N, van der Walt M, Mutshembele A, Berkowitz N, Suchard M, McCarthy K; SACCESS network. Sci Total Environ. 2023 Jul 26:165817. doi: 10.1016/j.scitotenv.2023.165817. Online ahead of print. PMID: 37506905

Analysis of the crystal structure of a parallel three-stranded coiled coil.
de March M, Hickey N, Geremia S. Proteins. 2023 Jul 27. doi: 10.1002/prot.26557. Online ahead of print. PMID: 37501532

Cathelicidin CATH-B1 Inhibits Pseudorabies Virus Infection via Direct Interaction and TLR4/JNK/IRF3-Mediated Interferon Activation.
Ye C, Wan C, Chen J, Li G, Li Y, Wang Y, Tao Q, Peng L, Fang R. J Virol. 2023 Jul 27;97(7):e0070623. doi: 10.1128/jvi.00706-23. Epub 2023 Jun 14. PMID: 37314341

Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study.
Polaris Observatory Collaborators. Lancet Gastroenterol Hepatol. 2023 Jul 27:S2468-1253(23)00197-8. doi: 10.1016/S2468-1253(23)00197-8. Online ahead of print. PMID: 37517414

Complete genome constellations of two bovine rotavirus A strains isolated in Japan reveal a unique T9 NSP3 genotype.
Hasan MA, Suzuki M, Sakai K, Kabir MH, Miyaoka Y, Hakim H, Kadota C, Shoham D, Takehara K. J Vet Med Sci. 2023 Jul 26. doi: 10.1292/jvms.23-0268. Online ahead of print. PMID: 37495525

Immunoinformatics and MD-simulation data suggest that Omicron spike epitopes are more interacting to IgG via better MHC recognition than Delta variant.
Sarkar A, Santra D, Sundar Panja A, Maiti S. Int Immunopharmacol. 2023 Jul 25;123:110636. doi: 10.1016/j.intimp.2023.110636. Online ahead of print. PMID: 37499394

Contribution of traditional Japanese Kampo medicines, kakkonto with shosaikotokakikyosekko, in treating patients with mild-to-moderate coronavirus disease 2019: Further analysis of a multicenter, randomized controlled trial.
Takayama S, Namiki T, Arita R, Ono R, Kikuchi A, Ohsawa M, Saito N, Suzuki S, Nakae H, Kobayashi S, Yoshino T, Ishigami T, Tanaka K, Takagi A, Yamaguchi T, Ishii T, Hisanaga A, Mitani K, Ito T. J Infect Chemother. 2023 Jul 26:S1341-321X(23)00175-7. doi: 10.1016/j.jiac.2023.07.013. Online ahead of print. PMID: 37507087

Temporally Associated Invasive Pneumococcal Disease and SARS-CoV-2 Infection, Alaska, USA, 2020-2021.
Newell K, Fischer M, Massey S, Orell L, Steinberg J, Tompkins M, Castrodale L, McLaughlin J. Emerg Infect Dis. 2023 Jul 28;29(9). doi: 10.3201/eid2909.230080. Online ahead of print. PMID: 37506683

High Engagement in Care in a Pediatric Medical Home for Children Impacted By Parental Substance Use.
Stulac SN, Costello E, Baker J, Elansary M, Reed K, Lasser KE. Clin Pediatr (Phila). 2023 Jul 29:99228231189140. doi: 10.1177/00099228231189140. Online ahead of print. PMID: 37515533

Effects of breakthrough infections on clinical characteristics and outcomes among patients with Japanese encephalitis.
Zhou Y, Zhao LL, Chen J, Zhang WX, Zhao SY, Wang C, Du J, Wei TT, Liu YQ, Lu QB, Liu M, Cui F. J Infect. 2023 Jul 24:S0163-4453(23)00385-7. doi: 10.1016/j.jinf.2023.07.012. Online ahead of print. PMID: 37495190

Reducing perinatal infection risk in newborns of mothers who received inadequate prenatal care.
Bitnun A, Sauvé L, Fanella S. Paediatr Child Health. 2023 Jul 22;28(5):307-323. doi: 10.1093/pch/pxad014. eCollection 2023 Aug. PMID: 37484040

Social Determinants of Health and COVID-19.
Mosnaim G, Carrasquel M, Wolfson AR, Peters J, Lang D, Rathkopf M. J Allergy Clin Immunol Pract. 2023 Jul 26:S2213-2198(23)00800-0. doi: 10.1016/j.jaip.2023.07.027. Online ahead of print. PMID: 37507069

Advances in new target molecules against schistosomiasis: A comprehensive discussion of physiological structure and nutrient intake.
Zhu P, Wu K, Zhang C, Batool SS, Li A, Yu Z, Huang J. PLoS Pathog. 2023 Jul 27;19(7):e1011498. doi: 10.1371/journal.ppat.1011498. eCollection 2023 Jul. PMID: 37498810

COVID-19 annual update: a narrative review.
Biancolella M, Colona VL, Luzzatto L, Watt JL, Mattiuz G, Conticello SG, Kaminski N, Mehrian-Shai R, Ko AI, Gonsalves GS, Vasiliou V, Novelli G, Reichardt JKV. Hum Genomics. 2023 Jul 24;17(1):68. doi: 10.1186/s40246-023-00515-2. PMID: 37488607

Public health infection prevention: An analysis of existing training during the COVID-19 pandemic.
Burton S, Landers T, Wilson M, Ortiz-Gumina C, Persaud A, McNeill Ransom M, Fox L, Murphy SA. Public Health. 2023 Jul 24;222:7-12. doi: 10.1016/j.puhe.2023.06.029. Online ahead of print. PMID: 37494870

The kynurenine pathway of tryptophan metabolism: a neglected therapeutic target of COVID-19 pathophysiology and immunotherapy.
Badawy AA. Biosci Rep. 2023 Jul 24:BSR20230595. doi: 10.1042/BSR20230595. Online ahead of print. PMID: 37486805

Novel phenanthrene imidazoles as telomeric G-quadruplex ligands trigger potent immunogenic cell death in triple-negative breast cancer.
Wang XD, Wang JX, Hu MH. Int J Biol Macromol. 2023 Jul 29:126068. doi: 10.1016/j.ijbiomac.2023.126068. Online ahead of print. PMID: 37524278

The potential of saliva as an accessible and sensitive sample type for the detection of respiratory pathogens and host immunity.
Laxton CS, Peno C, Hahn AM, Allicock OM, Perniciaro S, Wyllie AL. Lancet Microbe. 2023 Jul 26:S2666-5247(23)00135-0. doi: 10.1016/S2666-5247(23)00135-0. Online ahead of print. PMID: 37516121

Risk of Acute Myocardial Infarction Following Invasive Pneumococcal Disease: How Much Is Due to Antibiotic Treatments?
Rezahosseini O, Harboe ZB. Clin Infect Dis. 2023 Jul 26;77(2):330. doi: 10.1093/cid/ciad176. PMID: 36975109

Analysis of hepatocellular carcinoma associated with hepatitis B virus.
Zheng L. J Cell Mol Med. 2023 Jul 30. doi: 10.1111/jcmm.17867. Online ahead of print. PMID: 37517004

Challenges to the control of Mycobacterium bovis in livestock and wildlife populations in the South African context.
Davey S. Ir Vet J. 2023 Jul 25;76(Suppl 1):14. doi: 10.1186/s13620-023-00246-9. PMID: 37491403

Syphilis.
Peeling RW, Mabey D, Chen XS, Garcia PJ. Lancet. 2023 Jul 22;402(10398):336-346. doi: 10.1016/S0140-6736(22)02348-0. PMID: 37481272

Reconstruction of the unbinding pathways of new inhibitors of the SARS-CoV-2 papain-like protease using molecular dynamics simulation.
Rahebi P, Aryapour H. J Biomol Struct Dyn. 2023 Jul 28:1-14. doi: 10.1080/07391102.2023.2240424. Online ahead of print. PMID: 37505097

Visible light-induced specific protein reaction delineates early stages of cell adhesion.
Rahikainen R, Vester SK, Turkki P, Janosko CP, Deiters A, Hytönen VP, Howarth M. bioRxiv. 2023 Jul 22:2023.07.21.549850. doi: 10.1101/2023.07.21.549850. Preprint. PMID: 37503248

A recombinant Aspergillus oryzae fungus transmitted from larvae to adults of Anopheles stephensi mosquitoes inhibits malaria parasite oocyst development.

Kianifard L, Rafiqi AM, Akcakir O, Aly ASI, Billingsley PF, Uysal S. Sci Rep. 2023 Jul 27;13(1):12177. doi: 10.1038/s41598-023-38654-0. PMID: 37500682

A global investment case for hepatitis B elimination: a modelling study.
Seaman CP, Luong P, Xiao Y, Abeysuriya R, Howell J, Hellard M, Scott N. Lancet Gastroenterol Hepatol. 2023 Jul 27:S2468-1253(23)00156-5. doi: 10.1016/S2468-1253(23)00156-5. Online ahead of print. PMID: 37517417

A survey on Iranian midwives' knowledge about COVID-19 during pregnancy, delivery, postpartum, and neonatal feeding.
Azarkish F, Janghorban R. J Infect Dev Ctries. 2023 Jul 27;17(7):905-910. doi: 10.3855/jidc.16779. PMID: 37515789

Use of convalescent plasma to treat COVID-19: case studies.
Beneti SC, Marques LLM, Mattos G, Cardoso FAR. Braz J Biol. 2023 Jul 21;83:e262897. doi: 10.1590/1519-6984.262897. eCollection 2023. PMID: 37493679

The dominance of co-circulating SARS-CoV-2 variants in wastewater.
Pilapil JD, Notarte KI, Yeung KL. Int J Hyg Environ Health. 2023 Jul 29;253:114224. doi: 10.1016/j.ijheh.2023.114224. Online ahead of print. PMID: 37523818

In silico identification of cyclosporin derivatives as potential inhibitors for RdRp of rotavirus by molecular docking and molecular dynamic studies.
Sinha P, Yadav AK. J Biomol Struct Dyn. 2023 Jul 30:1-14. doi: 10.1080/07391102.2023.2239918. Online ahead of print. PMID: 37517053

Paired Capture and FISH Detection of Individual Virions Enable Cell-Free Determination of Infectious Titers.
Liu Y, Potts JL, Bloch D, Nian K, McCormick CA, Fanari O, Rouhanifard SH. ACS Sens. 2023 Jul 28;8(7):2563-2571. doi: 10.1021/acssensors.3c00239. Epub 2023 Jun 27. PMID: 37368999

Travel-Associated Dengue Cases - United States, 2010-2021.
Wong JM, Rivera A, Volkman HR, Torres-Velasquez B, Rodriguez DM, Paz-Bailey G, Adams LE. MMWR Morb Mortal Wkly Rep. 2023 Jul 28;72(30):821-826. doi: 10.15585/mmwr.mm7230a3. PMID: 37498793

Computational prediction of phytochemical inhibitors against the cap-binding domain of Rift Valley fever virus.
Muralitharan I, Sahoo AK, Augusthian PD, Samal A. Mol Divers. 2023 Jul 23. doi: 10.1007/s11030-023-10702-x. Online ahead of print. PMID: 37481749

The role of flagellin F in Vibrio Parahaemolyticus-induced intestinal immunity and functional domain identification.
Li Y, Yao H, Liu S, Song D, Wu C, Zhang S, Gao Q, Zhang L. Int J Biol Macromol. 2023 Jul 31;244:125404. doi: 10.1016/j.ijbiomac.2023.125404. Epub 2023 Jun 14. PMID: 37327919

Compendium of medically important snakes, venom activity and clinical presentations in Ghana.

Deikumah JP, Biney RP, Awoonor-Williams JK, Gyakobo MK. PLoS Negl Trop Dis. 2023 Jul 28;17(7):e0011050. doi: 10.1371/journal.pntd.0011050. Online ahead of print. PMID: 37506181

Liver Cell Type-Specific Targeting by Nanoformulations for Therapeutic Applications.
Kaps L, Limeres MJ, Schneider P, Svensson M, Zeyn Y, Fraude S, Cacicedo ML, Galle PR, Gehring S, Bros M. Int J Mol Sci. 2023 Jul 24;24(14):11869. doi: 10.3390/ijms241411869. PMID: 37511628

StackTTCA: a stacking ensemble learning-based framework for accurate and high-throughput identification of tumor T cell antigens.
Charoenkwan P, Schaduangrat N, Shoombuatong W. BMC Bioinformatics. 2023 Jul 28;24(1):301. doi: 10.1186/s12859-023-05421-x. PMID: 37507654

Recent advances in genome editing of bloodstream forms of Trypanosoma congolense using CRISPR-Cas9 ribonucleoproteins: Proof of concept.
Minet C, Chantal I, Berthier D. Exp Parasitol. 2023 Jul 27:108589. doi: 10.1016/j.exppara.2023.108589. Online ahead of print. PMID: 37516291

Nasal oxytocin administration does not influence eye gaze or perceived relationship of male volunteers with physicians in a simulated online consultation: a randomized, placebo-controlled trial.
Jongerius C, Hillen MA, Smets EMA, Mol MJ, Kooij ES, de Nood MA, Dalmaijer ES, Fliers E, Romijn JA, Quintana DS. Endocr Connect. 2023 Jul 31;12(8):e220377. doi: 10.1530/EC-22-0377. PMID: 37294605

Human skin-on-a-chip for mpox pathogenesis studies and preclinical drug evaluation.
Zhu J, Abaci HE. Trends Pharmacol Sci. 2023 Jul 26:S0165-6147(23)00150-5. doi: 10.1016/j.tips.2023.07.001. Online ahead of print. PMID: 37500295

Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma.
Gautam SK, Batra SK, Jain M. Mol Cancer. 2023 Jul 24;22(1):118. doi: 10.1186/s12943-023-01813-y. PMID: 37488598

The canonical Brucella species-host dependency is changing, however, the antibiotic susceptibility profiles remain unchanged.
Celik E, Kayman T, Buyuk F, Gulmez Saglam A, Abay S, Akar M, Karakaya E, Balkan Bozlak CE, Coskun MR, Buyuk E, Celebi O, Sahin M, Saticioglu IB, Durhan S, Baykal A, Ersoy Y, Otlu S, Aydin F. Microb Pathog. 2023 Jul 23;182:106261. doi: 10.1016/j.micpath.2023.106261. Online ahead of print. PMID: 37488036

Recruitment into antibody prevalence studies: a randomized trial of postcards vs. letters as invitations.
Ley C, Duan H, Parsonnet J. BMC Med Res Methodol. 2023 Jul 22;23(1):170. doi: 10.1186/s12874-023-01992-8. PMID: 37481522

Risk of uterine cervical cancer in inflammatory bowel disease: a systematic review and meta-analysis.
Kim J, Jung JH, Jo H, Kim MH, Kang DR, Kim HM. Scand J Gastroenterol. 2023 Jul 30:1-10. doi: 10.1080/00365521.2023.2238101. Online ahead of print. PMID: 37517000

Chlamydial and Gonococcal Genital Infections: A Narrative Review.
Rodrigues R, Vieira-Baptista P, Catalão C, Borrego MJ, Sousa C, Vale N. J Pers Med. 2023 Jul 21;13(7):1170. doi: 10.3390/jpm13071170. PMID: 37511783

Developing HIV risk prediction tools in four African settings.
Kansiime S, Hansen CH, Hayes R, Ruzagira E; PrEPVacc Study Team. Trop Med Int Health. 2023 Jul 27. doi: 10.1111/tmi.13916. Online ahead of print. PMID: 37496465

Identification and Characterization of Negative Regulators of Rgg1518 Quorum Sensing in Streptococcus pneumoniae.
Hu D, Laczkovich I, Federle MJ, Morrison DA. J Bacteriol. 2023 Jul 25;205(7):e0008723. doi: 10.1128/jb.00087-23. Epub 2023 Jun 21. PMID: 37341600

Plasmodium falciparum infection and disease in infancy associated with increased risk of malaria and anaemia in childhood.
Andronescu LR, Buchwald AG, Sharma A, Bauleni A, Mawindo P, Liang Y, Gutman JR, Mathanga DP, Chinkhumba J, Laufer MK. Malar J. 2023 Jul 26;22(1):217. doi: 10.1186/s12936-023-04646-8. PMID: 37496052

Isolation and identification of nontuberculous mycobacteria from raw milk and traditional cheese based on the 16S rRNA and hsp65 genes, Tehran, Iran.
Solaghani TH, Nazari R, Mosavari N, Tadayon K, Zolfaghari MR. Folia Microbiol (Praha). 2023 Jul 29. doi: 10.1007/s12223-023-01073-9. Online ahead of print. PMID: 37507582

Dietary restriction mitigates the age-associated decline in mouse B cell receptor repertoire diversity.
Monzó C, Gkioni L, Beyer A, Valenzano DR, Grönke S, Partridge L. Cell Rep. 2023 Jul 25;42(7):112722. doi: 10.1016/j.celrep.2023.112722. Epub 2023 Jun 28. PMID: 37384530

Drug repurposing of FDA-approved anti-viral drugs via computational screening against novel 6M03 SARS-COVID-19.
Waseem W, Zafar R, Jan MS, Alomar TS, Almasoud N, Rauf A, Khattak H. Ir J Med Sci. 2023 Jul 29. doi: 10.1007/s11845-023-03473-9. Online ahead of print. PMID: 37515684

Pandemic-related posttraumatic psychological growth in U.**S**. military veterans: A 3-year, nationally representative, longitudinal study.
Kang H, Na PJ, Fischer IC, Tsai J, Tedeschi RG, Pietrzak RH. Psychiatry Res. 2023 Aug;326:115370. doi: 10.1016/j.psychres.2023.115370. Epub 2023 Jul 24. PMID: 37499281

Severe acute respiratory syndrome coronavirus 2 infection in patients with autoimmune bullous diseases in China.
Zhang JL, Wang SH, Cui SN, Zhang J, Li SZ, Li L, Zuo YG. J Dermatol. 2023 Jul 27. doi: 10.1111/1346-8138.16900. Online ahead of print. PMID: 37501390

COVID-19 recurrence is related to disease-early profile T cells while detection of anti-S1 IgG is related to multifunctional T cells.

Santos CNO, Caldas GC, de Oliveira FA, da Silva AM, da Silva JS, da Silva RLL, de Jesus AR, Magalhães LS, de Almeida RP. Med Microbiol Immunol. 2023 Jul 25. doi: 10.1007/s00430-023-00776-7. Online ahead of print. PMID: 37488347

Clinical features and outcomes of hospitalised patients with COVID-19 and Parkinsonian disorders: A multicentre UK-based study.
Sorrell L, Leta V, Barnett A, Stevens K, King A, Inches J, Kobylecki C, Walker R, Chaudhuri KR, Martin H, Rideout J, Sneyd JR, Campbell S, Carroll C; COVID-19 PD UK study team. PLoS One. 2023 Jul 31;18(7):e0285349. doi: 10.1371/journal.pone.0285349. eCollection 2023. PMID: 37523365

Air pollution exposure, SARS-CoV-2 infection, and immune response in a cohort of healthcare workers of a large university hospital in Milan, Italy.
Fedrizzi L, Carugno M, Consonni D, Lombardi A, Bandera A, Bono P, Ceriotti F, Gori A, Pesatori AC. Environ Res. 2023 Jul 28:116755. doi: 10.1016/j.envres.2023.116755. Online ahead of print. PMID: 37517490

Feline herpesvirus 1 (FHV-1) enters the cell by receptor-mediated endocytosis.
Synowiec A, Dąbrowska A, Pachota M, Baouche M, Owczarek K, Niżański W, Pyrc K. J Virol. 2023 Jul 26:e0068123. doi: 10.1128/jvi.00681-23. Online ahead of print. PMID: 37493545

Cross protection to SARS-CoV-2 variants in hamsters with naturally-acquired immunity.
Beitari S, Duque D, Bavananthasivam J, Hewitt M, Sandhu JK, Hadžisejdić I, Tran A. Virol J. 2023 Jul 28;20(1):167. doi: 10.1186/s12985-023-02136-6. PMID: 37507719

Reverse Genetic Assessment of the Roles Played by the Spike Protein and ORF3 in Porcine Epidemic Diarrhea Virus Pathogenicity.
Kristen-Burmann C, Rogger P, Veiga IB, Riebesehl S, Rappe J, Ebert N, Sautter CA, Kelly JN, Stalder H, Ehmann R, Huber M, Posthaus H, Ruggli N, Thiel V, Tekes G. J Virol. 2023 Jul 27;97(7):e0196422. doi: 10.1128/jvi.01964-22. Epub 2023 Jun 26. PMID: 37358450

Assessing importance of SARS-CoV2 infection as cause of in utero fetal death: regional retrospective cohort study.
Nkobetchou M, Leruez-Ville M, Guilleminot T, Roux N, Petrilli G, Guimiot F, Saint-Frison MH, Deryabin I, Ville Y, Faure Bardon V. Ultrasound Obstet Gynecol. 2023 Jul 31. doi: 10.1002/uog.27439. Online ahead of print. PMID: 37519281

Bayesian sequential approach to monitor COVID-19 variants through test positivity rate from wastewater.
Montesinos-López JC, Daza-Torres ML, García YE, Herrera C, Bess CW, Bischel HN, Nuño M. mSystems. 2023 Jul 25:e0001823. doi: 10.1128/msystems.00018-23. Online ahead of print. PMID: 37489897

Multidimensional stressors and protective factors shaping physicians' work environments and work-related well-being in two large US cities during COVID-19.
Buchbinder M, Jenkins T, Staley J, Berlinger N, Buchbinder L, Goldberg L. Am J Ind Med. 2023 Jul 24. doi: 10.1002/ajim.23520. Online ahead of print. PMID: 37488786

Cytokine Responses during *Mycobacterium tuberculosis* H37Rv and *Ascaris lumbricoides* Costimulation Using Human THP-1 and Jurkat Cells, and a Pilot Human Tuberculosis and Helminth Coinfection Study.
Bhengu KN, Singh R, Naidoo P, Mpaka-Mbatha MN, Nembe-Mafa N, Mkhize-Kwitshana ZL. Microorganisms. 2023 Jul 21;11(7):1846. doi: 10.3390/microorganisms11071846. PMID: 37513018

Long-term neurological complications in COVID-19 survivors: study protocol of a prospective cohort study (NeurodegCoV-19).
Araújo N, Silva I, Campos P, Correia R, Calejo M, Freitas P, Seco M, Ribeiro L, Costa AR, Morais S, Pereira S, Firmino-Machado J, Rodrigues R, Pais J, Ruano L, Lunet N, Tedim-Cruz V. BMJ Open. 2023 Jul 30;13(7):e072981. doi: 10.1136/bmjopen-2023-072981. PMID: 37518072

Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5.
Tamura T, Yamasoba D, Oda Y, Ito J, Kamasaki T, Nao N, Hashimoto R, Fujioka Y, Suzuki R, Wang L, Ito H, Kashima Y, Kimura I, Kishimoto M, Tsuda M, Sawa H, Yoshimatsu K, Yamamoto Y, Nagamoto T, Kanamune J, Suzuki Y, Ohba Y; Genotype to Phenotype Japan (G2P-Japan) Consortium; Yokota I, Matsuno K, Takayama K, Tanaka S, Sato K, Fukuhara T. Commun Biol. 2023 Jul 24;6(1):772. doi: 10.1038/s42003-023-05081-w. PMID: 37488344

Antiplatelet agents for the treatment of adults with COVID-19.
Fischer AL, Messer S, Riera R, Martimbianco ALC, Stegemann M, Estcourt LJ, Weibel S, Monsef I, Andreas M, Pacheco RL, Skoetz N. Cochrane Database Syst Rev. 2023 Jul 25;7(7):CD015078. doi: 10.1002/14651858.CD015078. PMID: 37489818

Prevalence and development of a risk score for oral human papillomavirus infection in men who have sex with men in Mexico.
Carnalla M, Rojas-Martínez R, Barrientos-Gutiérrez T, Allen-Leigh B, León-Maldonado L, Gutiérrez-Xicoténcatl L, Portillo-Romero AJ, Nyitray AG, Salmerón J, Giuliano AR, Lazcano-Ponce E. J Oral Pathol Med. 2023 Jul 31. doi: 10.1111/jop.13474. Online ahead of print. PMID: 37525481

Phage-derived anti-idiotype and anti-YTE antibodies in development of MK-1654 pharmacokinetic and immune response assays.
Li A, Swanson M, Sullivan N, Homan Y, Nahas D, Mukhopadhyay S, Li HH, Cao Y, Xu W, Tang H, Vora KA, Chen Z. Bioanalysis. 2023 Jul 29. doi: 10.4155/bio-2023-0081. Online ahead of print. PMID: 37515532

Unveiling the Impact of the Omicron Variant: Insights from Genomic Surveillance in Mato Grosso do Sul, Midwest Brazil.
de Mello Almeida Maziero L, Giovanetti M, Fonseca V, Zardin MCSU, de Castro Lichs GG, de Rezende Romera GR, Tsuha DH, Frias DFR, Escandolhero VC, Demarchi LH, Domingues Castilho L, Barbosa KF, Tebet DGM, Xavier J, Fritsch H, Lima M, de Oliveira C, Santos EV, Kashima S, Said RFDC, Rosewell A, Croda J, Alcantara LCJ, Cavalheiro Maymone Gonçalves C. Viruses. 2023 Jul 22;15(7):1604. doi: 10.3390/v15071604. PMID: 37515290

A multi-state survey of farm-level preparedness towards African Swine Fever outbreak in Nigeria.
Ogundijo OA, Omotosho OO, Al-Mustapha AI, Abiola JO, Awosanya EJ, Odukoya A, Owoicho S, Oyewo M, Ibrahim A, Orum TG, Nanven MB, Bolajoko MB, Luka P, Adeyemo OK. Acta Trop. 2023 Jul 26:106989. doi: 10.1016/j.actatropica.2023.106989. Online ahead of print. PMID: 37507080

Viral etiologies of lower respiratory tract infections in children < 5 years of age in Addis Ababa, Ethiopia: a prospective case-control study.
Wadilo F, Feleke A, Gebre M, Mihret W, Seyoum T, Melaku K, Howe R, Mulu A, Mihret A. Virol J. 2023 Jul 23;20(1):163. doi: 10.1186/s12985-023-02131-x. PMID: 37481644

Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.
Mikulska M, Sepulcri C, Dentone C, Magne F, Balletto E, Baldi F, Labate L, Russo C, Mirabella M, Magnasco L, Di Grazia C, Ghiggi C, Raiola AM, Giacobbe DR, Vena A, Beltramini S, Bruzzone B, Lemoli RM, Angelucci E, Bassetti M. Clin Infect Dis. 2023 Jul 26;77(2):280-286. doi: 10.1093/cid/ciad181. PMID: 36976301

Blood monocyte and dendritic cell profiles among people living with HIV with Mycobacterium tuberculosis co-infection.

Rambaran S, Maseko TG, Lewis L, Hassan-Moosa R, Archary D, Ngcapu S, Garrett N, McKinnon LR, Padayatchi N, Naidoo K, Sivro A. BMC Immunol. 2023 Jul 21;24(1):21. doi: 10.1186/s12865-023-00558-z. PMID: 37480005

Assessing the representativeness of cluster randomized trials: Evidence from two large pragmatic trials in United States nursing homes.
Joyce NR, Robertson SE, McCreedy E, Ogarek J, Davidson EH, Mor V, Gravenstein S, Dahabreh IJ. Clin Trials. 2023 Jul 26:17407745231185055. doi: 10.1177/17407745231185055. Online ahead of print. PMID: 37493171

Genetic variation in the immunoglobulin heavy chain locus shapes the human antibody repertoire.
Rodriguez OL, Safonova Y, Silver CA, Shields K, Gibson WS, Kos JT, Tieri D, Ke H, Jackson KJL, Boyd SD, Smith ML, Marasco WA, Watson CT. Nat Commun. 2023 Jul 21;14(1):4419. doi: 10.1038/s41467-023-40070-x. PMID: 37479682

On asymptotic distributions of several test statistics for familial relatedness in linear mixed models.
Devogel N, Auer PL, Manansala R, Wang T. Stat Med. 2023 Jul 30;42(17):2962-2981. doi: 10.1002/sim.9762. Epub 2023 May 9. PMID: 37345498

Within-host rhinovirus evolution in upper and lower respiratory tract highlights capsid variability and mutation-independent compartmentalization.
Makhsous N, Goya S, Avendaño CC, Rupp J, Kuypers J, Jerome KR, Boeckh M, Waghmare A, Greninger AL. J Infect Dis. 2023 Jul 24:jiad284. doi: 10.1093/infdis/jiad284. Online ahead of print. PMID: 37486790

The human placenta exhibits a unique transcriptomic void.
Gong S, Gaccioli F, Aye ILMH, Avellino G, Cook E, Lawson ARJ, Harvey LMR, Smith GCS, Charnock-Jones DS. Cell Rep. 2023 Jul 25;42(7):112800. doi: 10.1016/j.celrep.2023.112800. Epub 2023 Jul 14. PMID: 37453066

Highly stable and versatile α-amylase from Anoxybacillus vranjensis ST4 suitable for various applications.
Slavić MŠ, Kojić M, Margetić A, Stanisavljević N, Gardijan L, Božić N, Vujčić Z. Int J Biol Macromol. 2023 Jul 29:126055. doi: 10.1016/j.ijbiomac.2023.126055. Online ahead of print. PMID: 37524287

Early versus late onset sepsis in neonates - Time to shift the paradigm?
Russell N, Barday M, Okomo U, Dramowski A, Sharland M, Bekker A. Clin Microbiol Infect. 2023 Jul 28:S1198-743X(23)00351-8. doi: 10.1016/j.cmi.2023.07.023. Online ahead of print. PMID: 37517521

The c-di-GMP signalling component YfiR regulates multiple bacterial phenotypes and virulence in Pseudomonas plecoglossicida.
Wang Y, Jin Y, Sun F, Zhang Y, Liu Q, Wang Q, Yang D, Zhang Y. J Appl Microbiol. 2023 Jul 27:lxad157. doi: 10.1093/jambio/lxad157. Online ahead of print. PMID: 37500265

The Endless Vulnerability of Migrant Children In-Transit across the Darién Gap.
Naranjo L, Williams Y, Levy J, Obando R, González JA, Pachar M, Chen R, Franco-Paredes C, Higuita NA, Henao-Martínez A, Diaz Y, Suárez JA. Am J Trop Med Hyg. 2023 Jul 24:tpmd220765. doi: 10.4269/ajtmh.22-0765. Online ahead of print. PMID: 37487560

CCR4 predicts the efficacy of abatacept in rheumatoid arthritis patients through the estimation of Th17 and Treg cell abundance.
Tanaka S, Etori K, Hattori K, Tamura J, Ikeda K, Kageyama T, Meguro K, Iwamoto T, Iwata A, Furuta S, Suto A, Suzuki K, Nakajima H. Mod Rheumatol. 2023 Jul 31:road077. doi: 10.1093/mr/road077. Online ahead of print. PMID: 37522614

MPL36, a major plasminogen (PLG) receptor in pathogenic Leptospira, has an essential role during infection.
Zhu W, Passalia FJ, Hamond C, Abe CM, Ko AI, Barbosa AS, Wunder EA Jr. PLoS Pathog. 2023 Jul 24;19(7):e1011313. doi: 10.1371/journal.ppat.1011313. Online ahead of print. PMID: 37486929

REGIONAL ANALYSIS OF INTACT AND DEFECTIVE HIV PROVIRUSES IN THE BRAIN OF VIREMIC AND VIRALLY SUPPRESSED PEOPLE WITH HIV.
Angelovich TA, Cochrane CR, Zhou J, Tumpach C, Byrnes SJ, Jamal Eddine J, Waring E, Busman-Sahay K, Deleage C, Jenkins TA, Hearps AC, Turville S, Gorry PR, Lewin SR, Brew BJ, Estes JD, Roche M, Churchill MJ. Ann Neurol. 2023 Jul 26. doi: 10.1002/ana.26750. Online ahead of print. PMID: 37493435

System Biology Approach to Identify the Hub Genes and Pathways Associated with Human H5N1 Infection.
Chaudhary RK, L A, Patil P, Mateti UV, Sah S, Mohanty A, Rath RS, Padhi BK, Malik S, Jassim KH, Al-Shammari MA, Waheed Y, Satapathy P, Barboza JJ, Rodriguez-Morales AJ, Sah R. Vaccines (Basel). 2023 Jul 21;11(7):1269. doi: 10.3390/vaccines11071269. PMID: 37515084

Inhibition of complement C3 signaling ameliorates locomotor and visual dysfunction in autoimmune inflammatory diseases.
Xu L, Xu H, Chen S, Jiang W, Afridi SK, Wang Y, Ren X, Zhao Y, Lai S, Qiu X, Alvin Huang YW, Cui Y, Yang H, Qiu W, Tang C. Mol Ther. 2023 Jul 21:S1525-0016(23)00397-0. doi: 10.1016/j.ymthe.2023.07.017. Online ahead of print. PMID: 37481702

Crystal structure of a variable region segment of Leptospira host-interacting outer surface protein, LigA, reveals the orientation of Ig-like domains.
Kumar P, Vyas P, Faisal SM, Chang YF, Akif M. Int J Biol Macromol. 2023 Jul 31;244:125445. doi: 10.1016/j.ijbiomac.2023.125445. Epub 2023 Jun 17. PMID: 37336372

Modeling and prediction of phase shifts in noisy two-cycle oscillations.
Nareddy VR, Machta J, Abbott K, Esmaeili S, Hastings A. J Math Biol. 2023 Jul 26;87(2):33. doi: 10.1007/s00285-023-01960-2. PMID: 37493847

Women's perceptions and preferences for cervical cancer screening in light of updated guidelines.
Bustamante G, Liebermann E, McNair K, Fontenot HB. J Am Assoc Nurse Pract. 2023 Jul 27. doi: 10.1097/JXX.0000000000000923. Online ahead of print. PMID: 37498967

Glycolipids from the gut symbiont *Bacteroides fragilis* are agonists for natural killer T cells and induce their regulatory differentiation.
Cameron G, Nguyen T, Ciula M, Williams SJ, Godfrey DI. Chem Sci. 2023 May 27;14(29):7887-7896. doi: 10.1039/d3sc02124f. eCollection 2023 Jul 26. PMID: 37502334

A novel multiplex qPCR-HRM assay for the simultaneous detection of four abortive zoonotic agents in cattle, sheep, and goats.
Modise BM, Mpoloka SW, Settypalli TBK, Hyera J, Natale A, Ceglie L, Gcebe N, Marobela-Raborokgwe C, Viljoen GJ, Cattoli G, Lamien CE. Sci Rep. 2023 Jul 28;13(1):12282. doi: 10.1038/s41598-023-39447-1. PMID: 37507444

The Susceptibility of BALB/c Mice to a Mouse-Adapted Ebola Virus Intravaginal Infection.
Escaffre O, Juelich TL, Smith JK, Zhang L, Bourne N, Freiberg AN. Viruses. 2023 Jul 21;15(7):1590. doi: 10.3390/v15071590. PMID: 37515275

Intratumoural Delivery of mRNA Loaded on a Cationic Hyper-Branched Cyclodextrin-Based Polymer Induced an Anti-Tumour Immunological Response in Melanoma.
Khazaei Monfared Y, Mahmoudian M, Zakeri-Milani P, Cecone C, Hayashi T, Ishii KJ, Conde J, Matencio A, Trotta F. Cancers (Basel). 2023 Jul 24;15(14):3748. doi: 10.3390/cancers15143748. PMID: 37509409

Localized delivery of Erlotinib using liposomal gel formulations for the treatment of oral squamous cell carcinoma.
Hariharan K, Mehta T, Shah J, Dave H, Sami A, Omri A. Int J Pharm. 2023 Jul 25;642:123144. doi: 10.1016/j.ijpharm.2023.123144. Epub 2023 Jun 16. PMID: 37330155

Integrative systems biology characterizes immune-mediated neurodevelopmental changes in murine Zika virus microcephaly.
Fujimura K, Guise AJ, Nakayama T, Schlaffner CN, Meziani A, Kumar M, Cheng L, Vaughan DJ, Kodani A, Van Haren S, Parker K, Levy O, Durbin AF, Bosch I, Gehrke L, Steen H, Mochida GH, Steen JA. iScience. 2023 May 19;26(7):106909. doi: 10.1016/j.isci.2023.106909. eCollection 2023 Jul 21. PMID: 37332674

Structures of SARS-CoV-2 N7-methyltransferase with DOT1L and PRMT7 inhibitors provide a platform for new antivirals.
Kottur J, White KM, Rodriguez ML, Rechkoblit O, Quintana-Feliciano R, Nayar A, García-Sastre A, Aggarwal AK. PLoS Pathog. 2023 Jul 31;19(7):e1011546. doi: 10.1371/journal.ppat.1011546. Online ahead of print. PMID: 37523415

Integrated NMR and MS Analysis of the Plasma Metabolome Reveals Major Changes in One-Carbon, Lipid, and Amino Acid Metabolism in Severe and Fatal Cases of COVID-19.
Gama-Almeida MC, Pinto GDA, Teixeira L, Hottz ED, Ivens P, Ribeiro H, Garrett R, Torres AG, Carneiro TIA, Barbalho BO, Ludwig C, Struchiner CJ, Assunção-Miranda I, Valente APC, Bozza FA, Bozza PT, Dos Santos GC Jr, El-Bacha T. Metabolites. 2023 Jul 24;13(7):879. doi: 10.3390/metabo13070879. PMID: 37512587

Long-term PM2.5 exposure, lung function, and cognitive function among middle-aged and older adults in China.
Ye Z, Li X, Lang H, Fang Y. J Gerontol A Biol Sci Med Sci. 2023 Jul 26:glad180. doi: 10.1093/gerona/glad180. Online ahead of print. PMID: 37493944

Prevalence and incidence of symptomatic pulmonary tuberculosis based on repeated population screening in a district in Ethiopia: a prospective cohort study.
Banti AB, Winje BA, Hinderaker SG, Heldal E, Abebe M, Dangisso MH, Datiko DG. BMJ Open. 2023 Jul 30;13(7):e070594. doi: 10.1136/bmjopen-2022-070594. PMID: 37518077

Evaluation of the diagnostic accuracy of two point-of-care tests for COVID-19 when used in symptomatic patients in community settings in the UK primary care COVID diagnostic accuracy platform trial (RAPTOR-C19).
Nicholson BD, Turner PJ, Fanshawe TR, Williams AJ, Amirthalingam G, Tonner S, Zambon M, Body R, Davies K, Perera R, de Lusignan S, Hayward GN, Hobbs FDR; RAPTOR-C19 Study Group and the CONDOR Steering Committee. PLoS One. 2023 Jul 21;18(7):e0288612. doi: 10.1371/journal.pone.0288612. eCollection 2023. PMID: 37478103

pH-sensitive HPMCP-chitosan nanoparticles containing 5-aminosalicylic acid and berberine for oral colon delivery in a rat model of ulcerative colitis.
Mahami S, Salehi M, Mehrabi M, Vahedi H, Hassani MS, Bitaraf FS, Omri A. Int J Biol Macromol. 2023 Jul 31;244:125332. doi: 10.1016/j.ijbiomac.2023.125332. Epub 2023 Jun 10. PMID: 37302632

Deciphering the emerging role of phytocompounds: Implications in the management of drug-resistant tuberculosis and ATDs-induced hepatic damage.
Ansari MA, Shoaib S, Alomary MN, Ather H, Ansari SMA, Hani U, Jamous YF, Alyahya SA, Alharbi JN, Imran MA, Wahab S, Ahmad W, Islam N. J Infect Public Health. 2023 Jul 26;16(9):1443-1459. doi: 10.1016/j.jiph.2023.07.016. Online ahead of print. PMID: 37523915

Synthetic Site-Specific Antibody-Ligand Conjugates Promote Asialoglycoprotein Receptor-Mediated Degradation of Extracellular Human PCSK9.
Donahue TC, Ou C, Yang Q, Flinko R, Zhang X, Zong G, Lewis GK, Wang LX. ACS Chem Biol. 2023 Jul 21;18(7):1611-1623. doi: 10.1021/acschembio.3c00229. Epub 2023 Jun 27. PMID: 37368876

Newborn screening for primary carnitine deficiency: who will benefit? - a retrospective cohort study.
Crefcoeur L, Ferdinandusse S, van der Crabben SN, Dekkers E, Fuchs SA, Huidekoper H, Janssen M, Langendonk J, Maase R, de Sain M, Rubio E, van Spronsen FJ, Vaz FM, Verschoof R, de Vries M, Wijburg F, Visser G, Langeveld M. J Med Genet. 2023 Jul 24:jmg-2023-109206. doi: 10.1136/jmg-2023-109206. Online ahead of print. PMID: 37487700

Prescribing patterns of fall risk-increasing drugs in older adults hospitalized for heart failure.
Liu E, Nahid M, Musse M, Chen L, Hilmer SN, Zullo A, Kwak MJ, Lachs M, Levitan EB, Safford MM, Goyal P. BMC Cardiovasc Disord. 2023 Jul 26;23(1):372. doi: 10.1186/s12872-023-03401-w. PMID: 37495948

T cell deletional tolerance restricts AQP4 but not MOG CNS autoimmunity.
Sagan SA, Moinfar Z, Moseley CE, Dandekar R, Spencer CM, Verkman AS, Ottersen OP, Sobel RA, Sidney J, Sette A, Anderson MS, Steinman L, Wilson MR, Sabatino JJ Jr, Zamvil SS. Proc Natl Acad Sci U S A. 2023 Jul 25;120(30):e2306572120. doi: 10.1073/pnas.2306572120. Epub 2023 Jul 18. PMID: 37463205

Prevalence of Hospital-Onset Bacteremia Pre- and Post-Implementation of a Needleless Blood Sampling Device From Existing Peripheral Catheters.
Yu KC, Ai C, Jung M, Johnson H, Smith S, LaJoie J, Denny G. J Infus Nurs. 2023 Jul 24. doi: 10.1097/NAN.0000000000000513. Online ahead of print. PMID: 37490579

Variability in Donor Lung Culture and Relative Humidity Impact the Stability of 2009 Pandemic H1N1 Influenza Virus on Nonporous Surfaces.
Qian Z, Morris DH, Avery A, Kormuth KA, Le Sage V, Myerburg MM, Lloyd-Smith JO, Marr LC, Lakdawala SS. Appl Environ Microbiol. 2023 Jul 26;89(7):e0063323. doi: 10.1128/aem.00633-23. Epub 2023 Jul 5. PMID: 37404191

Antimicrobial resistance landscape and COVID-19 impact in Egypt, Iraq, Jordan, and Lebanon: A survey-based study and expert opinion.
Bizri AR, El-Fattah AA, Bazaraa HM, Al Ramahi JW, Matar M, Ali RAN, El Masry R, Moussa J, Abbas AJA, Aziz MA. PLoS One. 2023 Jul 27;18(7):e0288550. doi: 10.1371/journal.pone.0288550. eCollection 2023. PMID: 37498951

Identification of a 1.4-kb-Long Sequence Located in the nsp12 and nsp13 Coding Regions of SARS-CoV-2 Genomic RNA That Mediates Efficient Viral RNA Packaging.
Terasaki K, Narayanan K, Makino S. J Virol. 2023 Jul 27;97(7):e0065923. doi: 10.1128/jvi.00659-23. Epub 2023 Jun 27. PMID: 37367225

The administration of methotrexate in patients with Still's disease, "real-life" findings from AIDA Network Still Disease Registry.
Ruscitti P, Sota J, Vitale A, Lopalco G, Iannone F, Morrone M, Giardini HAM, D'Agostin MA, Antonelli IPB, Almaghlouth I, Asfina KN, Khalil N, Sfikakis PP, Laskari K, Tektonidou M, Ciccia F, Iacono D, Riccio F, Ragab G, Hussein MA, Govoni M, Ruffilli F, Direskeneli H, Alibaz-Oner F, Giacomelli R, Navarini L, Bartoloni E, Riccucci I, Martín-Nares E, Torres-Ruiz J, Cipriani P, Di Cola I, Hernández-Rodríguez J, Gómez-Caverzaschi V, Dagna L, Tomelleri A, Makowska J, Brzezinska O, Iagnocco A, Bellis E, Caggiano V, Gaggiano C, Tarsia M, Mormile I, Emmi G, Sfriso P, Monti S, Erten Ş, Del Giudice E, Lubrano R, Conti

G, Olivieri AN, Lo Gullo A, Tharwat S, Karamanakos A, Gidaro A, Maggio MC, La Torre F, Cardinale F, Ogunjimi B, Maier A, Sebastiani GD, Opris-Belinski D, Frassi M, Viapiana O, Bizzi E, Carubbi F, Fotis L, Tufan A, Kardas RC, Więsik-Szewczyk E, Jahnz-Różyk K, Fabiani C, Frediani B, Balistreri A, Rigante D, Cantarini L. Semin Arthritis Rheum. 2023 Jul 21;62:152244. doi: 10.1016/j.semarthrit.2023.152244. Online ahead of print. PMID: 37517110

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H. N Engl J Med. 2023 Jul 27;389(4):335-347. doi: 10.1056/NEJMoa2303379. Epub 2023 Jun 5. PMID: 37272512

Patentes registradas en Patentscope

Estrategia de búqueda: *Vaccine in the title or abstract AND 20230721:20230731 as the publication date 36 records*

1.4213875IMPFSTOFFFORMULIERUNG MIT AGONISTEN DES TOLL-LIKE-REZEPTORS (TLR)
EP - 26.07.2023
Clasificación Internacional A61K 39/39 Nº de solicitud 21868893 Solicitante BHARAT BIOTECH INT LTD Inventor/a VADREVU KRISHNA MOHAN
The invention relates to novel agonist vaccine formulation, wherein the agonist is novel TLR7/8 agonist which is used as an adjuvant or an immunomodulator. More particularly, the invention relates to the preparation of vaccine formulations against viral infections using Algel-IMDG as an adjuvant. The invention also relates to development of vaccine formulations for severe viral infections using the novel Algel-IMDG as an adjuvant that comprises TLR 7/8 agonist chemisorbed on to surface of Aluminium hydroxide gel. The invention also relates to the use of novel Algel-IMDG formulation as an adjuvant in Vaccine composition against several other viral diseases like Covid-19 caused by SARS-CoV-2 either wild type or its variants, Japanese Encephalitis, recombinant Hepatitis B surface antigen etc.

2.3300743Fremgangsmåder til indgivelse af vaccine
DK - 24.07.2023
Clasificación Internacional A61K 39/02 Nº de solicitud 17202017 Solicitante Zoetis Services LLC Inventor/a Tucker, Cassius Mcallister
This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.

3.WO/2023/138755METHODS OF VACCINE DESIGN
WO - 27.07.2023
Clasificación Internacional G16B 5/20 Nº de solicitud PCT/EP2022/051042 Solicitante NEC LABORATORIES EUROPE GMBH Inventor/a GRAZIOLI, Filippo
A computer-implemented method of selecting one or more amino acid sequences for inclusion in a neoantigen vaccine from a set of candidate neoantigen amino acid sequences, the method comprising: retrieving a set of input data related to a patient; simulating a plurality of cancer cells based on the set of

input data, wherein simulating each cancer cell comprises predicting the cell surface presentation of said cancer cell; for each candidate neoantigen amino acid sequence, predicting a likelihood of said candidate neoantigen amino acid sequence eliciting an immune response to the cancer cells based on the predicted cell surface presentation of each cancer cell; and selecting the one or more amino acid sequences for inclusion in the vaccine that maximise a likelihood of the vaccine eliciting an immune response to the cancer cells based on the predicted likelihood of each candidate neoantigen amino acid sequence eliciting an immune response to the cancer cells.

4.20230233678DENDRITIC CELL TUMOR VACCINE AND USES THEREOF
US - 27.07.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 18169174 Solicitante SHENZHEN FRONTIERGATE BIOTECHNOLOGY CO., LTD Inventor/a Yang XU
The present disclosure provides a dendric cell tumor vaccine comprising a chimeric antigen receptor for activating the dendritic cell and a tumor antigen. The present disclosure also provides compositions and methods of making the dendritic cell tumor vaccine, and the methods of using the dendritic cell tumor vaccine to treat cancer.

5.WO/2023/138636CD24 VACCINE
WO - 27.07.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/CN2023/073026 Solicitante SHANGHAI WELLVAC BIOTECHNOLOGIES CO., LTD. Inventor/a LOU, Jueren
Provided is an immunogenic complex CD24 vaccine. The immunogenic complex CD24 vaccine comprises: (a) CD24 or an immunogenic fragment thereof; and (b) a carrier protein. The CD24 vaccine has prominent immunogenicity, and can prevent and treat CD24-related diseases.

6.WO/2023/138334RECOMBINANT NOVEL CORONAVIRUS PROTEIN VACCINE, AND PREPARATION METHOD AND USE THEREOF
WO - 27.07.2023
Clasificación Internacional C07K 14/165 Nº de solicitud PCT/CN2022/142937 Solicitante NATIONAL VACCINE AND SERUM INSTITUTE(NVSI) Inventor/a LI, Qiming
Provided is a recombinant novel coronavirus protein, comprising at least two artificially-constructed non-natural RBD fragments; a recombinant vaccine using same as a target antigen has the capacity for broad-spectrum protection across epidemic strains. The present invention achieves a polyvalent broad-spectrum protection effect.

7.20230233665ANTI- SARS-COV-2-INFECTION PROTEIN AND VACCINE
US - 27.07.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 17923303 Solicitante WestVac Biopharma Co., Ltd. Inventor/a Xiawei WEI
The present invention relates to the anti-SARS-CoV-2-infection protein and vaccine, and belongs to the field of medicine. Due to the lack of efficient drugs for SARS-CoV-2 infection prevention and treatment in the prior art, the present invention provides an anti-SARS-CoV-2-infection protein, which contains a domain that binds with the angiotensin-converting enzyme 2 (ACE2) receptor as contained in the SARS-CoV-2 S protein. One the other hand, the present invention also provides a vaccine for SARS-CoV-2 infection prevention and/or treatment, which comprises the anti-SARS-CoV-2-infection protein as well as the pharmaceutically acceptable excipient or auxiliary ingredient. The present invention mainly induces the production of antibodies in the body for immunoreaction and blocks the binding the SARS-CoV-2 S protein and the ACE2 receptor of the host cell, thus helping the host to fight against the corona virus infection.

8.WO/2023/138333RECOMBINANT SARS-COV-2 PROTEIN VACCINE, AND PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 27.07.2023
Clasificación Internacional C07K 14/165 Nº de solicitud PCT/CN2022/142936 Solicitante NATIONAL VACCINE AND SERUM INSTITUTE(NVSI) Inventor/a ZHANG, Xuefeng
Provided is a recombinant SARS-CoV-2 protein, containing at least two artificially constructed non-natural RBD fragments. A recombinant vaccine using the recombinant SARS-CoV-2 protein as a target antigen has a broad-spectrum protection ability across epidemic strains, and achieves a multivalent broad-spectrum protection effect.

9.20230233628DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF
US - 27.07.2023
Clasificación Internacional A61K 35/76 Nº de solicitud 17818610 Solicitante Takeda Vaccines, Inc. Inventor/a Derek WALLACE
The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.

10.20230236172T Cells That Respond To Patient Neoepitopes
US - 27.07.2023
Clasificación Internacional G01N 33/50 Nº de solicitud 17906782 Solicitante NantCell, Inc. Inventor/a Peter Sieling
Compositions and methods are presented that allow for detection and prediction of an immune response in a subject that is selected to receive or that has received a vaccine. In selected embodiments, whole blood is used as starting material to obtain both dendritic cells and T cells, and synthetic or recombinant polypeptide(s) are used that include an antigen of the vaccine. The dendritic cells are then exposed to the synthetic or recombinant polypeptide(s), and thusly exposed dendritic cells are combined with the T cells to generate antigen reactive T cells. For detection or quantification, the antigen reactive T cells are expanded in vitro prior to ELISPOT or FACS analysis. Advantageously, such systems and methods are especially suitable for ascertaining an immune response against cancer antigens following vaccination with an anti-cancer vaccine.

11.2614916Intradermal vaccine complement
GB - 26.07.2023
Clasificación Internacional A61K 39/09 Nº de solicitud 202200909 Solicitante OPTIVALENT LTD Inventor/a NICOLAS VAN DE VELDE
The invention relates to a method of treating streptococcus pneumoniae with intradermal immunogenic compositions, methods of administering such compositions, methods of use of the compositions in combination with pneumococcal vaccines, and kits comprising intradermal delivery devices and pre-filled syringes of the compositions. The immunogenic composition may comprise serotypes 3, 19A, and 35B, and may be conjugated to CRM197. The pneumococcal vaccine may be a 13-valent pneumococcal conjugate vaccine, such as Prevnar 13® (PCV13).

12.20230233663HIV VACCINE COMPOSITIONS, METHODS, AND USES THEREOF
US - 27.07.2023
Clasificación Internacional A61K 39/21 Nº de solicitud 18009684 Solicitante Sichuan Clover Biopharmaceuticals, Inc. Inventor/a Peng LIANG

The present invention discloses immunogenic compositions including recombinant peptides and proteins comprising human immunodeficiency viruses (HIV) antigens and immunogens, e.g., gp 120 protein peptides. In some aspects, the immunogenic composition comprises a secreted fusion protein comprising a soluble HIV viral antigen joined by in-frame fusion to a C-terminal portion of a collagen which is capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. In some aspects, the immunogenic compositions provided herein are useful for generating an immune response, e.g., for treating or preventing an HIV infection. In some aspects, the immunogenic compositions provided herein may be used in a vaccine composition, e.g., as part of a prophylactic and/or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic, and/or diagnostic methods, and related kits.

13.WO/2023/138770A LIVE ATTENUATED SARS-COV-2 AND A VACCINE MADE THEREOF
WO - 27.07.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/EP2022/051215 Solicitante FREIE UNIVERSITÄT BERLIN Inventor/a TRIMPERT, Jakob
The invention relates to a polynucleotide encoding a) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein; and/or b) at least one non-structural SARS-CoV-2 protein selected from the group consisting of non-structural protein (7), non-structural protein (8), non-structural protein (9), non-structural protein (10), non-structural protein (11), non-structural protein (12), an endoribonuclease, and a 2'-O-methyltransferase, wherein the polynucleotide comprises or consists of at least one sequence part comprising codon-pair deoptimizations in comparison to the SARS-CoV-2 genome. The invention further relates to a live attenuated SARS-CoV-2 comprising this polynucleotide, to a vaccine comprising this live attenuated SARS-CoV-2, as well as to associated methods.

14.20230233656Breast Cancer Vaccine
US - 27.07.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 18012432 Solicitante National Breast Cancer Coalition Inventor/a Keith L. Knutson
The invention relates to vaccines for breast cancer therapy. The invention also relates to methods of preventing and treating breast cancer using a breast cancer vaccine.

15.20230233662VACCINATION IN NEWBORNS AND INFANTS
US - 27.07.2023
Clasificación Internacional A61K 39/155 Nº de solicitud 18299676 Solicitante CureVac SE Inventor/a Karl-Josef KALLEN
The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

16.2030584Use of vitamin K in preventing or counteracting vaccine-related adverse events, symptoms, morbidity and/or mortality after vaccination against COVID-19 or another coronavirus
NL - 27.07.2023
Clasificación Internacional G01N 33/48 Nº de solicitud 2030584 Solicitante Emphysema Solutions BV Inventor/a Rob Janssen
A composition is provided comprising a therapeutically active amount of vitamin K for administering to a subject as prophylactic for preventing or reducing the risk of developing adverse events, symptoms,

morbidity and/or mortality by vaccination against COVID-19 or 5 another corona virus, or as therapeutic for preventing said adverse events, symptoms and morbidity becoming more severe and reducing the severity of said adverse events, symptoms and morbidity. Also provided is a diagnostic test to estimate the risk of developing adverse events, symptoms, morbidity or mortality by vaccination against COVID-19 or another corona virus in a subject involving assessing vitamin K status in blood, serum or 10 plasma of said subject.

17.20230233596BETA-GLUCAN FOR IMMUNO-ENHANCEMENT AND/OR IMMUNO-BALANCING, AND FOR ADJUVANT USE
US - 27.07.2023
Clasificación Internacional A61K 31/716 Nº de solicitud 18001994 Solicitante GN Corporation Co Ltd Inventor/a Takashi ONAKA
Methods for inducing, enhancing and/or balancing an immune response are provided. The methods include administering a beta-glucan produced by Aureobasidium pullulans AFO-202 (FERM BP-19327). The methods include administering a beta-glucan produced by Aureobasidium pullulans AFO-202 (FERM BP-19327) as a vaccine adjuvant.

18.20230233667CORONAVIRUS VACCINE
US - 27.07.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 17940967 Solicitante Affinivax, Inc. Inventor/a Gilles R. Besin
Compositions and methods for the prevention and/or treatment of SARS-CoV-2 infection and/or COVID-19 are described.

19.WO/2023/140724COMPOSICIÓN A BASE DE UN LISADO TUMORAL DE CÉLULAS DE CÁNCER DE MAMA, SU PROCESO DE OBTENCIÓN Y SU USO COMO AGENTE ANTITUMORAL
WO - 27.07.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/MX2023/050005 Solicitante UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN Inventor/a RODRÍGUEZ PADILLA, María Cristina
La presente invención describe una composición a base de un lisado tumoral de células de cáncer de mama tratadas con un extracto dializable de leucocitos de bazo de bovino (ICRP-LCT), su proceso de obtención y el uso de dicha composición como agente antitumoral, para el tratamiento y prevención de cáncer especialmente de cáncer de mama, esta formulación es utilizada en forma de vacuna para el tratamiento y prevención de cáncer de mama, sin necesidad de adyuvantes para ejercer su efecto. La acción del ICRP-LCT induce una potente respuesta inmune in vivo, reflejado una tasas de supervivencia a 60 días en el 90% (9/10) de los sujetos de estudio, así mismo el ICRP-LCT indujo la regresión tumoral en ocho de nueve sujetos de estudio y un 100% de sobrevivencia (9/9) de sujetos re-desafiados con células cancerosas tratados posteriormente con el ICRP-LCT, lo que demuestra el uso del ICRP-LCT para el tratamiento y prevención del cáncer de mama, así como fuertemente estimulación de la memoria inmune antitumoral a largo plazo por la vacunación profiláctica ICRP-LCT.

20.4213870MULTIVALENTE IMPFSTOFFZUSAMMENSETZUNGEN UND VERWENDUNGEN DAVON
EP - 26.07.2023
Clasificación Internacional A61K 39/108 Nº de solicitud 21772844 Solicitante JANSSEN PHARMACEUTICALS INC Inventor/a POOLMAN JAN THEUNIS
Compositions and methods are described for inducing an immune response againstextra-intestinal pathogenic *Escherichia coli* (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of *E. coli*

polysaccharide antigen O75 covalently bound to a carrier protein for the prevention of invasive ExPEC disease.

21.WO/2023/137947USE OF CCL11
WO - 27.07.2023
Clasificación Internacional C07K 19/00 Nº de solicitud PCT/CN2022/097092 Solicitante NEWISH TECHNOLOGY (BEIJING) CO., LTD. Inventor/a QI, Hailong
The present invention relates to the technical field of vaccine preparation, and in particular to an immune-enhancing delivery system formed by targeted antigen delivery by CCL11. The system further enhances immunogenicity by fusing a chemokine CCL11 with a corresponding antigen molecule, and adding a T2 label at a terminal of the antigen molecule. The system can be a nucleic acid vector or a fusion protein or the like to be applied to prevention and/or treatment of diseases caused by a corresponding antigen. According to the present invention, by utilizing a chemotactic binding capacity of CCL11 with a surface receptor of an immune cell such as a DC, different antigen proteins are transported to the surface of the DC, so that the efficiency of phagocytosis, processing and presentation of the DC on various antigen proteins is improved, and the effect of preventing and treating related diseases is improved. The key point of the present invention is that a T2 sequence added to an antigen can enhance an immune response.

22.20230233612PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
US - 27.07.2023
Clasificación Internacional A61K 35/17 Nº de solicitud 18176678 Solicitante Immatics Biotechnologies GmbH Inventor/a Heiko SCHUSTER
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

23.20230233670A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease
US - 27.07.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 18008937 Solicitante Bavarian Nordic A/S Inventor/a Jürgen Hausmann
The invention relates to a recombinant Modified Vaccinia Virus Ankara (MVA) encoding a spike (S) protein or a part thereof, such as a receptor-binding domain (RBD), and additional antigenic sequences derived from other proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease 19 (COVID-19).

24.4213941MULTIEPITOP-IMPFSTOFF ZUR BEHANDLUNG VON MORBUS ALZHEIMER
EP - 26.07.2023
Clasificación Internacional A61P 25/00 Nº de solicitud 21869944 Solicitante OTHAIR PROTHENA LTD Inventor/a BARBOUR ROBIN
The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (Aβ) peptide and an alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of Aβ and/or alpha-synuclein, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of alpha-synuclein seeds in a

subject having or at risk of developing Alzheimer's disease or other diseases containing alpha-synuclein and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (Aβ) peptide and an alpha-synuclein peptide.

25.20230235356AN IMPROVED MEASLES VIRUS VACCINE VECTOR BASED ON MULTIPLE TANDEM ADDITIONAL TRANSCRIPTION UNITS (ATUS)
US - 27.07.2023
Clasificación Internacional C12N 15/86 Nº de solicitud 18002362 Solicitante INSTITUT PASTEUR Inventor/a Phanramphoei NAMPRACHAN-FRANTZ
The application generally relates to enhanced recombinant nucleic acid constructs comprising a cDNA molecule encoding a full length antigenomic (+) RNA strand of a non-segmented negative-sense single-stranded RNA virus for expressing at least one heterologous polypeptide, protein, antigen, or antigenic fragment thereof. The application more particularly relates to constructs with multiple ATUs localized within a single intergenic region of a virus. The application also relates to the association between a construct with multiple ATUs and BAG plasmid to facilitate the introduction and expression of large inserts.

26.20230233658FORMULATION OF A PEPTIDE VACCINE
US - 27.07.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 17894945 Solicitante ISA Pharmaceuticals B.V. Inventor/a Gwenn Eveline MULDER
The invention relates to a novel reconstitution composition, a pharmaceutical composition and kit of parts comprising said reconstitution composition. The invention further relates to a method of treatment using said pharmaceutical composition and/or the pharmaceutical composition for use as a medicament. Also provided is a method for reconstituting dried peptides and a method for preparing a pharmaceutical composition using the reconstitution composition of the invention.

27.WO/2023/139542ACTIVE IMMUNIZATION FOR REDUCING OSTEOARTHRITIC, NEUROPATHIC, AND CANCER PAIN
WO - 27.07.2023
Clasificación Internacional A61K 38/16 Nº de solicitud PCT/IB2023/050517 Solicitante INSTITUT PASTEUR DE MONTEVIDEO Inventor/a BARBEITO ERBA, Luis Héctor
A recombinant fusion protein used for active immunization or vaccine in the treatment of pain in a subject and a method thereof. The recombinant fusion protein includes: a nerve growth factor (NGF); and substance P (SP) or a calcitonin gene-related peptide (CGRP). The pain can be associated with osteoarthritis (OA), neurogenic inflammation, neuropathy, rheumatoid arthritis, post-surgery or cancer. The invention is particularly useful for treating OA pain in animals.

28.20230233657INDOLEAMINE 2,3-DIOXYGENASE BASED IMMUNOTHERAPY
US - 27.07.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 18298263 Solicitante IO BIOTECH APS Inventor/a Mads Hald ANDERSEN
The invention relates to the field of prophylaxis and therapy of cancer. Provided is a Indoleamine 2,3-dioxygenase (IDO) or peptide fragments hereof that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of IDO or peptides derived herefrom or IDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to IDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. The invention also provides that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. The

invention further provides the prophylaxis and therapy of infections by the same means as described above. The use of IDO and immunogenic peptide fragments hereof in cancer and infection treatment, diagnosis and prognosis is also provided.

29.4213867ALPHA-SYNUCLEIN-IMPFSTOFF ZUR BEHANDLUNG VON SYNUKLEINOPATHIEN
EP - 26.07.2023
Clasificación Internacional A61K 38/08 Nº de solicitud 21869943 Solicitante PROTHENA BIOSCIENCES LTD Inventor/a BARBOUR ROBIN
The disclosure provides peptide compositions and immunotherapy compositions comprising alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of neurodegenerative diseases, such as Parkinson's disease, dementia with Lewy bodies (DLB), Alzheimer's disease or other synucleinopathies, with alpha-synuclein deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of alpha-synuclein, blocking the uptake by neurons and inhibiting propagation of alpha-synuclein seeds in a subject having or at risk of developing a neurodegenerative disease containing alpha-synuclein accumulations. The methods include administering to such patients the compositions comprising alpha-synuclein peptide.

30.WO/2023/140837OPTIMIZED AAV-BASED VACCINE
WO - 27.07.2023
Clasificación Internacional A61K 48/00 Nº de solicitud PCT/US2022/013015 Solicitante MASSACHUSETTS EYE AND EAR INFIRMARY Inventor/a VANDENBERGHE, Luc, H.
The present application relates to compositions and methods for eliciting an immune response in a subject using an Adeno-Associated Virus (AAV) AAV11 vector comprising an AAV11 capsid protein and a nucleic acid encoding a transgene operably linked to a promoter, wherein the transgene encodes an immunogenic polypeptide. Further disclosed are immunogenic polypeptides that are used for the compositions and methods.

31.20230233661VACCINE COMBINATION AGAINST REPIRATORY SYNCYTIAL VIRUS INFECTION
US - 27.07.2023
Clasificación Internacional A61K 39/155 Nº de solicitud 18003547 Solicitante Janssen Vaccines & Prevention B.V. Inventor/a Benoit Christophe Stephan CALLENDRET
Methods of safely inducing a protective immune response against respiratory syncytial virus (RSV) and methods of preventing infection and/or replication of RSV in human subjects are described. The methods include administering to the subjects (a) an effective amount of an adenoviral vector encoding a recombinant RSV F protein that is stabilized in a pre-fusion conformation, and (b) an effective amount of an RSV F protein that is stabilized in a pre-fusion conformation.

32.4213872COVID-19-IMPFSTOFF AUF PIV5-BASIS
EP - 26.07.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 21870396 Solicitante UNIV GEORGIA Inventor/a HE BIAO
The present invention provides constructs of the parainfluenza virus type-5 (PIV5) virus expressing the SARS-CoV-2 envelope spike (S) protein for use as safe, stable, efficacious, and cost-effective vaccines against COVID-19.

33.4213942BETA-AMYLOID-IMPFSTOFF ZUR BEHANDLUNG VON ALZHEIMER
EP - 26.07.2023
Clasificación Internacional A61P 25/28 Nº de solicitud 21869919 Solicitante OTHAIR PROTHENA LTD Inventor/a BARBOUR ROBIN

The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (Aβ) peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of Aβ, blocking the uptake by neurons, and clearing amyloid in a subject having or at risk of developing Alzheimer's disease or other diseases containing amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an. amyloid-beta (Aβ) peptide.

34.20230235354ENHANCEMENT OF THE PRODUCTION OF ADENOIDVIRUS-BASED GENETRANSFER VECTORS
US - 27.07.2023
Clasificación Internacional C12N 15/86 Nº de solicitud 17995128 Solicitante Greffex, Inc. Inventor/a Uwe D. STAERZ
In one aspect, the embodiments disclosed herein relate to the production of fully-deleted adenovirus-based gen delivery vectors packaged without the use of an adenoviral helper virus, and more particularly in their use in the transfer of genes and the expression of proteins, vaccine development, and cell engineering. In another aspect, the production of adenoviral vectors deleted of all adenoviral genes is described that carry genes of interest with detrimental or toxic activities to eukaryotic cells.

35.20230234850ADJUVANTED VACCINES
US - 27.07.2023
Clasificación Internacional C01B 25/36 Nº de solicitud 18172695 Solicitante Merck Sharp & Dohme LLC Inventor/a Akhilesh Bhambhani
Vaccine formulations are described comprising physically separated, lyophilized antigens and adjuvant components, which may be in lyoparticle form, as well as methods of using and making such formulations. Reconstituted formulations are also described.

36.20230232882Use of E. coli strains expressing high level of alpha-Gal to modulate immunity and provide protection against infectious diseases in animals
US - 27.07.2023
Clasificación Internacional A23L 33/135 Nº de solicitud 17999668 Solicitante Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Inventor/a Alejandro CABEZAS-CRUZ
The present invention concerns an *E. coli* strains expressing high level of α-Gal, in particular selected in the group consisting of *E. coli* Nissle 1917 strain, *E. coli* O111 strain, *E. coli* O86:B7 strain, and mixture thereof, as a probiotic and/or feed additive and/or oral vaccine in a non-human animal, in particular fish and poultry, to prevent and/or reduce an infectious disease caused by a pathogen expressing α-Gal on its surface.

alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Irina Crespo Molina icrespo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu

FINLAY EDICIONES